1. Agosta, F., Altomare, D., Festari, C., Orini, S., Gandolfo, F., Boccardi, M., Arbizu, J., Bouwman, F., Drzezga, A., Nestor, P., Nobili, F., Walker, Z., Pagani, M., 2018. Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington’s disease. Eur. J. Nucl. Med. Mol. Imaging 45, 1546–1556. https://doi.org/10.1007/s00259-018-4033-0
2. Aisen, P.S., Siemers, E., Michelson, D., Salloway, S., Sampaio, C., Carrillo, M.C., Sperling, R., Doody, R., Scheltens, P., Bateman, R., Weiner, M., Vellas, B., 2018. What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force. J. Prev. Alzheimer’s Dis. 5, 171–174. https://doi.org/10.14283/jpad.2018.23
3. Albani, D., Marizzoni, M., Ferrari, C., Fusco, F., Boeri, L., Raimondi, I., Jovicich, J., Babiloni, C., Soricelli, A., Lizio, R., Galluzzi, S., Cavaliere, L., Didic, M., Schonknecht, P., Molinuevo, J.L., Nobili, F., Parnetti, L., Payoux, P., Bocchio, L., Salvatore, M., Rossini, P.M., Tsolaki, M., Visser, P.J., Richardson, J.C., Wiltfang, J., Bordet, R., Blin, O., Forloni, G., Frisoni, G.B., Consortium, P., 2018. Plasma Abeta42 as Biomarker of Prodromal Alzheimer’s Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study. J. Alzheimers. Dis. https://doi.org/10.3233/JAD-180321
4. Amier, R.P., Smulders, M.W., van der Flier, W.M., Bekkers, S.C.A.M., Zweerink, A., Allaart, C.P., Demirkiran, A., Roos, S.T., Teunissen, P.F.A., Appelman, Y., van Royen, N., Kim, R.J., van Rossum, A.C., Nijveldt, R., 2018. Long-Term Prognostic Implications of Previous Silent Myocardial Infarction in Patients Presenting With Acute Myocardial Infarction. JACC. Cardiovasc. Imaging 11, 1773–1781. https://doi.org/10.1016/j.jcmg.2018.02.009
5. Arbizu, J., Festari, C., Altomare, D., Walker, Z., Bouwman, F., Rivolta, J., Orini, S., Barthel, H., Agosta, F., Drzezga, A., Nestor, P., Boccardi, M., Frisoni, G.B., Nobili, F., 2018. Clinical utility of FDG-PET for the clinical diagnosis in MCI. Eur. J. Nucl. Med. Mol. Imaging 45, 1497–1508. https://doi.org/10.1007/s00259-018-4039-7
6. Barnes, J., Bartlett, J.W., Wolk, D.A., van der Flier, W.M., Frost, C., 2018. Disease Course Varies According to Age and Symptom Length in Alzheimer’s Disease. J. Alzheimers. Dis. 64, 631–642. https://doi.org/10.3233/JAD-170841
7. Beeldman, E., Raaphorst, J., Klein Twennaar, M., Govaarts, R., Pijnenburg, Y.A.L., de Haan, R.J., de Visser, M., Schmand, B.A., 2018. The cognitive profile of behavioural variant FTD and its similarities with ALS: a systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry 89, 995–1002. https://doi.org/10.1136/jnnp-2017-317459
8. Bergeron, D., Gorno-Tempini, M.L., Rabinovici, G.D., Santos-Santos, M.A., Seeley, W., Miller, B.L., Pijnenburg, Y., Keulen, M.A., Groot, C., van Berckel, B.N.M., van der Flier, W.M., Scheltens, P., Rohrer, J.D., Warren, J.D., Schott, J.M., Fox, N.C., Sanchez-Valle, R., Grau-Rivera, O., Gelpi, E., Seelaar, H., Papma, J.M., van Swieten, J.C., Hodges, J.R., Leyton, C.E., Piguet, O., Rogalski, E.J., Mesulam, M.M., Koric, L., Nora, K., Pariente, J., Dickerson, B., Mackenzie, I.R., Hsiung, G.-Y.R., Belliard, S., Irwin, D.J., Wolk, D.A., Grossman, M., Jones, M., Harris, J., Mann, D., Snowden, J.S., Chrem-Mendez, P., Calandri, I.L., Amengual, A.A., Miguet-Alfonsi, C., Magnin, E., Magnani, G., Santangelo, R., Deramecourt, V., Pasquier, F., Mattsson, N., Nilsson, C., Hansson, O., Keith, J., Masellis, M., Black, S.E., Matias-Guiu, J.A., Cabrera-Martin, M.-N., Paquet, C., Dumurgier, J., Teichmann, M., Sarazin, M., Bottlaender, M., Dubois, B., Rowe, C.C., Villemagne, V.L., Vandenberghe, R., Granadillo, E., Teng, E., Mendez, M., Meyer, P.T., Frings, L., Lleo, A., Blesa, R., Fortea, J., Seo, S.W., Diehl-Schmid, J., Grimmer, T., Frederiksen, K.S., Sanchez-Juan, P., Chetelat, G., Jansen, W., Bouchard, R.W., Laforce, R.J., Visser, P.J., Ossenkoppele, R., 2018. Prevalence of amyloid-beta pathology in distinct variants of primary progressive  aphasia. Ann. Neurol. 84, 729–740. https://doi.org/10.1002/ana.25333
9. Bergeron, D., Ossenkoppele, R., Jr Laforce, R., 2018. Evidence-based Interpretation of Amyloid-beta PET Results: A Clinician’s Tool. Alzheimer Dis. Assoc. Disord. 32, 28–34. https://doi.org/10.1097/WAD.0000000000000239
10. Boon, B.D.C., Hoozemans, J.J.M., Lopuhaa, B., Eigenhuis, K.N., Scheltens, P., Kamphorst, W., Rozemuller, A.J.M., Bouwman, F.H., 2018. Neuroinflammation is increased in the parietal cortex of atypical Alzheimer’s disease. J. Neuroinflammation 15, 170. https://doi.org/10.1186/s12974-018-1180-y
11. Bos, I., Verhey, F.R., Ramakers, I.H.G.B., Jacobs, H.I.L., Soininen, H., Freund-Levi, Y., Hampel, H., Tsolaki, M., Wallin, A.K., van Buchem, M.A., Oleksik, A., Verbeek, M.M., Rikkert, M.O., van der Flier, W.M., Scheltens, P., Aalten, P., Visser, P.J., Vos, S.J.B., 2018. Correction to: Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline. Alzheimers. Res. Ther. https://doi.org/10.1186/s13195-018-0391-x
12. Bos, I., Vos, S.J.B., Jansen, W.J., Vandenberghe, R., Gabel, S., Estanga, A., Ecay-Torres, M., Tomassen, J., den Braber, A., Lleo, A., Sala, I., Wallin, A., Kettunen, P., Molinuevo, J.L., Rami, L., Chetelat, G., de la Sayette, V., Tsolaki, M., Freund-Levi, Y., Johannsen, P., Novak, G.P., Ramakers, I., Verhey, F.R., Visser, P.J., 2018. Amyloid-beta, Tau, and Cognition in Cognitively Normal Older Individuals: Examining the Necessity to Adjust for Biomarker Status in Normative Data. Front. Aging Neurosci. 10, 193. https://doi.org/10.3389/fnagi.2018.00193
13. Bos, I., Vos, S., Vandenberghe, R., Scheltens, P., Engelborghs, S., Frisoni, G., Molinuevo, J.L., Wallin, A., Lleo, A., Popp, J., Martinez-Lage, P., Baird, A., Dobson, R., Legido-Quigley, C., Sleegers, K., Van Broeckhoven, C., Bertram, L., Ten Kate, M., Barkhof, F., Zetterberg, H., Lovestone, S., Streffer, J., Visser, P.J., 2018. The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. Alzheimers. Res. Ther. 10, 64. https://doi.org/10.1186/s13195-018-0396-5
14. Bouts, M.J.R.J., Moller, C., Hafkemeijer, A., van Swieten, J.C., Dopper, E., van der Flier, W.M., Vrenken, H., Wink, A.M., Pijnenburg, Y.A.L., Scheltens, P., Barkhof, F., Schouten, T.M., de Vos, F., Feis, R.A., van der Grond, J., de Rooij, M., Rombouts, S.A.R.B., 2018. Single Subject Classification of Alzheimer’s Disease and Behavioral Variant Frontotemporal Dementia Using Anatomical, Diffusion Tensor, and Resting-State Functional Magnetic Resonance Imaging. J. Alzheimers. Dis. 62, 1827–1839. https://doi.org/10.3233/JAD-170893
15. Bouwman, F., Orini, S., Gandolfo, F., Altomare, D., Festari, C., Agosta, F., Arbizu, J., Drzezga, A., Nestor, P., Nobili, F., Walker, Z., Morbelli, S., Boccardi, M., 2018. Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia. Eur. J. Nucl. Med. Mol. Imaging 45, 1526–1533. https://doi.org/10.1007/s00259-018-4034-z
16. Bruun, M., Rhodius-Meester, H.F.M., Koikkalainen, J., Baroni, M., Gjerum, L., Lemstra, A.W., Barkhof, F., Remes, A.M., Urhemaa, T., Tolonen, A., Rueckert, D., van Gils, M., Frederiksen, K.S., Waldemar, G., Scheltens, P., Mecocci, P., Soininen, H., Lotjonen, J., Hasselbalch, S.G., van der Flier, W.M., 2018. Evaluating combinations of diagnostic tests to discriminate different dementia types. Alzheimer’s Dement. 10, 509–518. https://doi.org/10.1016/j.dadm.2018.07.003
17. Chakraborty, A., Chatterjee, M., Twaalfhoven, H., Del Campo Milan, M., Teunissen, C.E., Scheltens, P., Fontijn, R.D., van Der Flier, W.M., de Vries, H.E., 2018. Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer’s disease and vascular dementia. Alzheimers. Res. Ther. 10, 58. https://doi.org/10.1186/s13195-018-0385-8
18. Chakraborty, A., Kamermans, A., van Het Hof, B., Castricum, K., Aanhane, E., van Horssen, J., Thijssen, V.L., Scheltens, P., Teunissen, C.E., Fontijn, R.D., van der Flier, W.M., de Vries, H.E., 2018. Angiopoietin like-4 as a novel vascular mediator in capillary cerebral amyloid angiopathy. Brain 141, 3377–3388. https://doi.org/10.1093/brain/awy274
19. Chatterjee, M., Del Campo, M., Morrema, T.H.J., de Waal, M., van der Flier, W.M., Hoozemans, J.J.M., Teunissen, C.E., 2018. Contactin-2, a synaptic and axonal protein, is reduced in cerebrospinal fluid and brain tissue in Alzheimer’s disease. Alzheimers. Res. Ther. 10, 52. https://doi.org/10.1186/s13195-018-0383-x
20. Ciliz, M., Sartor, J., Lindig, T., Pilotto, A., Schaffer, E., Weiss, M., Scheltens, P., Becker, S., Hobert, M.A., Berg, D., Liepelt-Scarfone, I., Maetzler, W., 2018. Brain-Area Specific White Matter Hyperintensities: Associations to Falls in Parkinson’s Disease. J. Parkinsons. Dis. 8, 455–462. https://doi.org/10.3233/JPD-181351
21. Claus, J.J., Coenen, M., Staekenborg, S.S., Schuur, J., Tielkes, C.E.M., Koster, P., Scheltens, P., 2018. Cerebral White Matter Lesions have Low Impact on Cognitive Function in a Large Elderly Memory Clinic Population. J. Alzheimers. Dis. 63, 1129–1139. https://doi.org/10.3233/JAD-171111
22. Cohn-Hokke, P.E., van Swieten, J.C., Pijnenburg, Y.A.L., Tibben, A., Meijers-Heijboer, H., Kievit, A., 2018. The Effect of Predictive Testing in Adult-Onset Neurodegenerative Diseases on Social and Personal Life. J. Genet. Couns. 27, 947–954. https://doi.org/10.1007/s10897-017-0195-3
23. Collij, L., Konijnenberg, E., Reimand, J., Ten Kate, M., Den Braber, A., Lopes Alves, I., Zwan, M., Yaqub, M., Van Assema, D., Wink, A.M., Lammertsma, A., Scheltens, P., Visser, P.J., Barkhof, F., Van Berckel, B., 2018. Assessing Amyloid Pathology in Cognitively Normal Subjects using [(18)F]Flutemetamol PET: Comparing Visual Reads and Quantitative Methods. J. Nucl. Med. https://doi.org/10.2967/jnumed.118.211532
24. Dauwan, M., Linszen, M.M.J., Lemstra, A.W., Scheltens, P., Stam, C.J., Sommer, I.E., 2018. EEG-based neurophysiological indicators of hallucinations in Alzheimer’s disease: Comparison with dementia with Lewy bodies. Neurobiol. Aging 67, 75–83. https://doi.org/10.1016/j.neurobiolaging.2018.03.013
25. de Wilde, A., van Buchem, M.M., Otten, R.H.J., Bouwman, F., Stephens, A., Barkhof, F., Scheltens, P., van der Flier, W.M., 2018. Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review. Alzheimers. Res. Ther. 10, 72. https://doi.org/10.1186/s13195-018-0398-3
26. de Wilde, A., van der Flier, W.M., Pelkmans, W., Bouwman, F., Verwer, J., Groot, C., van Buchem, M.M., Zwan, M., Ossenkoppele, R., Yaqub, M., Kunneman, M., Smets, E.M.A., Barkhof, F., Lammertsma, A.A., Stephens, A., van Lier, E., Biessels, G.J., van Berckel, B.N., Scheltens, P., 2018. Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project. JAMA Neurol. 75, 1062–1070. https://doi.org/10.1001/jamaneurol.2018.1346
27. Del Campo, M., Galimberti, D., Elias, N., Boonkamp, L., Pijnenburg, Y.A., van Swieten, J.C., Watts, K., Paciotti, S., Beccari, T., Hu, W., Teunissen, C.E., 2018. Novel CSF biomarkers to discriminate FTLD and its pathological subtypes. Ann. Clin. Transl. Neurol. 5, 1163–1175. https://doi.org/10.1002/acn3.629
28. den Haan, J., Janssen, S.F., van de Kreeke, J.A., Scheltens, P., Verbraak, F.D., Bouwman, F.H., 2018. Retinal thickness correlates with parietal cortical atrophy in early-onset Alzheimer’s disease and controls. Alzheimer’s Dement. (Amsterdam, Netherlands) 10, 49–55. https://doi.org/10.1016/j.dadm.2017.10.005
29. den Haan, J., Morrema, T.H.J., Rozemuller, A.J., Bouwman, F.H., Hoozemans, J.J.M., 2018. Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer’s disease brains: Implications for in-vivo diagnostics. Acta Neuropathol. Commun. 6, 75. https://doi.org/10.1186/s40478-018-0577-2
30. Dicks, E., Tijms, B.M., Ten Kate, M., Gouw, A.A., Benedictus, M.R., Teunissen, C.E., Barkhof, F., Scheltens, P., van der Flier, W.M., 2018. Gray matter network measures are associated with cognitive decline in mild cognitive impairment. Neurobiol. Aging 61, 198–206. https://doi.org/10.1016/j.neurobiolaging.2017.09.029
31. Doorduijn, A.S., van de Rest, O., van der Flier, W.M., Visser, M., de van der Schueren, M.A.E., 2018. Energy and Protein Intake of Alzheimer’s Disease Patients Compared to Cognitively Normal Controls: Systematic Review. J. Am. Med. Dir. Assoc. https://doi.org/10.1016/j.jamda.2018.06.019
32. Drzezga, A., Altomare, D., Festari, C., Arbizu, J., Orini, S., Herholz, K., Nestor, P., Agosta, F., Bouwman, F., Nobili, F., Walker, Z., Frisoni, G.B., Boccardi, M., 2018. Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer’s disease. Eur. J. Nucl. Med. Mol. Imaging 45, 1487–1496. https://doi.org/10.1007/s00259-018-4032-1
33. Dufresne, J., Bowden, P., Thavarajah, T., Florentinus-Mefailoski, A., Chen, Z.Z., Tucholska, M., Norzin, T., Ho, M.T., Phan, M., Mohamed, N., Ravandi, A., Stanton, E., Slutsky, A.S., Dos Santos, C.C., Romaschin, A., Marshall, J.C., Addison, C., Malone, S., Heyland, D., Scheltens, P., Killestein, J., Teunissen, C., Diamandis, E.P., Siu, K.W.M., Marshall, J.G., 2018. The plasma peptidome. Clin. Proteomics 15, 39. https://doi.org/10.1186/s12014-018-9211-3
34. Duits, F.H., Brinkmalm, G., Teunissen, C.E., Brinkmalm, A., Scheltens, P., Van der Flier, W.M., Zetterberg, H., Blennow, K., 2018. Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease. Alzheimers. Res. Ther. 10, 5. https://doi.org/10.1186/s13195-017-0335-x
35. Eikelboom, W.S., van Rooij, J.G.J., van den Berg, E., Coesmans, M., Jiskoot, L.C., Singleton, E., Ossenkoppele, R., van Swieten, J.C., Seelaar, H., Papma, J.M., 2018. Neuropsychiatric Symptoms Complicating the Diagnosis of Alzheimer’s Disease: A Case Report. J. Alzheimers. Dis. https://doi.org/10.3233/JAD-180700
36. Facal, D., Carabias, M.A.R., Pereiro, A.X., Lojo-Seoane, C., Campos-Magdaleno, M., Jutten, R.J., Sikkes, S.A.M., Juncos-Rabadan, O., 2018. Assessing Everyday Activities Across the Dementia Spectrum with the Amsterdam IADL Questionnaire. Curr. Alzheimer Res. 15, 1261–1266. https://doi.org/10.2174/1567205015666180925113411
37. Fredericks, C.A., Brown, J.A., Deng, J., Kramer, A., Ossenkoppele, R., Rankin, K., Kramer, J.H., Miller, B.L., Rabinovici, G.D., Seeley, W.W., 2018. Intrinsic connectivity networks in posterior cortical atrophy: A role for the pulvinar? NeuroImage. Clin. https://doi.org/10.1016/j.nicl.2018.101628
38. Frisoni, G.B., Barkhof, F., Altomare, D., Berkhof, J., Boccardi, M., Canzoneri, E., Collij, L., Drzezga, A., Farrar, G., Garibotto, V., Gismondi, R., Gispert, J.-D., Jessen, F., Kivipelto, M., Alves, I.L., Molinuevo, J.-L., Nordberg, A., Payoux, P., Ritchie, C., Savicheva, I., Scheltens, P., Schmidt, M.E., Schott, J., Stephens, A., van Berckel, B., Vellas, B., Walker, Z., Raffa, N., 2018. AMYPAD Diagnostic and Patient Management Study: Rationale and design.Alzheimers. Dement. https://doi.org/10.1016/j.jalz.2018.09.003
39. Ganz, A.B., Beker, N., Hulsman, M., Sikkes, S., Bank, N.B., Scheltens, P., Smit, A.B., Rozemuller, A.J.M., Hoozemans, J.J.M., Holstege, H., 2018. Neuropathology and cognitive performance in self-reported cognitively healthy centenarians. Acta Neuropathol. Commun. 6, 64. https://doi.org/10.1186/s40478-018-0558-5
40. Gardiner, S.L., Harder, A.V.E., Campman, Y.J.M., Trompet, S., Gussekloo, J., van Belzen, M.J., Boogaard, M.W., Roos, R.A.C., Jansen, I.E., Pijnenburg, Y.A.L., Scheltens, P., van der Flier, W.M., Aziz, N.A., 2019. Repeat length variations in ATXN1 and AR modify disease expression in Alzheimer’s disease. Neurobiol. Aging 73, 230.e9-230.e17. https://doi.org/10.1016/j.neurobiolaging.2018.09.007
41. Geijselaers, S.L.C., Aalten, P., Ramakers, I.H.G.B., De Deyn, P.P., Heijboer, A.C., Koek, H.L., OldeRikkert, M.G.M., Papma, J.M., Reesink, F.E., Smits, L.L., Stehouwer, C.D.A., Teunissen, C.E., Verhey, F.R.J., van der Flier, W.M., Biessels, G.J., 2018. Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer’s Disease. J. Alzheimers. Dis. 61, 309–320. https://doi.org/10.3233/JAD-170522
42. Gerritsen, A.A.J., Bakker, C., Verhey, F.R.J., Bor, H., Pijnenburg, Y.A.L., de Vugt, M.E., Koopmans, R.T.C.M., 2018. The Progression of Dementia and Cognitive Decline in a Dutch 2-Year Cohort Study  of People with Young-Onset Dementia. J. Alzheimers. Dis. 63, 343–351. https://doi.org/10.3233/JAD-170859
43. Golla, S.S., Verfaillie, S.C., Boellaard, R., Adriaanse, S.M., Zwan, M.D., Schuit, R.C., Timmers, T., Groot, C., Schober, P., Scheltens, P., van der Flier, W.M., Windhorst, A.D., van Berckel, B.N., Lammertsma, A.A., 2018. Quantification of [(18)F]florbetapir: A test-retest tracer kinetic modelling study. J. Cereb. Blood Flow Metab. 271678X18783628. https://doi.org/10.1177/0271678X18783628
44. Gossink, F.T., Vijverberg, E., Krudop, W., Scheltens, P., Stek, M.L., Pijnenburg, Y.A.L., Dols, A., 2018. Predicting progression in the late onset frontal lobe syndrome. Int. psychogeriatrics 1–6. https://doi.org/10.1017/S1041610218001242
45. Gossink, F., Pijnenburg, Y., Scheltens, P., Pera, A., Kleverwal, R., Korten, N., Stek, M., Droes, R.-M., Dols, A., 2018. An intervention programme for caregivers of dementia patients with frontal behavioural changes: an explorative study with controlled effect on sense of competence. Psychogeriatrics 18, 451–459. https://doi.org/10.1111/psyg.12351
46. Gossink, F., Schouws, S., Krudop, W., Scheltens, P., Stek, M., Pijnenburg, Y., Dols, A., 2018. Social Cognition Differentiates Behavioral Variant Frontotemporal Dementia From Other Neurodegenerative Diseases and Psychiatric Disorders. Am. J. Geriatr. Psychiatry 26, 569–579. https://doi.org/10.1016/j.jagp.2017.12.008
47. Groot, C., Sudre, C.H., Barkhof, F., Teunissen, C.E., van Berckel, B.N.M., Seo, S.W., Ourselin, S., Scheltens, P., Cardoso, M.J., van der Flier, W.M., Ossenkoppele, R., 2018. Clinical phenotype, atrophy, and small vessel disease in APOEepsilon2 carriers with Alzheimer disease. Neurology 91, e1851–e1859. https://doi.org/10.1212/WNL.0000000000006503
48. Groot, C., Tolboom, N., Ikonomovic, M.D., Lammertsma, A.A., Boon, B.D.C., Barkhof, F., Scheltens, P., Klunk, W.E., Rozemuller, A.J.M., Ossenkoppele, R., van Berckel, B.N.M., 2018. Quantitative PET and Histology of Brain Biopsy Reveal Lack of Selective Pittsburgh Compound-B Binding to Intracerebral Amyloidoma. J. Alzheimers. Dis. 65, 71–77. https://doi.org/10.3233/JAD-180316
49. Groot, C., van Loenhoud, A.C., Barkhof, F., van Berckel, B.N.M., Koene, T., Teunissen, C.C., Scheltens, P., van der Flier, W.M., Ossenkoppele, R., 2018. Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease. Neurology 90, e149–e156. https://doi.org/10.1212/WNL.0000000000004802
50. Guerreiro, R., Ross, O.A., Kun-Rodrigues, C., Hernandez, D.G., Orme, T., Eicher, J.D., Shepherd, C.E., Parkkinen, L., Darwent, L., Heckman, M.G., Scholz, S.W., Troncoso, J.C., Pletnikova, O., Ansorge, O., Clarimon, J., Lleo, A., Morenas-Rodriguez, E., Clark, L., Honig, L.S., Marder, K., Lemstra, A., Rogaeva, E., St George-Hyslop, P., Londos, E., Zetterberg, H., Barber, I., Braae, A., Brown, K., Morgan, K., Troakes, C., Al-Sarraj, S., Lashley, T., Holton, J., Compta, Y., Van Deerlin, V., Serrano, G.E., Beach, T.G., Lesage, S., Galasko, D., Masliah, E., Santana, I., Pastor, P., Diez-Fairen, M., Aguilar, M., Tienari, P.J., Myllykangas, L., Oinas, M., Revesz, T., Lees, A., Boeve, B.F., Petersen, R.C., Ferman, T.J., Escott-Price, V., Graff-Radford, N., Cairns, N.J., Morris, J.C., Pickering-Brown, S., Mann, D., Halliday, G.M., Hardy, J., Trojanowski, J.Q., Dickson, D.W., Singleton, A., Stone, D.J., Bras, J., 2018. Investigating the genetic architecture of dementia with Lewy bodies: a two-stage  genome-wide association study. Lancet. Neurol. 17, 64–74. https://doi.org/10.1016/S1474-4422(17)30400-3
51. Haaksma, M.L., Rizzuto, D., Ramakers, I.H.G.B., Garcia-Ptacek, S., Marengoni, A., van der Flier, W.M., Verhey, F.R.J., Olde Rikkert, M.G.M., Melis, R.J.F., 2018. The Impact of Frailty and Comorbidity on Institutionalization and Mortality in Persons With Dementia: A Prospective Cohort Study. J. Am. Med. Dir. Assoc. https://doi.org/10.1016/j.jamda.2018.06.020
52. Harrison, J.E. Cognition comes of age: Comments on the new FDA draft guidance for early Alzheimer’s disease. Alzheimer’s Research & Therapy. 2018:10;61.
53. Harrison, J.E., Barry, H., Baune, B.T., Best, M.W., Bowie, C.R., Cha, D.S., Culpepper, L., Fossati, P., Greer, T.L., Harmer, C., Klag, E., Lam, R.W., Lee, Y., Mansur, R.B., Wittchen, H.U., McIntyre, R. Stability, reliability and validity of the THINC-it screening tool for cognitive impairment in depression: A psychometric exploration in healthy volunteers. International Journal of Methods in Psychiatric Research. 2018:7;e1736. doi: 10.1002/mpr.1736.
54. Harrison, J.E., Rentz, D., Brashear, H.R., Arrighi, H.M., Ropacki, M., Liu, E. Psychometric evaluation of the Neuropsychological Test Battery in individuals with normal cognition, Mild Cognitive Impairment, or mild to moderate Alzheimer’s disease: Results from a longitudinal study. Journal for the Prevention of Alzheimer’s disease. 2018:5;236-244. doi: 10.14283/jpad.2018.31.
55. Holstege, H., Beker, N., Dijkstra, T., Pieterse, K., Wemmenhove, E., Schouten, K., Thiessens, L., Horsten, D., Rechtuijt, S., Sikkes, S., van Poppel, F.W.A., Meijers-Heijboer, H., Hulsman, M., Scheltens, P., 2018. The 100-plus Study of cognitively healthy centenarians: rationale, design and cohort description. Eur. J. Epidemiol. 33, 1229–1249. https://doi.org/10.1007/s10654-018-0451-3
56. Hu, X., Teunissen, C.E., Spottke, A., Heneka, M.T., Duzel, E., Peters, O., Li, S., Priller, J., Buerger, K., Teipel, S., Laske, C., Verfaillie, S.C.J., Barkhof, F., Coll-Padros, N., Rami, L., Molinuevo, J.L., van der Flier, W.M., Jessen, F., 2018. Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer’s disease-Data from three memory clinic studies. Alzheimers. Dement. https://doi.org/10.1016/j.jalz.2018.09.002
57. Iaccarino, L., Tammewar, G., Ayakta, N., Baker, S.L., Bejanin, A., Boxer, A.L., Gorno-Tempini, M.L., Janabi, M., Kramer, J.H., Lazaris, A., Lockhart, S.N., Miller, B.L., Miller, Z.A., O’Neil, J.P., Ossenkoppele, R., Rosen, H.J., Schonhaut, D.R., Jagust, W.J., Rabinovici, G.D., 2018. Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer’s Disease. NeuroImage. Clin. 17, 452–464. https://doi.org/10.1016/j.nicl.2017.09.016
58. Jack, C.R.J., Bennett, D.A., Blennow, K., Carrillo, M.C., Dunn, B., Haeberlein, S.B., Holtzman, D.M., Jagust, W., Jessen, F., Karlawish, J., Liu, E., Molinuevo, J.L., Montine, T., Phelps, C., Rankin, K.P., Rowe, C.C., Scheltens, P., Siemers, E., Snyder, H.M., Sperling, R., 2018. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers. Dement. 14, 535–562. https://doi.org/10.1016/j.jalz.2018.02.018
59. Jansen, W.J., Ossenkoppele, R., Tijms, B.M., Fagan, A.M., Hansson, O., Klunk, W.E., van der Flier, W.M., Villemagne, V.L., Frisoni, G.B., Fleisher, A.S., Lleo, A., Mintun, M.A., Wallin, A., Engelborghs, S., Na, D.L., Chetelat, G., Molinuevo, J.L., Landau, S.M., Mattsson, N., Kornhuber, J., Sabri, O., Rowe, C.C., Parnetti, L., Popp, J., Fladby, T., Jagust, W.J., Aalten, P., Lee, D.Y., Vandenberghe, R., Resende de Oliveira, C., Kapaki, E., Froelich, L., Ivanoiu, A., Gabryelewicz, T., Verbeek, M.M., Sanchez-Juan, P., Hildebrandt, H., Camus, V., Zboch, M., Brooks, D.J., Drzezga, A., Rinne, J.O., Newberg, A., de Mendonca, A., Sarazin, M., Rabinovici, G.D., Madsen, K., Kramberger, M.G., Nordberg, A., Mok, V., Mroczko, B., Wolk, D.A., Meyer, P.T., Tsolaki, M., Scheltens, P., Verhey, F.R.J., Visser, P.J., Aarsland, D., Alcolea, D., Alexander, M., Almdahl, I.S., Arnold, S.E., Baldeiras, I., Barthel, H., van Berckel, B.N.M., Blennow, K., van Buchem, M.A., Cavedo, E., Chen, K., Chipi, E., Cohen, A.D., Forster, S., Fortea, J., Frederiksen, K.S., Freund-Levi, Y., Gkatzima, O., Gordon, M.F., Grimmer, T., Hampel, H., Hausner, L., Hellwig, S., Herukka, S.-K., Johannsen, P., Klimkowicz-Mrowiec, A., Kohler, S., Koglin, N., van Laere, K., de Leon, M., Lisetti, V., Maier, W., Marcusson, J., Meulenbroek, O., Mollergard, H.M., Morris, J.C., Nordlund, A., Novak, G.P., Paraskevas, G.P., Perera, G., Peters, O., Ramakers, I.H.G.B., Rami, L., Rodriguez-Rodriguez, E., Roe, C.M., Rot, U., Ruther, E., Santana, I., Schroder, J., Seo, S.W., Soininen, H., Spiru, L., Stomrud, E., Struyfs, H., Teunissen, C.E., Vos, S.J.B., van Waalwijk van Doorn, L.J.C., Waldemar, G., Wallin, A.K., Wiltfang, J., Zetterberg, H., 2018. Association of Cerebral Amyloid-beta Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA psychiatry 75, 84–95. https://doi.org/10.1001/jamapsychiatry.2017.3391
60. Jansen, W.J., Wilson, R.S., Visser, P.J., Nag, S., Schneider, J.A., James, B.D., Leurgans, S.E., Capuano, A.W., Bennett, D.A., Boyle, P.A., 2018. Age and the association of dementia-related pathology with trajectories of cognitive decline. Neurobiol. Aging 61, 138–145. https://doi.org/10.1016/j.neurobiolaging.2017.08.029
61. Jiskoot, L.C., Bocchetta, M., Nicholas, J.M., Cash, D.M., Thomas, D., Modat, M., Ourselin, S., Rombouts, S.A.R.B., Dopper, E.G.P., Meeter, L.H., Panman, J.L., van Minkelen, R., van der Ende, E.L., Donker Kaat, L., Pijnenburg, Y.A.L., Borroni, B., Galimberti, D., Masellis, M., Tartaglia, M.C., Rowe, J., Graff, C., Tagliavini, F., Frisoni, G.B., Laforce, R.J., Finger, E., de Mendonca, A., Sorbi, S., Papma, J.M., van Swieten, J.C., Rohrer, J.D., 2018. Presymptomatic white matter integrity loss in familial frontotemporal dementia in the GENFI cohort: A cross-sectional diffusion tensor imaging study. Ann. Clin. Transl. Neurol. 5, 1025–1036. https://doi.org/10.1002/acn3.601
62. Joling, M., Vriend, C., van der Zande, J.J., Lemstra, A.W., van den Heuvel, O.A., Booij, J., Berendse, H.W., 2018. Lower (123)I-FP-CIT binding to the striatal dopamine transporter, but not to the  extrastriatal serotonin transporter, in Parkinson’s disease compared with dementia with Lewy bodies. NeuroImage. Clin. 19, 130–136. https://doi.org/10.1016/j.nicl.2018.04.009
63. Jovicich, J., Babiloni, C., Ferrari, C., Marizzoni, M., Moretti, D. V, Del Percio, C., Lizio, R., Lopez, S., Galluzzi, S., Albani, D., Cavaliere, L., Minati, L., Didic, M., Fiedler, U., Forloni, G., Hensch, T., Molinuevo, J.L., Bartres Faz, D., Nobili, F., Orlandi, D., Parnetti, L., Farotti, L., Costa, C., Payoux, P., Rossini, P.M., Marra, C., Schonknecht, P., Soricelli, A., Noce, G., Salvatore, M., Tsolaki, M., Visser, P.J., Richardson, J.C., Wiltfang, J., Bordet, R., Blin, O., Frisoniand, G.B., 2018. Two-Year Longitudinal Monitoring of Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer’s Disease Using Topographical Biomarkers Derived from Functional Magnetic Resonance Imaging and Electroencephalographic Activity. J. Alzheimers. Dis. https://doi.org/10.3233/JAD-180158
64. Jutten, R.J., Harrison, J., Lee Meeuw Kjoe, P.R., Opmeer, E.M., Schoonenboom, N.S.M., de Jong, F.J., Ritchie, C.W., Scheltens, P., Sikkes, S.A.M., 2018. A novel cognitive-functional composite measure to detect changes in early Alzheimer’s disease: Test-retest reliability and feasibility. Alzheimer’s Dement. (Amsterdam, Netherlands) 10, 153–160. https://doi.org/10.1016/j.dadm.2017.12.002
65. Konijnenberg, E., Carter, S.F., Ten Kate, M., den Braber, A., Tomassen, J., Amadi, C., Wesselman, L., Nguyen, H.-T., van de Kreeke, J.A., Yaqub, M., Demuru, M., Mulder, S.D., Hillebrand, A., Bouwman, F.H., Teunissen, C.E., Serne, E.H., Moll, A.C., Verbraak, F.D., Hinz, R., Pendleton, N., Lammertsma, A.A., van Berckel, B.N.M., Barkhof, F., Boomsma, D.I., Scheltens, P., Herholz, K., Visser, P.J., 2018. The EMIF-AD PreclinAD study: study design and baseline cohort overview. Alzheimers. Res. Ther. 10, 75. https://doi.org/10.1186/s13195-018-0406-7
66. Kun-Rodrigues, C., Orme, T., Carmona, S., Hernandez, D.G., Ross, O.A., Eicher, J.D., Shepherd, C., Parkkinen, L., Darwent, L., Heckman, M.G., Scholz, S.W., Troncoso, J.C., Pletnikova, O., Dawson, T., Rosenthal, L., Ansorge, O., Clarimon, J., Lleo, A., Morenas-Rodriguez, E., Clark, L., Honig, L.S., Marder, K., Lemstra, A., Rogaeva, E., St George-Hyslop, P., Londos, E., Zetterberg, H., Barber, I., Braae, A., Brown, K., Morgan, K., Troakes, C., Al-Sarraj, S., Lashley, T., Holton, J., Compta, Y., Van Deerlin, V., Serrano, G.E., Beach, T.G., Lesage, S., Galasko, D., Masliah, E., Santana, I., Pastor, P., Diez-Fairen, M., Aguilar, M., Tienari, P.J., Myllykangas, L., Oinas, M., Revesz, T., Lees, A., Boeve, B.F., Petersen, R.C., Ferman, T.J., Escott-Price, V., Graff-Radford, N., Cairns, N.J., Morris, J.C., Pickering-Brown, S., Mann, D., Halliday, G.M., Hardy, J., Trojanowski, J.Q., Dickson, D.W., Singleton, A., Stone, D.J., Guerreiro, R., Bras, J., 2018. A comprehensive screening of copy number variability in dementia with Lewy bodies. Neurobiol. Aging. https://doi.org/10.1016/j.neurobiolaging.2018.10.019
67. Laforce, R.J., Soucy, J.-P., Sellami, L., Dallaire-Theroux, C., Brunet, F., Bergeron, D., Miller, B.L., Ossenkoppele, R., 2018. Molecular imaging in dementia: Past, present, and future. Alzheimers. Dement. 14, 1522–1552. https://doi.org/10.1016/j.jalz.2018.06.2855
68. Leeuwis, A.E., Prins, N.D., Hooghiemstra, A.M., Benedictus, M.R., Scheltens, P., Barkhof, F., van der Flier, W.M., 2018. Microbleeds are associated with depressive symptoms in Alzheimer’s disease. Alzheimer’s Dement. (Amsterdam, Netherlands) 10, 112–120. https://doi.org/10.1016/j.dadm.2017.11.006
69. Leeuwis, A.E., Smith, L.A., Melbourne, A., Hughes, A.D., Richards, M., Prins, N.D., Sokolska, M., Atkinson, D., Tillin, T., Jager, H.R., Chaturvedi, N., van der Flier, W.M., Barkhof, F., 2018. Cerebral Blood Flow and Cognitive Functioning in a Community-Based, Multi-Ethnic  Cohort: The SABRE Study.Front. Aging Neurosci. 10, 279. https://doi.org/10.3389/fnagi.2018.00279
70. Legdeur, N., Heymans, M.W., Comijs, H.C., Huisman, M., Maier, A.B., Visser, P.J., 2018. Age dependency of risk factors for cognitive decline. BMC Geriatr. 18, 187. https://doi.org/10.1186/s12877-018-0876-2
71. Legdeur, N., Badissi, M., Carter, S.F., de Crom, S., van de Kreeke, A., Vreeswijk, R., Trappenburg, M.C., Oudega, M.L., Koek, H.L., van Campen, J.P., Keijsers, C.J.P.W., Amadi, C., Hinz, R., Gordon, M.F., Novak, G., Podhorna, J., Serne, E., Verbraak, F., Yaqub, M., Hillebrand, A., Griffa, A., Pendleton, N., Kramer, S.E., Teunissen, C.E., Lammertsma, A., Barkhof, F., van Berckel, B.N.M., Scheltens, P., Muller, M., Maier, A.B., Herholz, K., Visser, P.J., 2018. Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study. BMC Geriatr. 18, 289. https://doi.org/10.1186/s12877-018-0984-z
72. Leijenaar, J.F., Groeneveld, G.J., van der Flier, W.M., Scheltens, P., Klaassen, E.S., Weinstein, H.C., Biessels, G.J., Barkhof, F., Prins, N.D., 2018. Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over Trial. JMIR Res. Protoc. 7, e80. https://doi.org/10.2196/resprot.9192
73. Lewczuk, P., Riederer, P., O’Bryant, S.E., Verbeek, M.M., Dubois, B., Visser, P.J., Jellinger, K.A., Engelborghs, S., Ramirez, A., Parnetti, L., Jack, C.R.J., Teunissen, C.E., Hampel, H., Lleo, A., Jessen, F., Glodzik, L., de Leon, M.J., Fagan, A.M., Molinuevo, J.L., Jansen, W.J., Winblad, B., Shaw, L.M., Andreasson, U., Otto, M., Mollenhauer, B., Wiltfang, J., Turner, M.R., Zerr, I., Handels, R., Thompson, A.G., Johansson, G., Ermann, N., Trojanowski, J.Q., Karaca, I., Wagner, H., Oeckl, P., van Waalwijk van Doorn, L., Bjerke, M., Kapogiannis, D., Kuiperij, H.B., Farotti, L., Li, Y., Gordon, B.A., Epelbaum, S., Vos, S.J.B., Klijn, C.J.M., Van Nostrand, W.E., Minguillon, C., Schmitz, M., Gallo, C., Lopez Mato, A., Thibaut, F., Lista, S., Alcolea, D., Zetterberg, H., Blennow, K., Kornhuber, J., 2018. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World J. Biol. Psychiatry 19, 244–328. https://doi.org/10.1080/15622975.2017.1375556
74. Linszen, M.M.J., van Zanten, G.A., Teunisse, R.J., Brouwer, R.M., Scheltens, P., Sommer, I.E., 2018. Auditory hallucinations in adults with hearing impairment: a large prevalence study. Psychol. Med. 1–8. https://doi.org/10.1017/S0033291718000594
75. Linszen, M.M.J., Lemstra, A.W., Dauwan, M., Brouwer, R.M., Scheltens, P., Sommer, I.E.C., 2018. Understanding hallucinations in probable Alzheimer’s disease: Very low prevalence rates in a tertiary memory clinic. Alzheimer’s Dement. (Amsterdam, Netherlands) 10, 358–362. https://doi.org/10.1016/j.dadm.2018.03.005
76. Liu, E., Wang, D., Sperling, R., Salloway, S., Fox, N.C., Blennow, K., Scheltens, P., Schmidt, M.E., Streffer, J., Novak, G., Einstein, S., Booth, K., Ketter, N., Brashear, H.R., 2018. Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab. Neurology 90, e877–e886. https://doi.org/10.1212/WNL.0000000000005060
77. Marizzoni, M., Ferrari, C., Jovicich, J., Albani, D., Babiloni, C., Cavaliere, L., Didic, M., Forloni, G., Galluzzi, S., Hoffmann, K.-T., Molinuevo, J.L., Nobili, F., Parnetti, L., Payoux, P., Ribaldi, F., Rossini, P.M., Schonknecht, P., Soricelli, A., Hensch, T., Tsolaki, M., Visser, P.J., Wiltfang, J., Richardson, J.C., Bordet, R., Blin, O., Frisoni, G.B., 2018. Predicting and Tracking Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer’s Disease: Structural Brain Biomarkers. J. Alzheimers. Dis. https://doi.org/10.3233/JAD-180152
78. Mattsson, N., Groot, C., Jansen, W.J., Landau, S.M., Villemagne, V.L., Engelborghs, S., Mintun, M.M., Lleo, A., Molinuevo, J.L., Jagust, W.J., Frisoni, G.B., Ivanoiu, A., Chetelat, G., Resende de Oliveira, C., Rodrigue, K.M., Kornhuber, J., Wallin, A., Klimkowicz-Mrowiec, A., Kandimalla, R., Popp, J., Aalten, P.P., Aarsland, D., Alcolea, D., Almdahl, I.S., Baldeiras, I., van Buchem, M.A., Cavedo, E., Chen, K., Cohen, A.D., Forster, S., Fortea, J., Frederiksen, K.S., Freund-Levi, Y., Gill, K.D., Gkatzima, O., Grimmer, T., Hampel, H., Herukka, S.-K., Johannsen, P., van Laere, K., de Leon, M.J., Maier, W., Marcusson, J., Meulenbroek, O., Mollergard, H.M., Morris, J.C., Mroczko, B., Nordlund, A., Prabhakar, S., Peters, O., Rami, L., Rodriguez-Rodriguez, E., Roe, C.M., Ruther, E., Santana, I., Schroder, J., Seo, S.W., Soininen, H., Spiru, L., Stomrud, E., Struyfs, H., Teunissen, C.E., Verhey, F.R.J., Vos, S.J.B., van Waalwijk van Doorn, L.J.C., Waldemar, G., Wallin, A.K., Wiltfang, J., Vandenberghe, R., Brooks, D.J., Fladby, T., Rowe, C.C., Drzezga, A., Verbeek, M.M., Sarazin, M., Wolk, D.A., Fleisher, A.S., Klunk, W.E., Na, D.L., Sanchez-Juan, P., Lee, D.Y., Nordberg, A., Tsolaki, M., Camus, V., Rinne, J.O., Fagan, A.M., Zetterberg, H., Blennow, K., Rabinovici, G.D., Hansson, O., van Berckel, B.N.M., van der Flier, W.M., Scheltens, P., Visser, P.J., Ossenkoppele, R., 2018. Prevalence of the apolipoprotein E epsilon4 allele in amyloid beta positive subjects across the spectrum of Alzheimer’s disease. Alzheimers. Dement. 14, 913–924. https://doi.org/10.1016/j.jalz.2018.02.009
79. Mattsson, N., Ossenkoppele, R., Smith, R., Strandberg, O., Ohlsson, T., Jogi, J., Palmqvist, S., Stomrud, E., Hansson, O., 2018. Greater tau load and reduced cortical thickness in APOE epsilon4-negative Alzheimer’s disease: a cohort study. Alzheimers. Res. Ther. 10, 77. https://doi.org/10.1186/s13195-018-0403-x
80. Meeter, L.H.H., Gendron, T.F., Sias, A.C., Jiskoot, L.C., Russo, S.P., Donker Kaat, L., Papma, J.M., Panman, J.L., van der Ende, E.L., Dopper, E.G., Franzen, S., Graff, C., Boxer, A.L., Rosen, H.J., Sanchez-Valle, R., Galimberti, D., Pijnenburg, Y.A.L., Benussi, L., Ghidoni, R., Borroni, B., Laforce, R.J., Del Campo, M., Teunissen, C.E., van Minkelen, R., Rojas, J.C., Coppola, G., Geschwind, D.H., Rademakers, R., Karydas, A.M., Oijerstedt, L., Scarpini, E., Binetti, G., Padovani, A., Cash, D.M., Dick, K.M., Bocchetta, M., Miller, B.L., Rohrer, J.D., Petrucelli, L., van Swieten, J.C., Lee, S.E., 2018. Poly(GP), neurofilament and grey matter deficits in C9orf72 expansion carriers. Ann. Clin. Transl. Neurol. 5, 583–597. https://doi.org/10.1002/acn3.559
81. Meeter, L.H.H., Vijverberg, E.G., Del Campo, M., Rozemuller, A.J.M., Donker Kaat, L., de Jong, F.J., van der Flier, W.M., Teunissen, C.E., van Swieten, J.C., Pijnenburg, Y.A.L., 2018. Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum. Neurology 90, e1231–e1239. https://doi.org/10.1212/WNL.0000000000005261
82. Molinuevo, J.L., Ayton, S., Batrla, R., Bednar, M.M., Bittner, T., Cummings, J., Fagan, A.M., Hampel, H., Mielke, M.M., Mikulskis, A., O’Bryant, S., Scheltens, P., Sevigny, J., Shaw, L.M., Soares, H.D., Tong, G., Trojanowski, J.Q., Zetterberg, H., Blennow, K., 2018. Current state of Alzheimer’s fluid biomarkers. Acta Neuropathol. 136, 821–853. https://doi.org/10.1007/s00401-018-1932-x
83. Nestor, P.J., Altomare, D., Festari, C., Drzezga, A., Rivolta, J., Walker, Z., Bouwman, F., Orini, S., Law, I., Agosta, F., Arbizu, J., Boccardi, M., Nobili, F., Frisoni, G.B., 2018. Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia. Eur. J. Nucl. Med. Mol. Imaging 45, 1509–1525. https://doi.org/10.1007/s00259-018-4035-y
84. Nobili, F., Arbizu, J., Bouwman, F., Drzezga, A., Agosta, F., Nestor, P., Walker, Z., Boccardi, M., 2018. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain (18) F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. Eur. J. Neurol. 25, 1201–1217. https://doi.org/10.1111/ene.13728
85. Nobili, F., Festari, C., Altomare, D., Agosta, F., Orini, S., Van Laere, K., Arbizu, J., Bouwman, F., Drzezga, A., Nestor, P., Walker, Z., Boccardi, M., 2018. Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders. Eur. J. Nucl. Med. Mol. Imaging 45, 1557–1566. https://doi.org/10.1007/s00259-018-4030-3
86. Oppedal, K., Ferreira, D., Cavallin, L., Lemstra, A.W., Ten Kate, M., Padovani, A., Rektorova, I., Bonanni, L., Wahlund, L.-O., Engedal, K., Nobili, F., Kramberger, M., Taylor, J.-P., Hort, J., Snaedal, J., Blanc, F., Walker, Z., Antonini, A., Westman, E., Aarsland, D., 2018. A signature pattern of cortical atrophy in dementia with Lewy bodies: A study on  333 patients from the European DLB consortium. Alzheimers. Dement. https://doi.org/10.1016/j.jalz.2018.09.011
87. Ossenkoppele, R., Hansson, O., 2018. Genetic characterization of amyloid-beta and tau network spread. Nat. Med. 24, 1790–1792. https://doi.org/10.1038/s41591-018-0277-2
88. Ossenkoppele, R., Rabinovici, G.D., Smith, R., Cho, H., Scholl, M., Strandberg, O., Palmqvist, S., Mattsson, N., Janelidze, S., Santillo, A., Ohlsson, T., Jogi, J., Tsai, R., La Joie, R., Kramer, J., Boxer, A.L., Gorno-Tempini, M.L., Miller, B.L., Choi, J.Y., Ryu, Y.H., Lyoo, C.H., Hansson, O., 2018. Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA 320, 1151–1162. https://doi.org/10.1001/jama.2018.12917
89. Ostrowitzki, S., Lasser, R.A., Dorflinger, E., Scheltens, P., Barkhof, F., Nikolcheva, T., Ashford, E., Retout, S., Hofmann, C., Delmar, P., Klein, G., Andjelkovic, M., Dubois, B., Boada, M., Blennow, K., Santarelli, L., Fontoura, P., 2018. Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. Alzheimers. Res. Ther. https://doi.org/10.1186/s13195-018-0409-4
90. Pendergrass, J.C., Targum, S.D, Harrison, J.E. Cognitive Impairment Associated with Cancer: A brief Review. Innovations in Clinical Neuroscience. 2018:15;36-44.
91. Perera, G., Pedersen, L., Ansel, D., Alexander, M., Arrighi, H.M., Avillach, P., Foskett, N., Gini, R., Gordon, M.F., Gungabissoon, U., Mayer, M.-A., Novak, G., Rijnbeek, P., Trifiro, G., van der Lei, J., Visser, P.J., Stewart, R., 2018. Dementia prevalence and incidence in a federation of European Electronic Health Record databases: The European Medical Informatics Framework resource. Alzheimers. Dement. 14, 130–139. https://doi.org/10.1016/j.jalz.2017.06.2270
92. Piersma, D., Fuermaier, A.B.M., de Waard, D., De Deyn, P.P., Davidse, R.J., de Groot, J., Doumen, M.J.A., Bredewoud, R.A., Claesen, R., Lemstra, A.W., Vermeeren, A., Ponds, R., Verhey, F., Brouwer, W.H., Tucha, O., 2018. The MMSE should not be the sole indicator of fitness to drive in mild Alzheimer’s dementia. Acta Neurol. Belg. 118, 637–642. https://doi.org/10.1007/s13760-018-1036-3
93. Piersma, D., Fuermaier, A.B.M., De Waard, D., Davidse, R.J., De Groot, J., Doumen, M.J.A., Bredewoud, R.A., Claesen, R., Lemstra, A.W., Scheltens, P., Vermeeren, A., Ponds, R., Verhey, F., De Deyn, P.P., Brouwer, W.H., Tucha, O., 2018. Assessing Fitness to Drive in Patients With Different Types of Dementia. Alzheimer Dis. Assoc. Disord. 32, 70–75. https://doi.org/10.1097/WAD.0000000000000221
94. Pijnenburg, Y.A.L., Dols, A., 2018. Meaning of psychiatric symptoms in frontotemporal dementia. J. Neurol. Neurosurg. Psychiatry. https://doi.org/10.1136/jnnp-2017-317556
95. Reus, L.M., Vijverberg, E.G., Tijms, B.M., Kate, M. Ten, Gossink, F., Krudop, W.A., Campo, M. Del, Teunissen, C.E., Barkhof, F., van der Flier, W.M., Visser, P.J., Dols, A., Pijnenburg, Y. Al, 2018. Disease trajectories in behavioural variant frontotemporal dementia, primary psychiatric and other neurodegenerative disorders presenting with behavioural change. J. Psychiatr. Res. 104, 183–191. https://doi.org/10.1016/j.jpsychires.2018.07.014
96. Rhodius-Meester, H.F.M., Liedes, H., Koene, T., Lemstra, A.W., Teunissen, C.E., Barkhof, F., Scheltens, P., van Gils, M., Lotjonen, J., van der Flier, W.M., 2018. Disease-related determinants are associated with mortality in dementia due to Alzheimer’s disease. Alzheimers. Res. Ther. 10, 23. https://doi.org/10.1186/s13195-018-0348-0
97. Rhodius-Meester, H.F.M., Tijms, B.M., Lemstra, A.W., Prins, N.D., Pijnenburg, Y.A.L., Bouwman, F., Scheltens, P., van der Flier, W.M., 2018. Survival in memory clinic cohort is short, even in young-onset dementia. J. Neurol. Neurosurg. Psychiatry. https://doi.org/10.1136/jnnp-2018-318820
98. Rimkus, C.M., Schoonheim, M.M., Steenwijk, M.D., Vrenken, H., Eijlers, A.J., Killestein, J., Wattjes, M.P., Leite, C.C., Barkhof, F., Tijms, B.M., 2018. Gray matter networks and cognitive impairment in multiple sclerosis. Mult. Scler. 1352458517751650. https://doi.org/10.1177/1352458517751650
99. Saridin, F.N., Schouws, S.N.T.M., de Jong, J., Pijnenburg, Y.A.L., Dols, A., 2018. Secondary mania as a possible presentation of a C9orf72 hexanucleotide repeat expansion. Bipolar Disord. https://doi.org/10.1111/bdi.12724
100. Schaeverbeke, J., Evenepoel, C., Declercq, L., Gabel, S., Meersmans, K., Bruffaerts, R., Adamczuk, K., Dries, E., Van Bouwel, K., Sieben, A., Pijnenburg, Y., Peeters, R., Bormans, G., Van Laere, K., Koole, M., Dupont, P., Vandenberghe, R., 2018. Distinct [(18)F]THK5351 binding patterns in primary progressive aphasia variants. Eur. J. Nucl. Med. Mol. Imaging 45, 2342–2357. https://doi.org/10.1007/s00259-018-4075-3
101. Schaeverbeke, J., Gabel, S., Meersmans, K., Bruffaerts, R., Liuzzi, A.G., Evenepoel, C., Dries, E., Van Bouwel, K., Sieben, A., Pijnenburg, Y., Peeters, R., Bormans, G., Van Laere, K., Koole, M., Dupont, P., Vandenberghe, R., 2018. Single-word comprehension deficits in the nonfluent variant of primary progressive aphasia. Alzheimers. Res. Ther. 10, 68. https://doi.org/10.1186/s13195-018-0393-8
102. Scheltens, N.M.E., Tijms, B.M., Heymans, M.W., Rabinovici, G.D., Cohn-Sheehy, B.I., Miller, B.L., Kramer, J.H., Wolfsgruber, S., Wagner, M., Kornhuber, J., Peters, O., Scheltens, P., van der Flier, W.M., 2018. Prominent Non-Memory Deficits in Alzheimer’s Disease Are Associated with Faster Disease Progression. J. Alzheimers. Dis. 65, 1029–1039. https://doi.org/10.3233/JAD-171088
103. Scheltens, N.M.E., van der Weijden, K., Adriaanse, S.M., van Assema, D., Oomen, P.P., Krudop, W.A., Lammertsma, A.A., Barkhof, F., Koene, T., Teunissen, C.E., Scheltens, P., van der Flier, W.M., Pijnenburg, Y.A.L., Yaqub, M., Ossenkoppele, R., van Berckel, B.N.M., 2018. Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer’s disease. NeuroImage. Clin. 19, 625–632. https://doi.org/10.1016/j.nicl.2018.05.024
104. Scheltens, P., Hallikainen, M., Grimmer, T., Duning, T., Gouw, A.A., Teunissen, C.E., Wink, A.M., Maruff, P., Harrison, J., van Baal, C.M., Bruins, S., Lues, I., Prins, N.D., 2018. Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study. Alzheimers. Res. Ther. 10, 107. https://doi.org/10.1186/s13195-018-0431-6
105. Scheltens, P., Prins, N., Lammertsma, A., Yaqub, M., Gouw, A., Wink, A.M., Chu, H.-M., van Berckel, B.N.M., Alam, J., 2018. An exploratory clinical study of p38alpha kinase inhibition in Alzheimer’s disease. Ann. Clin. Transl. Neurol. 5, 464–473. https://doi.org/10.1002/acn3.549
106. Schindler, S.E., Sutphen, C.L., Teunissen, C., McCue, L.M., Morris, J.C., Holtzman, D.M., Mulder, S.D., Scheltens, P., Xiong, C., Fagan, A.M., 2018.Upward drift in cerebrospinal fluid amyloid beta 42 assay values for more than 10 years. Alzheimers. Dement. 14, 62–70. https://doi.org/10.1016/j.jalz.2017.06.2264
107. Slot, R.E.R., Verfaillie, S.C.J., Overbeek, J.M., Timmers, T., Wesselman, L.M.P., Teunissen, C.E., Dols, A., Bouwman, F.H., Prins, N.D., Barkhof, F., Lammertsma, A.A., Van Berckel, B.N.M., Scheltens, P., Sikkes, S.A.M., Van der Flier, W.M., 2018. Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results. Alzheimers. Res. Ther. 10, 76. https://doi.org/10.1186/s13195-018-0390-y
108. Taskesen, E., Mishra, A., van der Sluis, S., Ferrari, R., Veldink, J.H., van Es, M.A., Smit, A.B., Posthuma, D., Pijnenburg, Y., 2018. Author Correction: Susceptible genes and disease mechanisms identified in frontotemporal dementia and frontotemporal dementia with Amyotrophic Lateral Sclerosis by DNA-methylation and GWAS. Sci. Rep. https://doi.org/10.1038/s41598-018-21308-x
109. Ten Kate, M., Dicks, E., Visser, P.J., van der Flier, W.M., Teunissen, C.E., Barkhof, F., Scheltens, P., Tijms, B.M., 2018. Atrophy subtypes in prodromal Alzheimer’s disease are associated with cognitive decline. Brain 141, 3443–3456. https://doi.org/10.1093/brain/awy264
110. Ten Kate, M., Ingala, S., Schwarz, A.J., Fox, N.C., Chetelat, G., van Berckel, B.N.M., Ewers, M., Foley, C., Gispert, J.D., Hill, D., Irizarry, M.C., Lammertsma, A.A., Molinuevo, J.L., Ritchie, C., Scheltens, P., Schmidt, M.E., Visser, P.J., Waldman, A., Wardlaw, J., Haller, S., Barkhof, F., 2018. Secondary prevention of Alzheimer’s dementia: neuroimaging contributions. Alzheimers. Res. Ther. 10, 112. https://doi.org/10.1186/s13195-018-0438-z
111. Ten Kate, M., Redolfi, A., Peira, E., Bos, I., Vos, S.J., Vandenberghe, R., Gabel, S., Schaeverbeke, J., Scheltens, P., Blin, O., Richardson, J.C., Bordet, R., Wallin, A., Eckerstrom, C., Molinuevo, J.L., Engelborghs, S., Van Broeckhoven, C., Martinez-Lage, P., Popp, J., Tsolaki, M., Verhey, F.R.J., Baird, A.L., Legido-Quigley, C., Bertram, L., Dobricic, V., Zetterberg, H., Lovestone, S., Streffer, J., Bianchetti, S., Novak, G.P., Revillard, J., Gordon, M.F., Xie, Z., Wottschel, V., Frisoni, G., Visser, P.J., Barkhof, F., 2018. MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. Alzheimers. Res. Ther. 10, 100. https://doi.org/10.1186/s13195-018-0428-1
112. Ten Kate, M., Sudre, C.H., den Braber, A., Konijnenberg, E., Nivard, M.G., Cardoso, M.J., Scheltens, P., Ourselin, S., Boomsma, D.I., Barkhof, F., Visser, P.J., 2018. White matter hyperintensities and vascular risk factors in monozygotic twins. Neurobiol. Aging 66, 40–48. https://doi.org/10.1016/j.neurobiolaging.2018.02.002
113. Ten Kate, M., Visser, P.J., Bakardjian, H., Barkhof, F., Sikkes, S.A.M., van der Flier, W.M., Scheltens, P., Hampel, H., Habert, M.-O., Dubois, B., Tijms, B.M., 2018. Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults. Front. Aging Neurosci. 10, 67. https://doi.org/10.3389/fnagi.2018.00067
114. Tesi, N., van der Lee, S.J., Hulsman, M., Jansen, I.E., Stringa, N., van Schoor, N., Meijers-Heijboer, H., Huisman, M., Scheltens, P., Reinders, M.J.T., van der Flier, W.M., Holstege, H., 2018. Centenarian controls increase variant effect sizes by an average twofold in an extreme case-extreme control analysis of Alzheimer’s disease. Eur. J. Hum. Genet. https://doi.org/10.1038/s41431-018-0273-5
115. Teunissen, C.E., Chiu, M.-J., Yang, C.-C., Yang, S.-Y., Scheltens, P., Zetterberg, H., Blennow, K., 2018. Plasma Amyloid-beta (Abeta42) Correlates with Cerebrospinal Fluid Abeta42 in Alzheimer’s Disease. J. Alzheimers. Dis. 62, 1857–1863. https://doi.org/10.3233/JAD-170784
116. Tijms, B.M., Ten Kate, M., Gouw, A.A., Borta, A., Verfaillie, S., Teunissen, C.E., Scheltens, P., Barkhof, F., van der Flier, W.M., 2018. Gray matter networks and clinical progression in subjects with predementia Alzheimer’s disease. Neurobiol. Aging 61, 75–81. https://doi.org/10.1016/j.neurobiolaging.2017.09.011
117. Tijms, B.M., Vermunt, L., Zwan, M.D., van Harten, A.C., van der Flier, W.M., Teunissen, C.E., Scheltens, P., Visser, P.J., 2018. Pre-amyloid stage of Alzheimer’s disease in cognitively normal individuals. Ann. Clin. Transl. Neurol. 5, 1037–1047. https://doi.org/10.1002/acn3.615
118. Tijms, B.M., Visser, P.J., 2018. Capturing the Alzheimer’s disease pathological cascade. Lancet. Neurol. 17, 199–200. https://doi.org/10.1016/S1474-4422(18)30043-7
119. Tijms, B.M., Visser, P.J., 2018. Chasing the start of sporadic Alzheimer’s disease running in families. Brain 141, 1589–1591. https://doi.org/10.1093/brain/awy113
120. Tijms, B.M., Willemse, E.A.J., Zwan, M.D., Mulder, S.D., Visser, P.J., van Berckel, B.N.M., van der Flier, W.M., Scheltens, P., Teunissen, C.E., 2018. Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid-beta  1-42 Analysis Results. Clin. Chem. 64, 576–585. https://doi.org/10.1373/clinchem.2017.281055
121. Timmers, T., van Berckel, B.N.M., Lammertsma, A.A., Ossenkoppele, R., 2018. Quantification of Tau Load in Alzheimer’s Disease Clinical Trials Using Positron  Emission Tomography. Methods Mol. Biol. 1750, 221–229. https://doi.org/10.1007/978-1-4939-7704-8_15
122. Tolonen, A., Rhodius-Meester, H.F.M., Bruun, M., Koikkalainen, J., Barkhof, F., Lemstra, A.W., Koene, T., Scheltens, P., Teunissen, C.E., Tong, T., Guerrero, R., Schuh, A., Ledig, C., Baroni, M., Rueckert, D., Soininen, H., Remes, A.M., Waldemar, G., Hasselbalch, S.G., Mecocci, P., van der Flier, W.M., Lotjonen, J., 2018. Data-Driven Differential Diagnosis of Dementia Using Multiclass Disease State Index Classifier. Front. Aging Neurosci. 10, 111. https://doi.org/10.3389/fnagi.2018.00111
123. van de Kreeke, J.A., Nguyen, H.T., Konijnenberg, E., Tomassen, J., den Braber, A., Ten Kate, M., Sudre, C.H., Barkhof, F., Boomsma, D.I., Tan, H.S., Verbraak, F.D., Visser, P.J., 2018. Retinal and Cerebral Microvasculopathy: Relationships and Their Genetic Contributions. Invest. Ophthalmol. Vis. Sci. 59, 5025–5031. https://doi.org/10.1167/iovs.18-25341
124. van den Kommer, T.N., Deeg, D.J.H., van der Flier, W.M., Comijs, H.C., 2018. Time Trend in Persistent Cognitive Decline: Results From the Longitudinal Aging Study Amsterdam. J. Gerontol. B. Psychol. Sci. Soc. Sci. 73, S57–S64. https://doi.org/10.1093/geronb/gbx151
125. van der Flier, W.M., Scheltens, P., 2018. Amsterdam Dementia Cohort: Performing Research to Optimize Care. J. Alzheimers. Dis. 62, 1091–1111. https://doi.org/10.3233/JAD-170850
126. van der Flier, W.M., Skoog, I., Schneider, J.A., Pantoni, L., Mok, V., Chen, C.L.H., Scheltens, P., 2018. Vascular cognitive impairment. Nat. Rev. Dis. Prim. 4, 18003. https://doi.org/10.1038/nrdp.2018.3
127. van der Lee, S.J., Teunissen, C.E., Pool, R., Shipley, M.J., Teumer, A., Chouraki, V., Melo van Lent, D., Tynkkynen, J., Fischer, K., Hernesniemi, J., Haller, T., Singh-Manoux, A., Verhoeven, A., Willemsen, G., de Leeuw, F.A., Wagner, H., van Dongen, J., Hertel, J., Budde, K., Willems van Dijk, K., Weinhold, L., Ikram, M.A., Pietzner, M., Perola, M., Wagner, M., Friedrich, N., Slagboom, P.E., Scheltens, P., Yang, Q., Gertzen, R.E., Egert, S., Li, S., Hankemeier, T., van Beijsterveldt, C.E.M., Vasan, R.S., Maier, W., Peeters, C.F.W., Jorgen Grabe, H., Ramirez, A., Seshadri, S., Metspalu, A., Kivimaki, M., Salomaa, V., Demirkan, A., Boomsma, D.I., van der Flier, W.M., Amin, N., van Duijn, C.M., 2018. Circulating metabolites and general cognitive ability and dementia: Evidence from 11 cohort studies. Alzheimers. Dement. 14, 707–722. https://doi.org/10.1016/j.jalz.2017.11.012
128. van der Zande, J.J., Gouw, A.A., van Steenoven, I., Scheltens, P., Stam, C.J., Lemstra, A.W., 2018. EEG Characteristics of Dementia With Lewy Bodies, Alzheimer’s Disease and Mixed Pathology. Front. Aging Neurosci. 10, 190. https://doi.org/10.3389/fnagi.2018.00190
129. van der Zande, J.J., Steenwijk, M.D., Ten Kate, M., Wattjes, M.P., Scheltens, P., Lemstra, A.W., 2018. Gray matter atrophy in dementia with Lewy bodies with and without concomitant Alzheimer’s disease pathology. Neurobiol. Aging 71, 171–178. https://doi.org/10.1016/j.neurobiolaging.2018.07.005
130. van Loenhoud, A.C., Groot, C., Vogel, J.W., van der Flier, W.M., Ossenkoppele, R., 2018. Is intracranial volume a suitable proxy for brain reserve? Alzheimers. Res. Ther. 10, 91. https://doi.org/10.1186/s13195-018-0408-5
131. Van Someren, E.J.W., Oosterman, J.M., Van Harten, B., Vogels, R.L., Gouw, A.A., Weinstein, H.C., Poggesi, A., Scheltens, P., Scherder, E.J.A., 2018. Medial temporal lobe atrophy relates more strongly to sleep-wake rhythm fragmentation than to age or any other known risk. Neurobiol. Learn. Mem. https://doi.org/10.1016/j.nlm.2018.05.017
132. van Steenoven, I., Majbour, N.K., Vaikath, N.N., Berendse, H.W., van der Flier, W.M., van de Berg, W.D.J., Teunissen, C.E., Lemstra, A.W., El-Agnaf, O.M.A., 2018. alpha-Synuclein species as potential cerebrospinal fluid biomarkers for dementia  with lewy bodies. Mov. Disord. 33, 1724–1733. https://doi.org/10.1002/mds.111
133. Verberk, I.M.W., Slot, R.E., Verfaillie, S.C.J., Heijst, H., Prins, N.D., van Berckel, B.N.M., Scheltens, P., Teunissen, C.E., van der Flier, W.M., 2018. Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes. Ann. Neurol. 84, 648–658. https://doi.org/10.1002/ana.25334
134. Verfaillie, S.C.J., Pichet Binette, A., Vachon-Presseau, E., Tabrizi, S., Savard, M., Bellec, P., Ossenkoppele, R., Scheltens, P., van der Flier, W.M., Breitner, J.C.S., Villeneuve, S., 2018. Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimer’s Disease. Biol. psychiatry. Cogn. Neurosci. neuroimaging 3, 463–472. https://doi.org/10.1016/j.bpsc.2017.11.012
135. Verfaillie, S.C.J., Slot, R.E.R., Dicks, E., Prins, N.D., Overbeek, J.M., Teunissen, C.E., Scheltens, P., Barkhof, F., van der Flier, W.M., Tijms, B.M., 2018. A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive decline. Hum. Brain Mapp. 39, 3143–3151. https://doi.org/10.1002/hbm.24065
136. Verfaillie, S.C.J., Slot, R.E., Tijms, B.M., Bouwman, F., Benedictus, M.R., Overbeek, J.M., Koene, T., Vrenken, H., Scheltens, P., Barkhof, F., van der Flier, W.M., 2018. Thinner cortex in patients with subjective cognitive decline is associated with steeper decline of memory. Neurobiol. Aging 61, 238–244. https://doi.org/10.1016/j.neurobiolaging.2017.09.009
137. Vermunt, L., Veal, C.D., Ter Meulen, L., Chrysostomou, C., van der Flier, W., Frisoni, G.B., Guessous, I., Kivipelto, M., Marizzoni, M., Martinez-Lage, P., Molinuevo, J.L., Porteous, D., Ritchie, K., Scheltens, P., Ousset, P.-J., Ritchie, C.W., Luscan, G., Brookes, A.J., Visser, P.J., 2018. European Prevention of Alzheimer’s Dementia Registry: Recruitment and prescreening approach for a longitudinal cohort and prevention trials. Alzheimers. Dement. 14, 837–842. https://doi.org/10.1016/j.jalz.2018.02.010
138. Vijverberg, E.G.B., Gossink, F., Krudop, W., Dols, A., Pijnenburg, Y.A.L., 2018. . Ned. Tijdschr. Geneeskd. 162.
139. Vogel, J.W., Mattsson, N., Iturria-Medina, Y., Strandberg, O.T., Scholl, M., Dansereau, C., Villeneuve, S., van der Flier, W.M., Scheltens, P., Bellec, P., Evans, A.C., Hansson, O., Ossenkoppele, R., 2018. Data-driven approaches for tau-PET imaging biomarkers in Alzheimer’s disease. Hum. Brain Mapp. https://doi.org/10.1002/hbm.24401
140. Vos, S.J.B., Visser, P.J., 2018. Preclinical Alzheimer’s Disease: Implications for Refinement of the Concept. J. Alzheimers. Dis. 64, S213–S227. https://doi.org/10.3233/JAD-179943
141. Walker, Z., Gandolfo, F., Orini, S., Garibotto, V., Agosta, F., Arbizu, J., Bouwman, F., Drzezga, A., Nestor, P., Boccardi, M., Altomare, D., Festari, C., Nobili, F., 2018. Clinical utility of FDG PET in Parkinson’s disease and atypical parkinsonism associated with dementia. Eur. J. Nucl. Med. Mol. Imaging 45, 1534–1545. https://doi.org/10.1007/s00259-018-4031-2
142. Weintraub, S., Carrillo, M.C., Farias, S.T., Goldberg, T.E., Hendrix, J.A., Jaeger, J., Knopman, D.S., Langbaum, J.B., Park, D.C., Ropacki, M.T., Sikkes, S.A.M., Welsh-Bohmer, K.A., Bain, L.J., Brashear, R., Budur, K., Graf, A., Martenyi, F., Storck, M.S., Randolph, C., 2018. Measuring cognition and function in the preclinical stage of Alzheimer’s disease. Alzheimer’s Dement. (New York, N. Y.) 4, 64–75. https://doi.org/10.1016/j.trci.2018.01.003
143. Wesselman, L.M.P., Schild, A.-K., Coll-Padros, N., van der Borg, W.E., Meurs, J.H.P., Hooghiemstra, A.M., Slot, R.E.R., Sannemann, L., Rami, L., Molinuevo, J.L., Bouwman, F.H., Jessen, F., van der Flier, W.M., Sikkes, S.A.M., 2018. Wishes and preferences for an online lifestyle program for brain health-A mixed methods study. Alzheimer’s Dement. (New York, N. Y.) 4, 141–149. https://doi.org/10.1016/j.trci.2018.03.003
144. Willemse, E.A.J., De Vos, A., Herries, E.M., Andreasson, U., Engelborghs, S., van der Flier, W.M., Scheltens, P., Crimmins, D., Ladenson, J.H., Vanmechelen, E., Zetterberg, H., Fagan, A.M., Blennow, K., Bjerke, M., Teunissen, C.E., 2018. Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study. Clin. Chem. 64, 927–937. https://doi.org/10.1373/clinchem.2017.283028
145. Willemse, E.A.J., van Maurik, I.S., Tijms, B.M., Bouwman, F.H., Franke, A., Hubeek, I., Boelaarts, L., Claus, J.J., Korf, E.S.C., van Marum, R.J., Roks, G., Schoonenboom, N., Verwey, N., Zwan, M.D., Wahl, S., van der Flier, W.M., Teunissen, C.E., 2018. Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer’s disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project. Alzheimer’s Dement. (Amsterdam, Netherlands) 10, 563–572. https://doi.org/10.1016/j.dadm.2018.08.006
146. Wink, A.M., Tijms, B.M., Ten Kate, M., Raspor, E., de Munck, J.C., Altena, E., Ecay-Torres, M., Clerigue, M., Estanga, A., Garcia-Sebastian, M., Izagirre, A., Martinez-Lage Alvarez, P., Villanua, J., Barkhof, F., Sanz-Arigita, E., 2018. Functional brain network centrality is related to APOE genotype in cognitively normal elderly. Brain Behav. 8, e01080. https://doi.org/10.1002/brb3.1080
147. Wolters, E.E., Golla, S.S. V, Timmers, T., Ossenkoppele, R., van der Weijden, C.W.J., Scheltens, P., Schwarte, L., Schuit, R.C., Windhorst, A.D., Barkhof, F., Yaqub, M., Lammertsma, A.A., Boellaard, R., van Berckel, B.N.M., 2018. A novel partial volume correction method for accurate quantification of [(18)F] flortaucipir in the hippocampus. EJNMMI Res. 8, 79. https://doi.org/10.1186/s13550-018-0432-2
148. Wong, T.H., van der Lee, S.J., van Rooij, J.G.J., Meeter, L.H.H., Frick, P., Melhem, S., Seelaar, H., Ikram, M.A., Rozemuller, A.J., Holstege, H., Hulsman, M., Uitterlinden, A., Neumann, M., Hoozemans, J.J.M., van Duijn, C.M., Rademakers, R., van Swieten, J.C., 2019. EIF2AK3 variants in Dutch patients with Alzheimer’s disease. Neurobiol. Aging 73, 229.e11-229.e18. https://doi.org/10.1016/j.neurobiolaging.2018.08.016
149. Zhang, M., Ferrari, R., Tartaglia, M.C., Keith, J., Surace, E.I., Wolf, U., Sato, C., Grinberg, M., Liang, Y., Xi, Z., Dupont, K., McGoldrick, P., Weichert, A., McKeever, P.M., Schneider, R., McCorkindale, M.D., Manzoni, C., Rademakers, R., Graff-Radford, N.R., Dickson, D.W., Parisi, J.E., Boeve, B.F., Petersen, R.C., Miller, B.L., Seeley, W.W., van Swieten, J.C., van Rooij, J., Pijnenburg, Y., van der Zee, J., Van Broeckhoven, C., Le Ber, I., Van Deerlin, V., Suh, E., Rohrer, J.D., Mead, S., Graff, C., Oijerstedt, L., Pickering-Brown, S., Rollinson, S., Rossi, G., Tagliavini, F., Brooks, W.S., Dobson-Stone, C., Halliday, G.M., Hodges, J.R., Piguet, O., Binetti, G., Benussi, L., Ghidoni, R., Nacmias, B., Sorbi, S., Bruni, A.C., Galimberti, D., Scarpini, E., Rainero, I., Rubino, E., Clarimon, J., Lleo, A., Ruiz, A., Hernandez, I., Pastor, P., Diez-Fairen, M., Borroni, B., Pasquier, F., Deramecourt, V., Lebouvier, T., Perneczky, R., Diehl-Schmid, J., Grafman, J., Huey, E.D., Mayeux, R., Nalls, M.A., Hernandez, D., Singleton, A., Momeni, P., Zeng, Z., Hardy, J., Robertson, J., Zinman, L., Rogaeva, E., 2018. A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Brain 141, 2895–2907. https://doi.org/10.1093/brain/awy238

1. Aalfs CM, Vervenne-van Spaendonk R, Pijnenburg YAL, Cohn-Hokke PE, Meijers HJ, Scheltens P. DNA diagnostics in dementia. Ned Tijdschr Geneeskd. 2017;161(0):D1774. Dutch.
2. Abushakra S, Porsteinsson A, Scheltens P, Sadowsky C, Vellas B, Cummings J, Gauthier S, Hey JA, Power A, Wang P, Shen L, Tolar M. Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer’s Disease Suggest Disease Modification Potential. J Prev Alzheimers Dis. 2017;4(3):149-156. doi: 10.14283/jpad.2017.26.
3. Aisen PS, Cummings J, Jack CR Jr, Morris JC, Sperling R, Frölich L, Jones RW, Dowsett SA, Matthews BR, Raskin J, Scheltens P, Dubois B. On the path to 2025: understanding the Alzheimer’s disease continuum. Alzheimers Res Ther. 2017 Aug 9;9(1):60. doi: 10.1186/s13195-017-0283-5. Review.
4. Babapour Mofrad R, Bouwman FH, Slot RER, Timmers T, van der Flier WM, Scheltens P, Teunissen CE. Lumbar puncture in patients with neurologic conditions. Alzheimers Dement (Amst). 2017 May 18;8:108-110. doi: 10.1016/j.dadm.2017.04.008.
5. Benedictus MR, Leeuwis AE, Binnewijzend MA, Kuijer JP, Scheltens P, Barkhof F, van der Flier WM, Prins ND. Lower cerebral blood flow is associated with faster cognitive decline in Alzheimer’s disease. Eur Radiol. 2017 Mar;27(3):1169-1175. doi: 10.1007/s00330-016-4450-z.
6. Bertens D, Tijms BM, Scheltens Ph, Teunissen CE, Visser PJ. Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population. Alzheimer’s Research & Therapy.2017;9(8).DOI: 10.1186/s13195-016-0233-7
7. Bertens D, Tijms BM, Vermunt L, Prins ND, Scheltens P, Visser PJ. The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer’s disease: Implications for trial design. Alzheimers Dement (N Y). 2017 Sep 21;3(4):513-523. doi: 10.1016/j.trci.2017.08.005.
8. Boomsma JMF, Exalto LG, Barkhof F, van den Berg E, de Bresser J, Heinen R, Koek HL, Prins ND, Scheltens P, Weinstein HC, van der Flier WM, Biessels GJ. Vascular Cognitive Impairment in a Memory Clinic Population: Rationale and Design of the “Utrecht-Amsterdam Clinical Features and Prognosis in Vascular Cognitive Impairment” (TRACE-VCI) Study.  JMIR Res Protoc. 2017 Apr 19;6(4):e60. doi: 10.2196/resprot.6864.
9. Bos I, Vos SJ, Frölich L, Kornhuber J, Wiltfang J, Maier W, Peters O, Rüther E, Engelborghs S, Niemantsverdriet E, De Roeck EE, Tsolaki M, Freund-Levi Y, Johannsen P, Vandenberghe R, Lleó A, Alcolea D, Frisoni GB, Galluzzi S, Nobili F, Morbelli S, Drzezga A, Didic M, van Berckel BN, Salmon E, Bastin C, Dauby S, Santana I, Baldeiras I, de Mendonça A, Silva D, Wallin A, Nordlund A, Coloma PM, Wientzek A, Alexander M, Novak GP, Gordon MF; Alzheimer’s Disease Neuroimaging Initiative, Wallin ÅK, Hampel H, Soininen H, Herukka SK, Scheltens P, Verhey FR, Visser PJ. The frequency and influence of dementia risk factors in prodromal Alzheimer’s disease.Neurobiol Aging. 2017 Aug;56:33-40. doi: 10.1016/j.neurobiolaging.2017.03.034.
10. Bridel C, Hoffmann T, Meyer A, Durieux S, Koel-Simmelink MA, Orth M, Scheltens P, Lues I, Teunissen CE. Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer’s disease patients. Alzheimers Res Ther. 2017 Jun 6;9(1):38. doi: 10.1186/s13195-017-0266-6.
11. Cha DS, Carmona NE, Mansur RB, Lee Y, Park HJ, Rodrigues NB, Subramaniapillaia M, Rosenblat JD, Pan Z, Lee JH, Lee JG, Almatham F, Alageel A, Shekotokhina M, Zhou AJ, Rong C, Harrison JE, McIntyre RS. Pain and major depressive disorder: Associations with cognitive impairment as measured by the THINC-integrated tool (THINC-it). Scandinavian Journal of Pain. 2017:1;62–67. doi: 10.1016/j.sjpain.2016.12.004.
12. Cha DS, Carmona NW, Subramaniapillai M, Mansur RB, Lee Y, Lee JH, Lee J, Rosenbalt JD, Shekotikhina M, Park C, Rong C, Greer TL, Lam R, Baune BT, Harrison J, McIntye RS. Cognitive impairment as measured by the THINC-integrated tool (THINC-it): Association with psychosocial function in major depressive disorder. Journal of Affective Disorders. J Affect Disord. 2017:222;14-20. doi: 10.1016/j.jad.2017.06.036.
13. Chakraborty A, de Wit NM, van der Flier WM, de Vries HE. The blood brain barrier in Alzheimer’s disease. Vascul Pharmacol. 2017 Feb;89:12-18. doi: 10.1016/j.vph.2016.11.008. Epub 2016 Nov 25. Review.
14. Chatterjee M, Nöding B, Willemse EAJ, Koel-Simmelink MJA, van der Flier WM, Schild D, Teunissen CE. Detection of contactin-2 in cerebrospinal fluid (CSF) of patients with Alzheimer’s disease using Fluorescence Correlation Spectroscopy (FCS). Clin Biochem. 2017 Dec;50(18):1061-1066. doi: 10.1016/j.clinbiochem.2017.08.017.
15. Claus JJ, Staekenborg SS, Holl DC, Roorda JJ, Schuur J, Koster P, Tielkes CEM, Scheltens P. Practical use of visual medial temporal lobe atrophy cut-off scores in Alzheimer’s disease: Validation in a large memory clinic population. Eur Radiol. 2017 Aug;27(8):3147-3155. doi: 10.1007/s00330-016-4726-3.
16. Cohn-Hokke PE, Holstege H, Weiss MM, van der Flier WM, Barkhof F, Sistermans EA, Pijnenburg YA, van Swieten JC, Meijers-Heijboer H, Scheltens P. A novel CCM2 variant in a family with non-progressive cognitive complaints and cerebral microbleeds. Am J Med Genet B Neuropsychiatr Genet. 2017 Apr;174(3):220-226. doi: 10.1002/ajmg.b.32468.
17. Costa A, Bak T, Caffarra P, Caltagirone C, Ceccaldi M, Collette F, Crutch S, Della Sala S, Démonet JF, Dubois B, Duzel E, Nestor P, Papageorgiou SG, Salmon E, Sikkes S, Tiraboschi P, van der Flier WM, Visser PJ, Cappa SF. The need for harmonisation and innovation of neuropsychological assessment in neurodegenerative dementias in Europe: consensus document of the Joint Program for Neurodegenerative Diseases Working Group. Alzheimers Res Ther. 2017 Apr 17;9(1):27. doi: 10.1186/s13195-017-0254-x. Review.
18. Crutch SJ, Schott JM, Rabinovici GD, Murray M, Snowden JS, van der Flier WM, Dickerson BC, Vandenberghe R, Ahmed S, Bak TH, Boeve BF, Butler C, Cappa SF, Ceccaldi M, de Souza LC, Dubois B, Felician O, Galasko D, Graff-Radford J, Graff-Radford NR, Hof PR, Krolak-Salmon P, Lehmann M, Magnin E, Mendez MF, Nestor PJ, Onyike CU, Pelak VS, Pijnenburg Y, Primativo S, Rossor MN, Ryan NS, Scheltens P, Shakespeare TJ, Suárez González A, Tang-Wai DF, Yong KXX, Carrillo M, Fox NC; Alzheimer’s Association ISTAART Atypical Alzheimer’s Disease and Associated Syndromes Professional Interest Area. Consensus classification of posterior cortical atrophy. Alzheimers Dement. 2017 Aug;13(8):870-884. doi: 10.1016/j.jalz.2017.01.014.
19. Cummings J, Scheltens P, McKeith I, Blesa R, Harrison JE, Bertolucci PH, Rockwood K, Wilkinson D, Wijker W, Bennett DA, Shah RC. Effect Size Analyses of Souvenaid in Patients with Alzheimer’s Disease.
20. Size Analyses of Souvenaid in Patients with Alzheimer’s Disease. J Alzheimers Dis. 2017;55(3):1131-1139.
21. de Leeuw FA, Peeters CFW, Kester MI, Harms AC, Struys EA, Hankemeier T, van Vlijmen HWT, van der Lee SJ, van Duijn CM, Scheltens P, Demirkan A, van de Wiel MA, van der Flier WM, Teunissen CE. Blood-based metabolic signatures in Alzheimer’s disease. Alzheimers Dement (Amst). 2017 Sep 6;8:196-207. doi: 10.1016/j.dadm.2017.07.006.
22. de Wilde A, van Maurik IS, Kunneman M, Bouwman F, Zwan M, Willemse EA, Biessels GJ, Minkman M, Pel R, Schoonenboom NS, Smets EM, Wattjes MP, Barkhof F, Stephens A, van Lier EJ, Batrla-Utermann R, Scheltens P, Teunissen CE, van Berckel BN, van der Flier WM. Alzheimer’s biomarkers in daily practice (ABIDE) project: Rationale and design. Alzheimers Dement (Amst). 2017 Jan 23;6:143-151. doi: 10.1016/j.dadm.2017.01.003. eCollection 2017.
23. Demuru M, Gouw AA, Hillebrand A, Stam CJ, van Dijk BW, Scheltens P, Tijms BM, Konijnenberg E, Ten Kate M, den Braber A, Smit DJA, Boomsma DI, Visser PJ. Functional and effective whole brain connectivity using magnetoencephalography to identify monozygotic twin pairs. Sci Rep. 2017 Aug 29;7(1):9685. doi: 10.1038/s41598-017-10235-y.
24. den Haan J, Verbraak FD, Visser PJ, Bouwman FH. Retinal thickness in Alzheimer’s disease: A systematic review and meta-analysis. Alzheimers Dement (Amst). 2017 Jan 25;6:162-170. doi: 10.1016/j.dadm.2016.12.014. eCollection 2017.
25. Dicks E, Tijms BM, Ten Kate M, Gouw AA, Benedictus MR, Teunissen CE, Barkhof F, Scheltens P, van der Flier WM. Gray matter network measures are associated with cognitive decline in mild cognitive impairment. Neurobiol Aging. 2018 Jan;61:198-206. doi: 10.1016/j.neurobiolaging.2017.09.029.
26. Engelborghs S, Niemantsverdriet E, Struyfs H, Blennow K, Brouns R, Comabella M, Dujmovic I, van der Flier W, Frölich L, Galimberti D, Gnanapavan S, Hemmer B, Hoff E, Hort J, Iacobaeus E, Ingelsson M, Jan de Jong F, Jonsson M, Khalil M, Kuhle J, Lleó A, de Mendonça A, Molinuevo JL, Nagels G, Paquet C, Parnetti L, Roks G, Rosa-Neto P, Scheltens P, Skårsgard C, Stomrud E, Tumani H, Visser PJ, Wallin A, Winblad B, Zetterberg H, Duits F, Teunissen CE. Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimers Dement (Amst). 2017 May 18;8:111-126. doi: 10.1016/j.dadm.2017.04.007.
27. Engels MMA, van der Flier WM, Stam CJ, Hillebrand A, Scheltens P, van Straaten ECW. Alzheimer’s disease: The state of the art in resting-state magnetoencephalography. Clin Neurophysiol. 2017 Aug;128(8):1426-1437. doi: 10.1016/j.clinph.2017.05.012. Epub 2017 May 21. Review.
28. Engels MMA, Yu M, Stam CJ, Gouw AA, van der Flier WM, Scheltens P, van Straaten ECW, Hillebrand A. Directional information flow in patients with Alzheimer’s disease. A source-space resting-state MEG study. Neuroimage Clin. 2017 Jun 17;15:673-681. doi: 10.1016/j.nicl.2017.06.025. eCollection 2017.
29. Freeze WM, Jacobs HI, Gronenschild EH, Jansen JF, Burgmans S, Aalten P, Clerx L, Vos SJ, van Buchem MA, Barkhof F, van der Flier WM, Verbeek MM, Rikkert MO, Backes WH, Verhey FR; LeARN project. White Matter Hyperintensities Potentiate Hippocampal Volume Reduction in Non-Demented Older Individuals with Abnormal Amyloid-β. J Alzheimers Dis. 2017;55(1):333-342.
30. Frisoni GB, Boccardi M, Barkhof F, Blennow K, Cappa S, Chiotis K, Démonet JF, Garibotto V, Giannakopoulos P, Gietl A, Hansson O, Herholz K, Jack CR Jr, Nobili F, Nordberg A, Snyder HM, Ten Kate M, Varrone A, Albanese E, Becker S, Bossuyt P, Carrillo MC, Cerami C, Dubois B, Gallo V, Giacobini E, Gold G, Hurst S, Lönneborg A, Lovblad KO, Mattsson N, Molinuevo JL, Monsch AU, Mosimann U, Padovani A, Picco A, Porteri C, Ratib O, Saint-Aubert L, Scerri C, Scheltens P, Schott JM, Sonni I, Teipel S, Vineis P, Visser PJ, Yasui Y, Winblad B. Strategic roadmap for an early diagnosis of Alzheimer’s disease based on biomarkers. Lancet Neurol. 2017 Aug;16(8):661-676. doi: 10.1016/S1474-4422(17)30159-X. Epub 2017 Jul 11. Review.
31. Fuermaier AB, Piersma D, de Waard D, Davidse RJ, de Groot J, Doumen MJ, Bredewoud RA, Claesen R, Lemstra AW, Scheltens P, Vermeeren A, Ponds R, Verhey F, Brouwer WH, Tucha O. Assessing fitness to drive-A validation study on patients with mild cognitive impairment. Traffic Inj Prev. 2017 Feb 17;18(2):145-149. doi: 10.1080/15389588.2016.1232809
32. Geijselaers SLC, Aalten P, Ramakers IHGB, De Deyn PP, Heijboer AC, Koek HL, OldeRikkert MGM, Papma JM, Reesink FE, Smits LL, Stehouwer CDA, Teunissen CE, Verhey FRJ, van der Flier WM, Biessels GJ; Parelsnoer Institute Neurodegenerative Diseases study group. Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer’s Disease. J Alzheimers Dis. 2017 Nov 16. doi: 10.3233/JAD-170522.
33. Golla SSV, Timmers T, Ossenkoppele R, Groot C, Verfaillie S, Scheltens P, van der Flier WM, Schwarte L, Mintun MA, Devous M, Schuit RC, Windhorst AD, Lammertsma AA, Boellaard R, van Berckel BNM, Yaqub M. Quantification of Tau Load Using [18F]AV1451 PET. Mol Imaging Biol. 2017 Dec;19(6):963-971. doi: 10.1007/s11307-017-1080-z.
34. Gossink FT, Vijverberg EG, Krudop W, Scheltens P, Stek ML, Pijnenburg YA, Dols A. Psychosis in behavioral variant frontotemporal dementia.Neuropsychiatr Dis Treat. 2017 Apr 13;13:1099-1106. doi: 10.2147/NDT.S127863.
35. Gouw AA, Alsema AM, Tijms BM, Borta A, Scheltens P, Stam CJ, van der Flier WM. EEG spectral analysis as a putative early prognostic biomarker in nondemented, amyloid positive subjects. Neurobiol Aging. 2017 Sep;57:133-142. doi: 10.1016/j.neurobiolaging.2017.05.017.
36. Groot C, van Loenhoud AC, Barkhof F, van Berckel BNM, Koene T, Teunissen CC, Scheltens P, van der Flier WM, Ossenkoppele R. Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease. Neurology. 2017 Dec 13. pii: 10.1212/WNL.0000000000004802. doi: 10.1212/WNL.0000000000004802
37. Hafkemeijer A, Möller C, Dopper EG, Jiskoot LC, van den Berg-Huysmans AA, van Swieten JC, van der Flier WM, Vrenken H, Pijnenburg YA, Barkhof F, Scheltens P, van der Grond J, Rombouts SA. A Longitudinal Study on Resting State Functional Connectivity in Behavioral Variant Frontotemporal Dementia and Alzheimer’s Disease. J Alzheimers Dis. 2017;55(2):521-537.
38. Handels RLH, Vos SJB, Kramberger MG, Jelic V, Blennow K, van Buchem M, van der Flier W, Freund-Levi Y, Hampel H, Olde Rikkert M, Oleksik A, Pirtosek Z, Scheltens P, Soininen H, Teunissen C, Tsolaki M, Wallin AK, Winblad B, Verhey FRJ, Visser PJ. Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers.Alzheimers Dement. 2017 Aug;13(8):903-912. doi: 10.1016/j.jalz.2016.12.015.
39. Handels RLH, Wimo A, Dodel R, Kramberger MG, Visser PJ, Molinuevo JL, Verhey FRJ, Winblad B. Cost-Utility of Using Alzheimer’s Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia. J Alzheimers Dis. 2017;60(4):1477-1487. doi: 10.3233/JAD-170324.
40. Harper L, Bouwman F, Burton EJ, Barkhof F, Scheltens P, O’Brien JT, Fox NC, Ridgway GR, Schott JM. Patterns of atrophy in pathologically confirmed dementias: a voxelwise analysis. J Neurol Neurosurg Psychiatry. 2017 Nov;88(11):908-916. doi: 10.1136/jnnp-2016-314978.
41. Harvey PD, Sabbagh M, Harrison JE, Ginsberg HN, Chapman MJ, Manvelian G, Moryusef A, Mandel J, Farnier M. No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials. European Heart Journal. 2017:39;374–381. http://dx.doi.org/10.1093/eurheartj/ehx661.
42. Herukka SK, Simonsen AH, Andreasen N, Baldeiras I, Bjerke M, Blennow K, Engelborghs S, Frisoni GB, Gabryelewicz T, Galluzzi S, Handels R, Kramberger MG, Kulczyńska A, Molinuevo JL, Mroczko B, Nordberg A, Oliveira CR, Otto M, Rinne JO, Rot U, Saka E, Soininen H, Struyfs H, Suardi S, Visser PJ, Winblad B, Zetterberg H, Waldemar G. Recommendations for cerebrospinal fluid Alzheimer’s disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimers Dement. 2017 Mar;13(3):285-295. doi: 10.1016/j.jalz.2016.09.009. Epub 2016 Oct 27. Review.
43. Holstege H, van der Lee SJ, Hulsman M, Wong TH, van Rooij JG, Weiss M, Louwersheimer E, Wolters FJ, Amin N, Uitterlinden AG, Hofman A, Ikram MA, van Swieten JC, Meijers-Heijboer H, van der Flier WM, Reinders MJ, van Duijn CM, Scheltens P. Characterization of pathogenic SORL1 genetic variants for association with Alzheimer’s disease: a clinical interpretation strategy. Eur J Hum Genet. 2017 Aug;25(8):973-981. doi: 10.1038/ejhg.2017.87.
44. Hooghiemstra AM, Bertens AS, Leeuwis AE, Bron EE, Bots ML, Brunner-La Rocca HP, de Craen AJM, van der Geest RJ, Greving JP, Kappelle LJ, Niessen WJ, van Oostenbrugge RJ, van Osch MJP, de Roos A, van Rossum AC, Biessels GJ, van Buchem MA, Daemen MJAP, van der Flier WM; Heart-Brain Connection Consortium. The Missing Link in the Pathophysiology of Vascular Cognitive Impairment: Design of the Heart-Brain Study.Cerebrovasc Dis Extra. 2017 Oct 10;7(3):140-152. doi: 10.1159/000480738.
45. Hooghiemstra AM, Ramakers IHGB, Sistermans N, Pijnenburg YAL, Aalten P, Hamel REG3, Melis RJF, Verhey FRJ, Olde Rikkert MGM, Scheltens P, van der Flier WM; 4C Study Group. Gait Speed and Grip Strength Reflect Cognitive Impairment and Are Modestly Related to Incident Cognitive Decline in Memory Clinic Patients With Subjective Cognitive Decline and Mild Cognitive Impairment: Findings From the 4C Study.J Gerontol A Biol Sci Med Sci. 2017 Jun 1;72(6):846-854. doi: 10.1093/gerona/glx003.
46. Jansen WJ, Handels RL, Visser PJ, Aalten P, Bouwman F, Claassen J, van Domburg P, Hoff E, Hoogmoed J, Leentjens AF, Rikkert MO, Oleksik AM, Smid M, Scheltens P, Wolfs C, Verhey F, Ramakers IH. The Diagnostic and Prognostic Value of Neuropsychological Assessment in Memory Clinic Patients. J Alzheimers Dis. 2017;55(2):679-689.
47. Jansen WJ, Ossenkoppele R, Tijms BM, Fagan AM, Hansson O, Klunk WE, van der Flier WM, Villemagne VL, Frisoni GB, Fleisher AS, Lleó A, Mintun MA, Wallin A, Engelborghs S, Na DL, Chételat G, Molinuevo JL, Landau SM, Mattsson N, Kornhuber J, Sabri O, Rowe CC, Parnetti L, Popp J, Fladby T, Jagust WJ, Aalten P, Lee DY, Vandenberghe R, Resende de Oliveira C, Kapaki E, Froelich L, Ivanoiu A, Gabryelewicz T, Verbeek MM, Sanchez-Juan P, Hildebrandt H, Camus V, Zboch M, Brooks DJ, Drzezga A, Rinne JO, Newberg A, de Mendonça A, Sarazin M, Rabinovici GD, Madsen K, Kramberger MG, Nordberg A, Mok V, Mroczko B, Wolk DA, Meyer PT, Tsolaki M, Scheltens P, Verhey FRJ, Visser PJ; Amyloid Biomarker Study Group, Aarsland D, Alcolea D, Alexander M, Almdahl IS, Arnold SE, Baldeiras I, Barthel H, van Berckel BNM, Blennow K, van Buchem MA, Cavedo E, Chen K, Chipi E, Cohen AD, Förster S, Fortea J, Frederiksen KS, Freund-Levi Y, Gkatzima O, Gordon MF, Grimmer T, Hampel H, Hausner L, Hellwig S, Herukka SK, Johannsen P, Klimkowicz-Mrowiec A, Köhler S, Koglin N, van Laere K, de Leon M, Lisetti V, Maier W, Marcusson J, Meulenbroek O, Møllergård HM, Morris JC, Nordlund A, Novak GP, Paraskevas GP, Perera G, Peters O, Ramakers IHGB, Rami L, Rodríguez-Rodríguez E, Roe CM, Rot U, Rüther E, Santana I, Schröder J, Seo SW, Sorininen H, Spiru L, Stomrud E, Struyfs H, Teunissen CE, Vos SJB, van Waalwijk van Doorn LJC, Waldemar G, Wallin ÅK, Wiltfang J, Zetterberg H. Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry. 2017 Nov 29. doi: 10.1001/jamapsychiatry.2017.3391
48. Jansen WJ, Wilson RS, Visser PJ, Nag S, Schneider JA, James BD, Leurgans SE, Capuano AW, Bennett DA, Boyle PA. Age and the association of dementia-related pathology with trajectories of cognitive decline. Neurobiol Aging. 2018 Jan;61:138-145. doi: 10.1016/j.neurobiolaging.2017.08.029
49. Jutten RJ, Harrison J, de Jong FJ, Alemand A, Ritchiee CW, Scheltens Ph Sikkes SAM. A composite measure of cognitive and functional progression in Alzheimer’s disease: Design of the Capturing Changes in Cognition study. Alzheimer’s & Dementia: Translational Research & Clinical Interventions. 2017;3(1):130-138.
50. Jutten RJ, Peeters CFW, Leijdesdorff SMJ, Visser PJ, Maier AB, Terwee CB, Scheltens P, Sikkes SAM. Detecting functional decline from normal aging to dementia: Development and validation of a short version of the Amsterdam IADL Questionnaire. Alzheimers Dement (Amst). 2017 Mar 31;8:26-35. doi: 10.1016/j.dadm.2017.03.002. eCollection 2017
51. Konijnenberg E, Fereshtehnejad SM, Kate MT, Eriksdotter M, Scheltens P, Johannsen P, Waldemar G, Visser PJ. Early-Onset Dementia: Frequency, Diagnostic Procedures, and Quality Indicators in Three European Tertiary Referral Centers. Alzheimer Dis Assoc Disord. 2017 Apr-Jun;31(2):146-151. doi: 10.1097/WAD.0000000000000152.
52. Krudop WA, Dols A, Kerssens CJ, Eikelenboom P, Prins ND, Möller C, Schouws S, Rhebergen D, van Exel E, van der Flier WM, Sikkes S, Scheltens P, Stek ML, Pijnenburg YAL. The Pitfall of Behavioral Variant Frontotemporal Dementia Mimics Despite Multidisciplinary Application of the FTDC Criteria.J Alzheimers Dis. 2017;60(3):959-975. doi: 10.3233/JAD-170608.
53. Kun-Rodrigues C, Ross OA, Orme T, Shepherd C, Parkkinen L, Darwent L, Hernandez D, Ansorge O, Clark LN, Honig LS, Marder K, Lemstra A, Scheltens P, van der Flier W, Louwersheimer E, Holstege H, Rogaeva E, St George-Hyslop P, Londos E, Zetterberg H, Barber I, Braae A, Brown K, Morgan K, Maetzler W, Berg D, Troakes C, Al-Sarraj S, Lashley T, Holton J, Compta Y, Van Deerlin V, Trojanowski JQ, Serrano GE, Beach TG, Clarimon J, Lleó A, Morenas-Rodríguez E, Lesage S, Galasko D, Masliah E, Santana I, Diez M, Pastor P, Tienari PJ, Myllykangas L, Oinas M, Revesz T, Lees A, Boeve BF, Petersen RC, Ferman TJ, Escott-Price V, Graff-Radford N, Cairns NJ, Morris JC, Stone DJ, Pickering-Brown S, Mann D, Dickson DW, Halliday GM, Singleton A, Guerreiro R, Bras J. Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. Neurobiol Aging. 2017 Jan;49:214.e13-214.e15. doi: 10.1016/j.neurobiolaging.2016.08.023.
54. Kunneman M, Pel-Littel R, Bouwman FH, Gillissen F, Schoonenboom NSM, Claus JJ, van der Flier WM, Smets EMA. Patients’ and caregivers’ views on conversations and shared decision making in diagnostic testing for Alzheimer’s disease: The ABIDE project. Alzheimers Dement (N Y). 2017 May 10;3(3):314-322. doi: 10.1016/j.trci.2017.04.002.
55. Kunneman M, Smets EMA, Bouwman FH, Schoonenboom NSM, Zwan MD, Pel-Littel R, van der Flier WM. Clinicians’ views on conversations and shared decision making in diagnostic testing for Alzheimer’s disease: The ABIDE project. Alzheimers Dement (N Y). 2017 May 10;3(3):305-313. doi: 10.1016/j.trci.2017.03.009.
56. Lacour A, Espinosa A, Louwersheimer E, Heilmann S, Hernández I, Wolfsgruber S, Fernández V, Wagner H, Rosende-Roca M, Mauleón A, Moreno-Grau S, Vargas L, Pijnenburg YA, Koene T, Rodríguez-Gómez O, Ortega G, Ruiz S, Holstege H, Sotolongo-Grau O, Kornhuber J, Peters O, Frölich L, Hüll M, Rüther E, Wiltfang J, Scherer M, Riedel-Heller S, Alegret M, Nöthen MM, Scheltens P, Wagner M, Tárraga L, Jessen F, Boada M, Maier W, van der Flier WM, Becker T, Ramirez A, Ruiz A. Genome-wide significant risk factors for Alzheimer’s disease: role in progression to dementia due to Alzheimer’s disease among subjects with mild cognitive impairment. Mol Psychiatry. 2017 Jan;22(1):153-160. doi: 10.1038/mp.2016.18.
57. Leeuwis AE, Benedictus MR, Kuijer JPA, Binnewijzend MAA, Hooghiemstra AM, Verfaillie SCJ, Koene T, Scheltens P, Barkhof F, Prins ND, van der Flier WM. Lower cerebral blood flow is associated with impairment in multiple cognitive domains in Alzheimer’s disease. Alzheimers Dement. 2017 May;13(5):531-540. doi: 10.1016/j.jalz.2016.08.013.
58. Leeuwis AE, Hooghiemstra AM, Amier R, Ferro DA, Franken L, Nijveldt R, Kuijer JPA, Bronzwaer ASGT, van Lieshout JJ, Rietberg MB, Veerbeek JM, Huijsmans RJ, Backx FJG, Teunissen CE, Bron EE, Barkhof F, Prins ND, Shahzad R, Niessen WJ, de Roos A, van Osch MJP, van Rossum AC, Biessels GJ, van der Flier WM: on behalf of the Heart Brain Connection study group. Design of the ExCersion-VCI study: The effect of aerobic exercise on cerebral perfusion in patients with vascular cognitive impairment.Alzheimer’s & Dementia: Translational Research & Clinical Interventions. 2017 June;3 (2):157–16. DOI: http://dx.doi.org/10.1016/j.trci.2017.02.002
59. Legdeur N, Binnekade TT, Otten RH, Badissi M, Scheltens P, Visser PJ, Maier AB. Cognitive functioning of individuals aged 90 years and older without dementia: A systematic review. Ageing Res Rev. 2017 Mar 8;36:42-49. doi: 10.1016/j.arr.2017.02.006.
60. Leijenaar JF, van Maurik IS, Kuijer JPA, van der Flier WM, Scheltens P, Barkhof F, Prins ND. Lower cerebral blood flow in subjects with Alzheimer’s dementia, mild cognitive impairment, and subjective cognitive decline using two-dimensional phase-contrast magnetic resonance imaging.Alzheimers Dement (Amst). 2017 Nov 2;9:76-83. doi: 10.1016/j.dadm.2017.10.001.
61. Lemstra AW, de Beer MH, Teunissen CE, Schreuder C, Scheltens P, van der Flier WM, Sikkes SA. Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2017 Feb;88(2):113-118. doi: 10.1136/jnnp-2016-313775.
62. Lewczuk P, Riederer P, O’Bryant SE, Verbeek MM, Dubois B, Visser PJ, Jellinger KA, Engelborghs S, Ramirez A, Parnetti L, Jack CR Jr, Teunissen CE, Hampel H, Lleó A, Jessen F, Glodzik L, de Leon MJ, Fagan AM, Molinuevo JL, Jansen WJ, Winblad B, Shaw LM, Andreasson U, Otto M, Mollenhauer B, Wiltfang J, Turner MR, Zerr I, Handels R, Thompson AG, Johansson G, Ermann N, Trojanowski JQ, Karaca I, Wagner H, Oeckl P, van Waalwijk van Doorn L, Bjerke M, Kapogiannis D, Kuiperij HB, Farotti L, Li Y, Gordon BA, Epelbaum S, Vos SJB, Klijn CJM, Van Nostrand WE, Minguillon C, Schmitz M, Gallo C, Lopez Mato A, Thibaut F, Lista S, Alcolea D, Zetterberg H, Blennow K, Kornhuber J; Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence Thibaut. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World J Biol Psychiatry. 2017 Oct 27:1-85. doi: 10.1080/15622975.2017.1375556.
63. López ME, Engels MMA, van Straaten ECW, Bajo R, Delgado ML, Scheltens Ph, Hillebrand A,. Stam CJ, Maestú F. MEG Beamformer-Based Reconstructions of Functional Networks in Mild Cognitive Impairment.Front. Aging Neurosci., 25 April 2017. https://doi.org/10.3389/fnagi.2017.00107
64. Louwersheimer E, Cohn-Hokke PE, Pijnenburg YA, Weiss MM, Sistermans EA, Rozemuller AJ, Hulsman M, van Swieten JC, van Duijn CM, Barkhof F, Koene T, Scheltens P, Van der Flier WM, Holstege H. Rare Genetic Variant in SORL1 May Increase Penetrance of Alzheimer’s Disease in a Family with Several Generations of APOE-ɛ4 Homozygosity. J Alzheimers Dis. 2017;56(1):63-74. doi: 10.3233/JAD-160091.
65. McIntyre RS, Barry H, Baune BT, Best MW, Bowie CR, Cha DS, Culpepper L, Fossati P, Greer TL, Harmer C, Klag E, Lam RW, Lee Y, Mansur RB, Wittchen H-U, Harrison JE. The THINC-integrated tool (THINC-it) screening assessment for cognitive dysfunction: Validation in patients with Major Depressive Disorder. Journal of Clinical Psychiatry, 2017:78;873-881. doi: 10.4088/JCP.16m11329.
66. Miller AM, Balasa M, Blennow K, Gardiner M, Rutkowska A, Scheltens P, Teunissen CE, Visser PJ, Winblad B, Waldemar G, Lawlor B. Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe. J Alzheimers Dis. 2017;60(1):201-210. doi: 10.3233/JAD-170502.
67. Mo Y, Stromswold J, Wilson K, Holder D, Sur C, Laterza O, Savage MJ, Struyk A, Scheltens P, Teunissen CE, Burke J, Macaulay SL, Bråthen G, Sando SB, White LR, Weiss C, Cowes A, Bush MM, DeSilva G, Darby DG, Rainey-Smith SR, Surls J, Sagini E, Tanen M, Altman A, Luthman J, Egan MF. A multinational study distinguishing Alzheimer’s and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging. Alzheimers Dement (Amst). 2017 Mar 6;6:201-209. doi: 10.1016/j.dadm.2017.02.004.
68. Molinuevo JL, Rabin LA, Amariglio R, Buckley R, Dubois B, Ellis KA, Ewers M, Hampel H, Klöppel S, Rami L, Reisberg B, Saykin AJ, Sikkes S, Smart CM, Snitz BE, Sperling R, van der Flier WM, Wagner M, Jessen F; Subjective Cognitive Decline Initiative (SCD-I) Working Group. Implementation of subjective cognitive decline criteria in research studies. Alzheimers Dement. 2017 Mar;13(3):296-311. doi: 10.1016/j.jalz.2016.09.012.
69. Morbelli S, Bauckneht M, Scheltens P. Imaging biomarkers in Alzheimer’s disease: added value in the clinical setting. Q J Nucl Med Mol Imaging. 2017 Dec;61(4):360-371. doi: 10.23736/S1824-4785.17.03011-4.
70. Nathan PJ, Lim YY, Abbott R, Galluzzi S, Marizzoni M, Babiloni C, Albani D, Bartres-Faz D, Didic M, Farotti L, Parnetti L, Salvadori N, Müller BW, Forloni G, Girtler N, Hensch T, Jovicich J, Leeuwis A, Marra C, Molinuevo JL, Nobili F, Pariente J, Payoux P, Ranjeva JP, Rolandi E, Rossini PM, Schönknecht P, Soricelli A, Tsolaki M, Visser PJ, Wiltfang J, Richardson JC, Bordet R, Blin O, Frisoni GB; PharmaCog Consortium. Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnestic mild cognitive impairment (MCI). Neurobiol Aging. 2017 May;53:1-10. doi: 10.1016/j.neurobiolaging.2017.01.013.
71. Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, Ashford E, Retout S, Hofmann C, Delmar P, Klein G, Andjelkovic M, Dubois B, Boada M, Blennow K, Santarelli L, Fontoura P; SCarlet RoAD Investigators. A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. Alzheimers Res Ther. 2017 Dec 8;9(1):95. doi: 10.1186/s13195-017-0318-y.
72. Perera G, Pedersen L, Ansel D, Alexander M, Arrighi HM, Avillach P, Foskett N, Gini R, Gordon MF, Gungabissoon U, Mayer MA, Novak G, Rijnbeek P, Trifirò G, van der Lei J, Visser PJ, Stewart R. Dementia prevalence and incidence in a federation of European Electronic Health Record databases: The European Medical Informatics Framework resource. Alzheimers Dement. 2017 Jul 21. pii: S1552-5260(17)32523-2. doi: 10.1016/j.jalz.2017.06.2270.
73. Piersma D, Fuermaier ABM, De Waard D, Davidse RJ, De Groot J, Doumen MJA, Bredewoud RA, Claesen R, Lemstra AW, Scheltens P, Vermeeren A, Ponds R, Verhey F, De Deyn PP, Brouwer WH, Tucha O. Assessing Fitness to Drive in Patients With Different Types of Dementia. Alzheimer Dis Assoc Disord. 2017 Nov 17. doi: 10.1097/WAD.0000000000000221
74. Reijs BLR, Ramakers IHGB, Elias-Sonnenschein L, Teunissen CE, Koel-Simmelink M, Tsolaki M, Wahlund LO, Waldemar G, Hausner L, Johannsen P, Vanderstichele H, Verhey F, Devanand DP, Visser PJ. Relation of Odor Identification with Alzheimer’s Disease Markers in Cerebrospinal Fluid and Cognition. J Alzheimers Dis. 2017;60(3):1025-1034. doi: 10.3233/JAD-170564.
75. Reijs BLR, Ramakers IHGB, Köhler S, Teunissen CE, Koel-Simmelink M, Nathan PJ, Tsolaki M, Wahlund LO, Waldemar G, Hausner L, Vandenberghe R, Johannsen P, Blackwell A, Vanderstichele H, Verhey F, Visser PJ. Memory Correlates of Alzheimer’s Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study. J Alzheimers Dis. 2017;60(3):1119-1128. doi: 10.3233/JAD-160766.
76. Reijs BLR, Vos SJB, Soininen H, Lötjonen J, Koikkalainen J, Pikkarainen M, Hall A, Vanninen R, Liu Y, Herukka SK, Freund-Levi Y, Frisoni GB, Frölich L, Nobili F, Rikkert MO, Spiru L, Tsolaki M, Wallin ÅK, Scheltens P, Verhey F, Visser PJ. Association Between Later Life Lifestyle Factors and Alzheimer’s Disease Biomarkers in Non-Demented Individuals: A Longitudinal Descriptive Cohort Study. J Alzheimers Dis. 2017;60(4):1387-1395. doi: 10.3233/JAD-170039.
77. Rhodius-Meester HFM, Benedictus MR, Wattjes MP, Barkhof F, Scheltens Ph, Muller M, van der Flier WM. MRI Visual Ratings of Brain Atrophy and White Matter Hyperintensities across the Spectrum of Cognitive Decline Are Differently Affected by Age and Diagnosis. Front. Aging Neurosci., 09 May 2017 | https://doi.org/10.3389/fnagi.2017.00117
78. Sartor J, Bettecken K, Bernhard FP, Hofmann M, Gladow T, Lindig T, Ciliz M, Ten Kate M, Geritz J, Heinzel S, Benedictus M, Scheltens P, Hobert MA, Maetzler W. White Matter Changes-Related Gait and Executive Function Deficits: Associations with Age and Parkinson’s Disease. Front Aging Neurosci. 2017 Jun 30;9:213. doi: 10.3389/fnagi.2017.00213.
79. Scheltens NME, Tijms BM, Koene T, Barkhof F, Teunissen CE, Wolfsgruber S, Wagner M, Kornhuber J, Peters O, Cohn-Sheehy BI, Rabinovici GD, Miller BL, Kramer JH, Scheltens P, van der Flier WM; Alzheimer’s Disease Neuroimaging Initiative; German Dementia Competence Network; University of California San Francisco Memory and Aging Center; Amsterdam Dementia Cohort. Cognitive subtypes of probable Alzheimer’s disease robustly identified in four cohorts. Alzheimers Dement. 2017 Nov;13(11):1226-1236. doi: 10.1016/j.jalz.2017.03.002.
80. Scheltens P, Gillissen F, Bouwman FH, van der Flier WM. Doctor, is my mother suffering from dementia? Ned Tijdschr Geneeskd. 2017;161(0):D2086. Dutch.
81. Scheltens P, Zwan M, Ossenkoppele R, Bouwman F, van Berckel BN. Amyloid PET imaging in patients with Alzheimer’s disease Ned Tijdschr Geneeskd. 2017;161(0):D808. Dutch.
82. Schindler SE, Sutphen CL, Teunissen C, McCue LM, Morris JC, Holtzman DM, Mulder SD, Scheltens P, Xiong C, Fagan AM. Upward drift in cerebrospinal fluid amyloid β 42 assay values for more than 10 years.Alzheimers Dement. 2017 Jul 12. pii: S1552-5260(17)32516-5. doi: 10.1016/j.jalz.2017.06.2264.
83. Simonsen AH, Herukka SK, Andreasen N, Baldeiras I, Bjerke M, Blennow K, Engelborghs S, Frisoni GB, Gabryelewicz T, Galluzzi S, Handels R, Kramberger MG, Kulczyńska A, Molinuevo JL, Mroczko B, Nordberg A, Oliveira CR, Otto M, Rinne JO, Rot U, Saka E, Soininen H, Struyfs H, Suardi S, Visser PJ, Winblad B, Zetterberg H, Waldemar G. Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimers Dement. 2017 Mar;13(3):274-284. doi: 10.1016/j.jalz.2016.09.008. Epub 2016 Oct 27. Review.
84. Skillbäck T, Mattsson N, Hansson K, Mirgorodskaya E, Dahlén R, van der Flier W, Scheltens P, Duits F, Hansson O, Teunissen C, Blennow K, Zetterberg H, Gobom J. A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer’s disease. Sci Rep. 2017 Oct 17;7(1):13333. doi: 10.1038/s41598-017-13831-0.
85. Slot RE, Van Harten AC, Kester MI, Jongbloed W, Bouwman FH, Teunissen CE, Scheltens P, Veerhuis R, van der Flier WM. Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer’s Disease in Non-Demented Elderly. J Alzheimers Dis. 2017;56(2):687-697. doi: 10.3233/JAD-151068.
86. Smart CM, Karr JE, Areshenkoff CN, Rabin LA, Hudon C, Gates N, Ali JI, Arenaza-Urquijo EM, Buckley RF, Chetelat G, Hampel H, Jessen F, Marchant NL, Sikkes SAM, Tales A, van der Flier WM, Wesselman L; and the Subjective Cognitive Decline Initiative (SCD-I) Working Group. Non-Pharmacologic Interventions for Older Adults with Subjective Cognitive Decline: Systematic Review, Meta-Analysis, and Preliminary Recommendations. Neuropsychol Rev. 2017 Sep;27(3):245-257. doi: 10.1007/s11065-017-9342-8. Epub 2017 Mar 7. Review.
87. Soininen H, Solomon A, Visser PJ, Hendrix SB, Blennow K, Kivipelto M, Hartmann T; LipiDiDiet clinical study group. 24-month intervention with a specific multinutrient in people with prodromal Alzheimer’s disease (LipiDiDiet): a randomised, double-blind, controlled trial. Lancet Neurol. 2017 Dec;16(12):965-975. doi: 10.1016/S1474-4422(17)30332-0.
88. Ten Kate M, Barkhof F, Boccardi M, Visser PJ, Jack CR Jr, Lovblad KO, Frisoni GB, Scheltens P; Geneva Task Force for the Roadmap of Alzheimer’s Biomarkers. Clinical validity of medial temporal atrophy as a biomarker for Alzheimer’s disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017 Apr;52:167-182.e1. doi: 10.1016/j.neurobiolaging.2016.05.024. Review.
89. Ten Kate M, Barkhof F, Visser PJ, Teunissen CE, Scheltens P, van der Flier WM, Tijms BM. Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment. Alzheimers Res Ther. 2017 Sep 12;9(1):73. doi: 10.1186/s13195-017-0299-x.
90. Tijms BM, Bertens D, Slot RE, Gouw AA, Teunissen CE, Scheltens P, van der Flier WM, Visser PJ. Low normal cerebrospinal fluid Aβ42 levels predict clinical progression in nondemented subjects. Ann Neurol. 2017 May;81(5):749-753. doi: 10.1002/ana.24921.
91. Tijms BM, Ten Kate M, Gouw AA, Borta A, Verfaillie S, Teunissen CE, Scheltens P, Barkhof F, van der Flier WM. Gray matter networks and clinical progression in subjects with predementia Alzheimer’s disease.Neurobiol Aging. 2018 Jan;61:75-81. doi: 10.1016/j.neurobiolaging.2017.09.011.
92. Tijms BM, Willemse EAJ, Zwan MD, Mulder SD, Visser PJ, van Berckel BNM, van der Flier WM, Scheltens P, Teunissen CE. Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid-β 1-42 Analysis Results. Clin Chem. 2017 Dec 5. pii: clinchem.2017.281055. doi: 10.1373/clinchem.2017.281055.
93. van Dalen JW, Moll van Charante EP, Caan MWA, Scheltens P, Majoie CBLM, Nederveen AJ, van Gool WA, Richard E. Effect of Long-Term Vascular Care on Progression of Cerebrovascular Lesions: Magnetic Resonance Imaging Substudy of the PreDIVA Trial (Prevention of Dementia by Intensive Vascular Care). Stroke. 2017 Jul;48(7):1842-1848. doi: 10.1161/STROKEAHA.117.017207.
94. van der Flier WM, Kunneman M, Bouwman FH, Petersen RC, Smets EMA. Diagnostic dilemmas in Alzheimer’s disease: Room for shared decision making. Alzheimers Dement (N Y). 2017 May 9;3(3):301-304. doi: 10.1016/j.trci.2017.03.008
95. van Harten AC, Jongbloed W, Teunissen CE, Scheltens P, Veerhuis R, van der Flier WM. CSF ApoE predicts clinical progression in nondemented APOEε4 carriers. Neurobiol Aging. 2017 Sep;57:186-194. doi: 10.1016/j.neurobiolaging.2017.04.002. Epub 2017 Apr 12.
96. van Loenhoud AC, Wink AM, Groot C, Verfaillie SCJ, Twisk J, Barkhof F, van Berckel B, Scheltens P, van der Flier WM, Ossenkoppele R. A neuroimaging approach to capture cognitive reserve: Application to Alzheimer’s disease.Hum Brain Mapp. 2017 Sep;38(9):4703-4715. doi: 10.1002/hbm.23695
97. van Maurik IS, Zwan MD, Tijms BM, Bouwman FH, Teunissen CE, Scheltens P, Wattjes MP, Barkhof F, Berkhof J, van der Flier WM; Alzheimer’s Disease Neuroimaging Initiative. Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer’s Biomarkers in Daily Practice (ABIDE) Project. JAMA Neurol. 2017 Oct 16. doi: 10.1001/jamaneurol.2017.2712.
98. Van Mierlo LD, Wouters H, Sikkes SA, Van der Flier WM, Prins ND, Bremer JA, Koene T, Van Hout HP. Screening for Mild Cognitive Impairment and Dementia with Automated, Anonymous Online and Telephone Cognitive Self-Tests. J Alzheimers Dis. 2017;56(1):249-259. doi: 10.3233/JAD-160566.
99. van Waalwijk van Doorn LJ, Gispert JD, Kuiperij HB, Claassen JA, Arighi A, Baldeiras I, Blennow K, Bozzali M, Castelo-Branco M, Cavedo E, Emek-Savaş DD, Eren E, Eusebi P, Farotti L, Fenoglio C, Ormaechea JF, Freund-Levi Y, Frisoni GB, Galimberti D, Genc S, Greco V, Hampel H, Herukka SK, Liu Y, Lladó A, Lleó A, Nobili FM, Oguz KK, Parnetti L, Pereira J, Picco A, Pikkarainen M, de Oliveira CR, Saka E, Salvadori N, Sanchez-Valle R, Santana I, Scarpini E, Scheltens P, Soininen H, Tarducci R, Teunissen C, Tsolaki M, Urbani A, Vilaplana E, Visser PJ, Wallin AK, Yener G, Molinuevo JL, Meulenbroek O, Verbeek MM. Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer’s Disease Patients and Controls after Correction for Ventricular Volumes. J Alzheimers Dis. 2017;56(2):543-555. doi: 10.3233/JAD-160668.
100. van Wijk N, Slot RER, Duits FH, Strik M, Biesheuvel E, Sijben JWC, Blankenstein MA, Bierau J, van der Flier WM, Scheltens P, Teunissen CE. Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer’s disease dementia. Alzheimers Dement (Amst). 2017 May 16;8:139-146. doi: 10.1016/j.dadm.2017.04.005.
101. Vandenberghe R, Riviere ME, Caputo A, Sovago J, Maguire RP, Farlow M, Marotta G, Sanchez-Valle R, Scheltens P, Ryan JM, Graf A. Active Aβ immunotherapy CAD106 in Alzheimer’s disease: A phase 2b study.Alzheimers Dement (N Y). 2016 Dec 23;3(1):10-22. doi: 10.1016/j.trci.2016.12.003.
102. Verfaillie SCJ, Slot RE, Tijms BM, Bouwman F, Benedictus MR, Overbeek JM, Koene T, Vrenken H, Scheltens P, Barkhof F, van der Flier WM. Thinner cortex in patients with subjective cognitive decline is associated with steeper decline of memory. Neurobiol Aging. 2018 Jan;61:238-244. doi: 10.1016/j.neurobiolaging.2017.09.009.
103. Vijverberg EG, Dols A, Krudop WA, Del Campo Milan M, Kerssens CJ, Gossink F, Prins ND, Stek ML, Scheltens P, Teunissen CE, Pijnenburg YA. Cerebrospinal fluid biomarker examination as a tool to discriminate behavioral variant frontotemporal dementia from primary psychiatric disorders. Alzheimers Dement (Amst). 2017 Mar 2;7:99-106. doi: 10.1016/j.dadm.2017.01.009.
104. Vijverberg EGB, Gossink F, Krudop W, Sikkes S, Kerssens C, Prins N, Stek M, Scheltens P, Pijnenburg Y, Dols A. The Diagnostic Challenge of the Late-Onset Frontal Lobe Syndrome: Clinical Predictors for Primary Psychiatric Disorders Versus Behavioral Variant Frontotemporal Dementia. J Clin Psychiatry. 2017 Oct 31. pii: 16m11078. doi: 10.4088/JCP.16m11078.
105. Vijverberg EG, Pijnenburg AC, Scheltens P, Pijnenburg YA. Chronic traumatic encephalopathy: an old acquaintance in athletes Ned Tijdschr Geneeskd. 2017;161(0):D465. Dutch.
106. Vijverberg EGB, Schouws S, Meesters PD, Verwijk E, Comijs H, Koene T, Schreuder C, Beekman A, Scheltens P, Stek M, Pijnenburg Y, Dols A. Cognitive Deficits in Patients With Neuropsychiatric Symptoms: A Comparative Study Between Behavioral Variant Frontotemporal Dementia and Primary Psychiatric Disorders. J Clin Psychiatry. 2017 Sep/Oct;78(8):e940-e946. doi: 10.4088/JCP.16m11019.
107. Vijverberg EGB, Tijms BM, Dopp J, Hong YJ, Teunissen CE, Barkhof F, Scheltens P, Pijnenburg YAL. Gray matter network differences between behavioral variant frontotemporal dementia and Alzheimer’s disease.Neurobiol Aging. 2017 Feb;50:77-86. doi: 10.1016/j.neurobiolaging.2016.11.005.
108. Visser PJ, Tijms B. Brain Amyloid Pathology and Cognitive Function: Alzheimer Disease Without Dementia? JAMA. 2017 Jun 13;317(22):2285-2287. doi: 10.1001/jama.2017.6895.
109. Vos SJB, van Boxtel MPJ, Schiepers OJG, Deckers K, de Vugt M, Carrière I, Dartigues JF, Peres K, Artero S, Ritchie K, Galluzzo L, Scafato E, Frisoni GB, Huisman M, Comijs HC, Sacuiu SF, Skoog I, Irving K, O’Donnell CA, Verhey FRJ, Visser PJ, Köhler S. Modifiable Risk Factors for Prevention of Dementia in Midlife, Late Life and the Oldest-Old: Validation of the LIBRA Index. J Alzheimers Dis. 2017;58(2):537-547. doi: 10.3233/JAD-161208.
110. Voyle N, Patel H, Folarin A, Newhouse S, Johnston C, Visser PJ, Dobson RJ, Kiddle SJ; EDAR and DESCRIPA study groups and the Alzheimer’s Disease Neuroimaging Initiative. Genetic Risk as a Marker of Amyloid-β and Tau Burden in Cerebrospinal Fluid. J Alzheimers Dis. 2017;55(4):1417-1427. doi: 10.3233/JAD-160707.
111. Willemse EAJ, van Uffelen KWJ, van der Flier WM, Teunissen CE. Effect of long-term storage in biobanks on cerebrospinal fluid biomarker Aβ1-42, T-tau, and P-tau values. Alzheimers Dement (Amst). 2017 Apr 4;8:45-50. doi: 10.1016/j.dadm.2017.03.005.
112. Yu M, Engels MM, Hillebrand A, van Straaten EC, Gouw AA, Teunissen C, van der Flier WM, Scheltens P, Stam CJ. Selective impairment of hippocampus and posterior hub areas in Alzheimer’s disease: an MEG-based multiplex network study. Brain. 2017 Mar 16. doi: 10.1093/brain/awx050.
113. Zwan MD, Bouwman FH, Konijnenberg E, van der Flier WM, Lammertsma AA, Verhey FR, Aalten P, van Berckel BN, Scheltens P. Diagnostic impact of [18F]flutemetamol PET in early-onset dementia. Alzheimers Res Ther. 2017 Jan 17;9(1):2. doi: 10.1186/s13195-016-0228-4.

• Adriaanse SM, Wink AM, Tijms BM, Ossenkoppele R, Verfaillie SC, Lammertsma AA, Boellaard R, Scheltens P, van Berckel BN, Barkhof F.The Association of Glucose Metabolism and Eigenvector Centrality in Alzheimer’s Disease. Brain Connect. 2016 Feb;6(1):1-8.
• Alvarez-Jimenez R, Groeneveld GJ, van Gerven JM, Goulooze SC, Baakman AC, Hay JL, Stevens J.Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjects. Br J Clin Pharmacol. 2016 Oct;82(4):1011-21.
• Baakman AC, ’t Hart E, Kay DG, Stevens J, Klaassen ES, Maelicke A, Groeneveld GJ. First in human study with a prodrug of galantamine: Improved benefit-risk ratio?Alzheimer’s & Dementia: Translational Research & Clinical Intervention. 2016 Jan;2(1):13-22
• Binnewijzend MA, Benedictus MR, Kuijer JP, van der Flier WM, Teunissen CE, Prins ND, Wattjes MP, van Berckel BN, Scheltens P, Barkhof F. Cerebral perfusion in the predementia stages of Alzheimer’s disease. Eur Radiol. 2016 Feb;26(2):506-14.
• Bittner T, Zetterberg H, Teunissen CE, Ostlund RE Jr, Militello M, Andreasson U, Hubeek I, Gibson D, Chu DC, Eichenlaub U, Heiss P, Kobold U, Leinenbach A, Madin K, Manuilova E, Rabe C, Blennow K. Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1-42) in human cerebrospinal fluid. Alzheimers Dement. 2016 May;12(5):517-26
• Blauwendraat C, Francescatto M, Gibbs JR, Jansen IE, Simón-Sánchez J, Hernandez DG, Dillman AA, Singleton AB, Cookson MR, Rizzu P, Heutink P. Comprehensive promoter level expression quantitative trait loci analysis of the human frontal lobe. Genome Med. 2016 Jun 10;8(1):65.
• Blauwendraat C, Wilke C, Jansen IE, Schulte C, Simón-Sánchez J, Metzger FG, Bender B, Gasser T, Maetzler W, Rizzu P, Heutink P, Synofzik M. Pilot whole-exome sequencing of a German early-onset Alzheimer’s disease cohort reveals a substantial frequency of PSEN2 variants. Neurobiol Aging. 2016 Jan;37:208.e11-7.
• Boelaarts L, Scheltens P, de Jonghe J. Does MRI Increase the Diagnostic Confidence of Physicians in an Outpatient Memory Clinic. Dement Geriatr Cogn Dis Extra. 2016 Jun 25;6(2):242-51.
• Bowles C, Qin C, Ledig C, Guerrero R, Gunn R, Hammers A, Sakka E, Dickie DA, Valdés Hernández M, Royle N, Wardlaw J, Rhodius-Meester H, Tijms B, Lemstra AW, van der Flier W, Barkhof F, Scheltens P, Rueckert D. Pseudo-healthy Image Synthesis for White Matter Lesion Segmentation Tsaftaris S et al (eds) Simulation and Synthesis in Medical Imaging. SASHIMI 2016. Lecture Notes in Computer Science, vol 9968. Springer, Cham
• Brodaty H, Woolf C, Andersen S, Barzilai N, Brayne C, Cheung KS, Corrada MM, Crawford JD, Daly C, Gondo Y, Hagberg B, Hirose N, Holstege H, Kawas C, Kaye J, Kochan NA, Lau BH, Lucca U, Marcon G, Martin P, Poon LW, Richmond R, Robine JM, Skoog I, Slavin MJ, Szewieczek J, Tettamanti M, Viña J, Perls T, Sachdev PS. ICC-dementia (International Centenarian Consortium – dementia): an international consortium to determine the prevalence and incidence of dementia in centenarians across diverse ethnoracial and sociocultural groups. BMC Neurol. 2016 Apr 21;16:52.
• Chételat G, Ossenkoppele R, Villemagne VL, Perrotin A, Landeau B, Mézenge F, Jagust WJ, Dore V, Miller BL, Egret S, Seeley WW, van der Flier WM, La Joie R, Ames D, van Berckel BN, Scheltens P, Barkhof F, Rowe CC, Masters CL, de La Sayette V, Bouwman F, Rabinovici GD. Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer’s disease. Brain. 2016 Sep;139(Pt 9):2528-39.
• Claus JJ, Staekenborg SS, Roorda JJ, Stevens M, Herderschee D, van Maarschalkerweerd W, Schuurmans L, Tielkes CE, Koster P, Bavinck C, Scheltens P.Low Prevalence of Mixed Dementia in a Cohort of 2,000 Elderly Patients in a Memory Clinic Setting.J Alzheimers Dis. 2016;50(3):797-806.
• Collij LE, Heeman F, Kuijer JP, Ossenkoppele R, Benedictus MR, Möller C, Verfaillie SC, Sanz-Arigita EJ, van Berckel BN, van der Flier WM, Scheltens P, Barkhof F, Wink AM. Application of Machine Learning to Arterial Spin Labeling in Mild Cognitive Impairment and Alzheimer Disease. Radiology. 2016 Dec;281(3):865-875.
• Cover KS, van Schijndel RA, Versteeg A, Leung KK, Mulder ER, Jong RA, Visser PJ, Redolfi A, Revillard J, Grenier B, Manset D, Damangir S, Bosco P, Vrenken H, van Dijk BW, Frisoni GB, Barkhof F; Alzheimer’s Disease Neuroimaging Initiative, neuGRID. Reproducibility of hippocampal atrophy rates measured with manual, FreeSurfer, AdaBoost, FSL/FIRST and the MAPS-HBSI methods in Alzheimer’s disease. Psychiatry Res. 2016 Jun 30;252:26-35.
• Crutcher E, Ali M,Harrison JE, Sovago J, Gomez-Mancilla B, Schaaf CP. (2016) Assessment of cognitive outcome measures in teenagers with 15q13.3 microdeletion syndrome. J Autism Dev Disorders 46(4):1455-63.
• Cummings J, Aisen PS, DuBois B, Frölich L, Jack CR Jr, Jones RW, Morris JC, Raskin J, Dowsett SA, Scheltens P. Drug development in Alzheimer’s disease: the path to 2025. Alzheimers Res Ther. 2016 Sep 20;8:39.
• Cummings J, Scheltens P, McKeith I, Blesa R, Harrison J. et al. (2016) Effect size analyses of Souvenaid in patients with Alzheimer’s disease. Alzheimer’s Research & Therapy. 2016;55;1131-1139.
• Dauwan M, van Dellen E, van Boxtel L, van Straaten EC, de Waal H, Lemstra AW, Gouw AA, van der Flier WM, Scheltens P, Sommer IE, Stam CJ. EEG-directed connectivity from posterior brain regions is decreased in dementia with Lewy bodies: a comparison with Alzheimer’s disease and controls. Neurobiol Aging. 2016 May;41:122-9.
• Dauwan M, van der Zande JJ, van Dellen E, Sommer IE, Scheltens P, Lemstra AW, Stam CJ. Random forest to differentiate dementia with Lewy bodies from Alzheimer’s disease. Alzheimers Dement (Amst). 2016 Aug 19;4:99-106.
• de Beer MH, Scheltens P. Cognitive Decline in Patients with Chronic Hydrocephalus and Normal Aging: ‘Growing into Deficits’. Dement Geriatr Cogn Dis Extra. 2016 Oct 12;6(3):500-507.
• de van der Schueren MA, Lonterman-Monasch S, van der Flier WM, Kramer MH, Maier AB, Muller M. Malnutrition and Risk of Structural Brain Changes Seen on Magnetic Resonance Imaging in Older Adults. J Am Geriatr Soc. 2016 Dec;64(12):2457-2463.
• Dols A, van Liempt S, Gossink F, Krudop WA, Sikkes S, Pijnenburg YA, Stek ML. Identifying Specific Clinical Symptoms of Behavioral Variant Frontotemporal Dementia Versus Differential Psychiatric Disorders in Patients Presenting With a Late-Onset Frontal Lobe Syndrome. J Clin Psychiatry. 2016 Oct;77(10):1391-1395.
• Dols A, Krudop W, Möller C, Shulman K, Sajatovic M, Pijnenburg YA. Late life bipolar disorder evolving into frontotemporal dementia mimic. Neuropsychiatr Dis Treat. 2016 Sep 7;12:2207-12.
• Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, Bakardjian H, Benali H, Bertram L, Blennow K, Broich K, Cavedo E, Crutch S, Dartigues JF, Duyckaerts C, Epelbaum S, Frisoni GB, Gauthier S, Genthon R, Gouw AA, Habert MO, Holtzman DM, Kivipelto M, Lista S, Molinuevo JL, O’Bryant SE, Rabinovici GD, Rowe C, Salloway S, Schneider LS, Sperling R, Teichmann M, Carrillo MC, Cummings J, Jack CR Jr; Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer’s Association on “The Preclinical State of AD”; July 23, 2015; Washington DC, USA. Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016 Mar;12(3):292-323.
• Dubois B, Padovani A, Scheltens P, Rossi A, Dell’Agnello G. Timely Diagnosis for Alzheimer’s Disease: A Literature Review on Benefits and Challenges. J Alzheimers Dis. 2016;49(3):617-31.
• Duits FH, Martinez-Lage P, Paquet C, Engelborghs S, Lleó A, Hausner L, Molinuevo JL, Stomrud E, Farotti L, Ramakers IH, Tsolaki M, Skarsgård C, Åstrand R, Wallin A, Vyhnalek M, Holmber-Clausen M, Forlenza OV, Ghezzi L, Ingelsson M, Hoff EI, Roks G, de Mendonça A, Papma JM, Izagirre A, Taga M, Struyfs H, Alcolea DA, Frölich L, Balasa M, Minthon L, Twisk JW, Persson S, Zetterberg H, van der Flier WM, Teunissen CE, Scheltens P, Blennow K. Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. Alzheimers Dement. 2016 Feb;12(2):154-63.
• Engels MM, Hillebrand A, van der Flier WM, Stam CJ, Scheltens P, van Straaten EC. Slowing of Hippocampal Activity Correlates with Cognitive Decline in Early Onset Alzheimer’s Disease. An MEG Study with Virtual Electrodes. Front Hum Neurosci. 2016 May 20;10:238.
• Galluzzi S, Marizzoni M, Babiloni C, Albani D, Antelmi L, Bagnoli C, Bartres-Faz D, Cordone S, Didic M, Farotti L, Fiedler U, Forloni G, Girtler N, Hensch T, Jovicich J, Leeuwis A, Marra C, Molinuevo JL, Nobili F, Pariente J, Parnetti L, Payoux P, Del Percio C, Ranjeva JP, Rolandi E, Rossini PM, Schönknecht P, Soricelli A, Tsolaki M, Visser PJ, Wiltfang J, Richardson JC, Bordet R, Blin O, Frisoni GB; PharmaCog Consortium. Clinical and biomarker profiling of prodromal Alzheimer’s disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a ‘European ADNI study’. J Intern Med. 2016 Jun;279(6):576-91.
• Gossink FT, Dols A, Kerssens CJ, Krudop WA, Kerklaan BJ, Scheltens P, Stek ML, Pijnenburg YA. Psychiatric diagnoses underlying the phenocopy syndrome of behavioural variant frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2016 Jan;87(1):64-8.
• Gossink FT, Dols A, Krudop WA, Sikkes SA, Kerssens CJ, Prins ND, Scheltens P, Stek ML, Pijnenburg YA. Formal Psychiatric Disorders are not Overrepresented in Behavioral Variant Frontotemporal Dementia. J Alzheimers Dis. 2016;51(4):1249-56.
• Groot C, Hooghiemstra AM, Raijmakers PG, van Berckel BN, Scheltens P, Scherder EJ, van der Flier WM, Ossenkoppele R. The effect of physical activity on cognitive function in patients with dementia: A meta-analysis of randomized control trials. Ageing Res Rev. 2016 Jan;25:13-23.
• Guerreiro R, Escott-Price V, Darwent L, Parkkinen L, Ansorge O, Hernandez DG, Nalls MA, Clark L, Honig L, Marder K, van der Flier W, Holstege H, Louwersheimer E, Lemstra A, Scheltens P, Rogaeva E, St George-Hyslop P, Londos E, Zetterberg H, Ortega-Cubero S, Pastor P, Ferman TJ, Graff-Radford NR, Ross OA, Barber I, Braae A, Brown K, Morgan K, Maetzler W, Berg D, Troakes C, Al-Sarraj S, Lashley T, Compta Y, Revesz T, Lees A, Cairns NJ, Halliday GM, Mann D, Pickering-Brown S, Powell J, Lunnon K, Lupton MK; International Parkinson’s Disease Genomics Consortium., Dickson D, Hardy J, Singleton A, Bras J. Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson’s and Alzheimer’s diseases. Neurobiol Aging. 2016 Feb;38:214.e7-10.
• Hafkemeijer A, Möller C, Dopper EG, Jiskoot LC, van den Berg-Huysmans AA, van Swieten JC, van der Flier WM, Vrenken H, Pijnenburg YA, Barkhof F, Scheltens P, van der Grond J, Rombouts SA. Differences in structural covariance brain networks between behavioral variant frontotemporal dementia and Alzheimer’s disease. Hum Brain Mapp. 2016 Mar;37(3):978-88.
• Handels RL, Joore MA, Vos SJ, Aalten P, Ramakers IH, Rikkert MO, Scheltens P, Jansen WJ, Visser PJ, van Berckel BM, van Domburg P, Smid M, Hoff E, Hoogmoed J, Bouwman F, Claassen J, Leentjens AF, Wolfs CA, Severens JL, Verhey FR. Added Prognostic Value of Cerebrospinal Fluid Biomarkers in Predicting Decline in Memory Clinic Patients in a Prospective Cohort. J Alzheimers Dis. 2016 Mar 31;52(3):875-85.
• Harper L, Fumagalli GG, Barkhof F, Scheltens P, O’Brien JT, Bouwman F, Burton EJ, Rohrer JD, Fox NC, Ridgway GR, Schott JM. MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases. Brain. 2016 Apr;139(Pt 4):1211-25.
• Harrison JE. (2016) Measuring the mind: Detecting cognitive deficits and measuring cognitive change in patients with depression, in McIntyre RS & Cha D (Eds.) Cognitive Impairment in Major Depressive Disorder, Cambridge, Cambridge University Press.
• Harrison JE, Lam RW, Baune BT, McIntyre RS. Selection of cognitive tests for trials of therapeutic agents. The Lancet Psychiatry. 2016:8;1-13.
• Harrison JE, Lophaven S, Olsen CK. Which cognitive domains are improved by treatment with vortioxetine? Intl J Neuropsychopharm. 2016:19;1–6.
• Hattink B, Droes RM, Sikkes S, Oostra E, Lemstra AW. Evaluation of the Digital Alzheimer Center: Testing Usability and Usefulness of an Online Portal for Patients with Dementia and Their Carers. JMIR Res Protoc. 2016 Jul 21;5(3):e144.
• Hepp DH, Vergoossen DL, Huisman E, Lemstra AW; Netherlands Brain Bank., Berendse HW, Rozemuller AJ, Foncke EM, van de Berg WD. Distribution and Load of Amyloid-β Pathology in Parkinson Disease and Dementia with Lewy Bodies. J Neuropathol Exp Neurol. 2016 Oct;75(10):936-945.
• Hillebrand A, Tewarie P, van Dellen E, Yu M, Carbo EW, Douw L, Gouw AA, van Straaten EC, Stam CJ. Direction of information flow in large-scale resting-state networks is frequency-dependent. Proc Natl Acad Sci U S A. 2016 Apr 5;113(14):3867-72.
• Jack CR Jr, Knopman DS, Chételat G, Dickson D, Fagan AM, Frisoni GB, Jagust W, Mormino EC, Petersen RC, Sperling RA, van der Flier WM, Villemagne VL, Visser PJ, Vos SJ. Suspected non-Alzheimer disease pathophysiology–concept and controversy. Nat Rev Neurol. 2016 Feb;12(2):117-24.
• Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, Hampel H, Jagust WJ, Johnson KA, Knopman DS, Petersen RC, Scheltens P, Sperling RA, Dubois B. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016 Aug 2;87(5):539-47.
• Janssen N, Handels RL, Koehler S, Ramakers IH, Hamel RE, Olde Rikkert MG, Scheltens P, Bouwman FH, van der Flier WM, Wolfs CA, de Vugt ME, Evers SM, Verhey FR. Combinations of Service Use Types of People With Early Cognitive Disorders. J Am Med Dir Assoc. 2016 Jul 1;17(7):620-5.
• Jokinen H, Melkas S, Madureira S, Verdelho A, Ferro JM, Fazekas F, Schmidt R, Scheltens P, Barkhof F, Wardlaw JM, Inzitari D, Pantoni L, Erkinjuntti T. Cognitive reserve moderates long-term cognitive and functional outcome in cerebral small vessel disease. J Neurol Neurosurg Psychiatry. 2016 Dec;87(12):1296-1302.
• Jovicich J, Minati L, Marizzoni M, Marchitelli R, Sala-Llonch R, Bartrés-Faz D, Arnold J, Benninghoff J, Fiedler U, Roccatagliata L, Picco A, Nobili F, Blin O, Bombois S, Lopes R, Bordet R, Sein J, Ranjeva JP, Didic M, Gros-Dagnac H, Payoux P, Zoccatelli G, Alessandrini F, Beltramello A, Bargalló N, Ferretti A, Caulo M, Aiello M, Cavaliere C, Soricelli A, Parnetti L, Tarducci R, Floridi P, Tsolaki M, Constantinidis M, Drevelegas A, Rossini PM, Marra C, Schönknecht P, Hensch T, Hoffmann KT, Kuijer JP, Visser PJ, Barkhof F, Frisoni GB; PharmaCog Consortium. Longitudinal reproducibility of default-mode network connectivity in healthy elderly participants: A multicentric resting-state fMRI study. Neuroimage. 2016 Jan 1;124(Pt A):442-54.
• Kerssens CJ, Krudop WA, Prins ND, van Berckel BN, Rozemuller A, Seeley WW, Scheltens P, Stek ML, Pijnenburg YA. Schizophrenia as a mimic of behavioral variant frontotemporal dementia. Neurocase. 2016 Jun;22(3):285-8.
• Koikkalainen J, Rhodius-Meester H, Tolonen A, Barkhof F, Tijms B, Lemstra AW, Tong T, Guerrero R, Schuh A, Ledig C, Rueckert D, Soininen H, Remes AM, Waldemar G, Hasselbalch S, Mecocci P, van der Flier W, Lötjönen J. Differential diagnosis of neurodegenerative diseases using structural MRI data. Neuroimage Clin. 2016 Mar 5;11:435-49.
• Konijnenberg E, Fereshtehnejad SM, Kate MT, Eriksdotter M, Scheltens P, Johannsen P, Waldemar G, Visser PJ. Early-Onset Dementia: Frequency, Diagnostic Procedures, and Quality Indicators in Three European Tertiary Referral Centers. Alzheimer Dis Assoc Disord. 2016 May 6.
• Krudop WA, Dols A, Kerssens CJ, Prins ND, Möller C, Schouws S, Barkhof F, van Berckel BN, Teunissen CE, van der Flier WM, Scheltens P, Sikkes SA, Stek ML, Pijnenburg YA. Impact of Imaging and Cerebrospinal Fluid Biomarkers on Behavioral Variant Frontotemporal Dementia Diagnosis within a Late-Onset Frontal Lobe Syndrome Cohort. Dement Geriatr Cogn Disord. 2016;41(1-2):16-26.
• Kwok T, Lee J, Ma RC, Wong SY, Kung K, Lam A, Ho CS, Lee V, Harrison J, Lam L. A randomized placebo controlled trial of vitamin B12 supplementation to prevent cognitive decline in cognitively normal older diabetic people with borderline low serum vitamin B12. 2016:36;1509-1515.
• Ledig C, KaltwangS, Tolonen A, Koikkalainen J, Scheltens P, Barkhof F, Rhodius-Meester H, Tijms B, Lemstra AW, van der Flier W, Lötjöen J, Rueckert D. Differential Dementia Diagnosis on Incomplete Data with Latent Trees Ourselin S. et al (eds) Medical Image Computing and Computer-Assisted Intervention – MICCAI 2016. MICCAI 2016. Lecture Notes in Computer Science, vol 9901. Springer, Cham
• Leeuwis AE, Benedictus MR, Kuijer JP, Binnewijzend MA, Hooghiemstra AM, Verfaillie SC, Koene T, Scheltens P, Barkhof F, Prins ND, van der Flier WM. Lower cerebral blood flow is associated with impairment in multiple cognitive domains in Alzheimer’s disease. Alzheimers Dement. 2016 Sep 28. pii: S1552-5260(16)32893-X.
• Lehmann S, Teunissen CE. Editorial: Biomarkers of Alzheimer’s Disease: The Present and the Future. Front Neurol. 2016 Sep 27;7:158.
• Lelental N, Brandner S, Kofanova O, Blennow K, Zetterberg H, Andreasson U, Engelborghs S, Mroczko B, Gabryelewicz T, Teunissen C, Mollenhauer B, Parnetti L, Chiasserini D, Molinuevo JL, Perret-Liaudet A, Verbeek MM, Andreasen N, Brosseron F, Bahl JM, Herukka SK, Hausner L, Frölich L, Labonte A, Poirier J, Miller AM, Zilka N, Kovacech B, Urbani A, Suardi S, Oliveira C, Baldeiras I, Dubois B, Rot U, Lehmann S, Skinningsrud A, Betsou F, Wiltfang J, Gkatzima O, Winblad B, Buchfelder M, Kornhuber J, Lewczuk P. Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. J Alzheimers Dis. 2016 Mar 1;52(1):51-64.
• Liao W, Hamel RE, Olde Rikkert MG, Oosterveld SM, Aalten P, Verhey FR, Scheltens P, Sistermans N, Pijnenburg YA, van der Flier WM, Ramakers IH, Melis RJ. A profile of The Clinical Course of Cognition and Comorbidity in Mild Cognitive Impairment and Dementia Study (The 4C study): two complementary longitudinal, clinical cohorts in the Netherlands. BMC Neurol. 2016 Nov 25;16(1):242.
• Linszen MM, Brouwer RM, Heringa SM, Sommer IE. Increased risk of psychosis in patients with hearing impairment: Review and meta-analyses. Neurosci Biobehav Rev. 2016 Mar;62:1-20.Louwersheimer E, Wolfsgruber S, Espinosa A, Lacour A, Heilmann-Heimbach S, Alegret M, Hernández I, Rosende-Roca M, Tárraga L, Boada M, Kornhuber J, Peters O, Frölich L, Hüll M, Rüther E, Wiltfang J, Scherer M, Riedel-Heller S, Jessen F, Nöthen MM, Maier W, Koene T, Scheltens P, Holstege H, Wagner M, Ruiz A, van der Flier WM, Becker T, Ramirez A.Alzheimer’s disease risk variants modulate endophenotypes in mild cognitive impairment. Alzheimers Dement. 2016 Aug;12(8):872-81.
• Louwersheimer E, Keulen MA, Steenwijk MD, Wattjes MP, Jiskoot LC, Vrenken H, Teunissen CE, van Berckel BN, van der Flier WM, Scheltens P, van Swieten JC, Pijnenburg YA. Heterogeneous Language Profiles in Patients with Primary Progressive Aphasia due to Alzheimer’s Disease. J Alzheimers Dis. 2016;51(2):581-90.
• Madureira S, Verdelho A, Moleiro C, Santos C, Scheltens P, Gouw A, Ferro J. White Matter Changes and Cognitive Decline in a Ten-Year Follow-Up Period: A Pilot Study on a Single-Center Cohort from the Leukoaraiosis and Disability Study. Dement Geriatr Cogn Disord. 2016;41(5-6):303-13.
• Majbour NK, Vaikath NN, van Dijk KD, Ardah MT, Varghese S, Vesterager LB, Montezinho LP, Poole S, Safieh-Garabedian B, Tokuda T, Teunissen CE, Berendse HW, van de Berg WD, El-Agnaf OM. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease. Mol Neurodegener. 2016 Jan 19;11:7.
• Marchitelli R, Minati L, Marizzoni M, Bosch B, Bartrés-Faz D, Müller BW, Wiltfang J, Fiedler U, Roccatagliata L, Picco A, Nobili F, Blin O, Bombois S, Lopes R, Bordet R, Sein J, Ranjeva JP, Didic M, Gros-Dagnac H, Payoux P, Zoccatelli G, Alessandrini F, Beltramello A, Bargalló N, Ferretti A, Caulo M, Aiello M, Cavaliere C, Soricelli A, Parnetti L, Tarducci R, Floridi P, Tsolaki M, Constantinidis M, Drevelegas A, Rossini PM, Marra C, Schönknecht P, Hensch T, Hoffmann KT, Kuijer JP, Visser PJ, Barkhof F, Frisoni GB, Jovicich J. Test-retest reliability of the default mode network in a multi-centric fMRI study of healthy elderly: Effects of data-driven physiological noise correction techniques. Hum Brain Mapp. 2016 Jun;37(6):2114-32.
• McAllister-Williams RH, Bones K, Goodwin GM, Harrison JE, Katona C, Rasmussen J, Strong S, Young AH. Analysing UK clinicians’ understanding of cognitive symptoms in major depression: a survey of primary care physicians and psychiatrists. Journal of Affective Disorders. 2016:207;346-352.
• McIntyre RS, Harrison JE, Loft H, Jacobson W, Olsen CK. The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder (MDD): a Meta-Analysis of Three Randomized Controlled Trials. Intl J Neuropsychopharm.2016:19;1-9.
• Meeter LH, Patzke H, Loewen G, Dopper EG, Pijnenburg YA, van Minkelen R, van Swieten JC. Progranulin Levels in Plasma and Cerebrospinal Fluid in Granulin Mutation Carriers. Dement Geriatr Cogn Dis Extra. 2016 Jul 22;6(2):330-340.
• Meeter LH, Dopper EG, Jiskoot LC, Sanchez-Valle R, Graff C, Benussi L, Ghidoni R, Pijnenburg YA, Borroni B, Galimberti D, Laforce RJ, Masellis M, Vandenberghe R, Ber IL, Otto M, van Minkelen R, Papma JM, Rombouts SA, Balasa M, Öijerstedt L, Jelic V, Dick KM, Cash DM, Harding SR, Jorge Cardoso M, Ourselin S, Rossor MN, Padovani A, Scarpini E, Fenoglio C, Tartaglia MC, Lamari F, Barro C, Kuhle J, Rohrer JD, Teunissen CE, van Swieten JC. Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Ann Clin Transl Neurol. 2016 Jul 1;3(8):623-36.
• Millenaar JK, de Vugt ME, Bakker C, van Vliet D, Pijnenburg YA, Koopmans RT, Verhey FR. The Impact of Young Onset Dementia on Informal Caregivers Compared with Late Onset Dementia: Results from the NeedYD Study. Am J Geriatr Psychiatry. 2016 Jun;24(6):467-74.
• Miller AM, Rutkowska A, Bahl JM, Herukka SK, Koel-Simmelink MJ, Kruse N, Mollenhauer B, Siloaho M, Skinningsrud A, Zetterberg H, Teunissen CE, Lawlor BA. Multicenter immunoassay validation of cerebrospinal fluid neurofilament light: a biomarker for neurodegeneration. Bioanalysis. 2016 Nov;8(21):2243-2254.
• Möller C, Pijnenburg YA, van der Flier WM, Versteeg A, Tijms B, de Munck JC, Hafkemeijer A, Rombouts SA, van der Grond J, van Swieten J, Dopper E, Scheltens P, Barkhof F, Vrenken H, Wink AM. Alzheimer Disease and Behavioral Variant Frontotemporal Dementia: Automatic Classification Based on Cortical Atrophy for Single-Subject Diagnosis. Radiology. 2016 Jun;279(3):838-48.
• Möller C, Hafkemeijer A, Pijnenburg YA, Rombouts SA, van der Grond J, Dopper E, van Swieten J, Versteeg A, Steenwijk MD, Barkhof F, Scheltens P, Vrenken H, van der Flier WM. Different patterns of cortical gray matter loss over time in behavioral variant frontotemporal dementia and Alzheimer’s disease. Neurobiol Aging. 2016 Feb;38:21-31.
• Mortamais M, Ash JA, Harrison JE, Kaye J, Kramer J, Randolph C, Pose C, Albala B, Ropacki M, Ritchie CW, Ritchie K. (2016) Detecting cognitive changes in preclinical Alzheimer’s disease: a review of its feasibility, Alzheimer’s and Dementia. 2016:13;468-492.
• Ossenkoppele R, Schonhaut DR, Schöll M, Lockhart SN, Ayakta N, Baker SL, O’Neil JP, Janabi M, Lazaris A, Cantwell A, Vogel J, Santos M, Miller ZA, Bettcher BM, Vossel KA, Kramer JH, Gorno-Tempini ML, Miller BL, Jagust WJ, Rabinovici GD. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. Brain. 2016 May;139(Pt 5):1551-67.
• Pasquini M, Benedictus MR, Boulouis G, Rossi C, Dequatre-Ponchelle N, Cordonnier C. Incident Cerebral Microbleeds in a Cohort of Intracerebral Hemorrhage. Stroke. 2016 Mar;47(3):689-94.
• Piersma D, Fuermaier AB, de Waard D, Davidse RJ, de Groot J, Doumen MJ, Bredewoud RA, Claesen R, Lemstra AW, Vermeeren A, Ponds R, Verhey F, Brouwer WH, Tucha O. Prediction of Fitness to Drive in Patients with Alzheimer’s Dementia. PLoS One. 2016 Feb 24;11(2):e0149566.
• Podhorna J, Krahnke T, Shear M, Harrison JE (2016) Alzheimer’s Disease Assessment Scale – Cognitive subscale variants in mild cognitive impairment and mild Alzheimer’s disease: change over time and the effects of enrichment strategies. Alzheimer’s Res Therapy 8(8): 1-13.
• Qin C, Guerrero Moreno R, Bowles C, Ledig C, Scheltens P, Barkhof F, Rhodius-Meester H, Tijms B, Lemstra AW, van der Flier WM, Glocker B, Rueckert D. A Semi-supervised Large Margin Algorithm for White Matter Hyperintensity Segmentation Wang L. et al (eds) Machine Learning in Medical Imaging. MLMI 2016. Lecture Notes in Computer Science, vol 10019. Springer, Cham
• Rhodius-Meester HF, Koikkalainen J, Mattila J, Teunissen CE, Barkhof F, Lemstra AW, Scheltens P, Lötjönen J, van der Flier WM. Integrating Biomarkers for Underlying Alzheimer’s Disease in Mild Cognitive Impairment in Daily Practice: Comparison of a Clinical Decision Support System with Individual Biomarkers. J Alzheimers Dis. 2016;50(1):261-70.
• Ritchie K, Ropacki M, Albala B, Harrison JE, Kay J, Kramer J, Randolph C, Ritchie CW. Recommended cognitive outcomes in pre-clinical Alzheimer’s disease: consensus statement from the European Prevention of Alzheimer’s Dementia (EPAD) Project. Alzheimer’s and Dementia. 2016;13:186-195.
• Rosenberger AF, Morrema TH, Gerritsen WH, van Haastert ES, Snkhchyan H, Hilhorst R, Rozemuller AJ, Scheltens P, van der Vies SM, Hoozemans JJ. Increased occurrence of protein kinase CK2 in astrocytes in Alzheimer’s disease pathology. J Neuroinflammation. 2016 Jan 6;13:4.
• Rosenberger AF, Hilhorst R, Coart E, García Barrado L, Naji F, Rozemuller AJ, van der Flier WM, Scheltens P, Hoozemans JJ, van der Vies SM. Protein Kinase Activity Decreases with Higher Braak Stages of Alzheimer’s Disease Pathology. J Alzheimers Dis. 2016;49(4):927-43.
• Rudolph S, Klein AN, Tusche M, Schlosser C, Elfgen A, Brener O, Teunissen C, Gremer L, Funke SA, Kutzsche J, Willbold D. Correction: Competitive Mirror Image Phage Display Derived Peptide Modulates Amyloid Beta Aggregation and Toxicity. PLoS One. 2016 Jul 12;11(7):e0159470.
• Rudolph S, Klein AN, Tusche M, Schlosser C, Elfgen A, Brener O, Teunissen C, Gremer L, Funke SA, Kutzsche J, Willbold D. Competitive Mirror Image Phage Display Derived Peptide Modulates Amyloid Beta Aggregation and Toxicity. PLoS One. 2016 Feb 3;11(2):e0147470.
• Sassi C, Nalls MA, Ridge PG, Gibbs JR, Ding J, Lupton MK, Troakes C, Lunnon K, Al-Sarraj S, Brown KS, Medway C, Clement N, Lord J, Turton J, Bras J, Almeida MR; ARUK Consortium., Holstege H, Louwersheimer E, van der Flier WM, Scheltens P, Van Swieten JC, Santana I, Oliveira C, Morgan K, Powell JF, Kauwe JS, Cruchaga C, Goate AM, Singleton AB, Guerreiro R, Hardy J. ABCA7 p.G215S as potential protective factor for Alzheimer’s disease. Neurobiol Aging. 2016 Oct;46:235.e1-9.
• Scheltens NM, Galindo-Garre F, Pijnenburg YA, van der Vlies AE, Smits LL, Koene T, Teunissen CE, Barkhof F, Wattjes MP, Scheltens P, van der Flier WM. The identification of cognitive subtypes in Alzheimer’s disease dementia using latent class analysis. J Neurol Neurosurg Psychiatry. 2016 Mar;87(3):235-43.
• Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM. Alzheimer’s disease. Lancet. 2016 Jul 30;388(10043):505-17.
• Schott JM, Crutch SJ, Carrasquillo MM, Uphill J, Shakespeare TJ, Ryan NS, Yong KX, Lehmann M, Ertekin-Taner N, Graff-Radford NR, Boeve BF, Murray ME, Khan QU, Petersen RC, Dickson DW, Knopman DS, Rabinovici GD, Miller BL, González AS, Gil-Néciga E, Snowden JS, Harris J, Pickering-Brown SM, Louwersheimer E, van der Flier WM, Scheltens P, Pijnenburg YA, Galasko D, Sarazin M, Dubois B, Magnin E, Galimberti D, Scarpini E, Cappa SF, Hodges JR, Halliday GM, Bartley L, Carrillo MC, Bras JT, Hardy J, Rossor MN, Collinge J, Fox NC, Mead S. Genetic risk factors for the posterior cortical atrophy variant of Alzheimer’s disease. Alzheimers Dement. 2016 Aug;12(8):862-71.
• Schöll M, Lockhart SN, Schonhaut DR, O’Neil JP, Janabi M, Ossenkoppele R, Baker SL, Vogel JW, Faria J, Schwimmer HD, Rabinovici GD, Jagust WJ. PET Imaging of Tau Deposition in the Aging Human Brain. Neuron. 2016 Mar 2;89(5):971-82.
• Semenov AV, Devyatov IA, de Visser PJ, Klapwijk TM. Coherent Excited States in Superconductors due to a Microwave Field. Phys Rev Lett. 2016 Jul 22;117(4):047002.
• Skrobot OA, O’Brien J, Black S, Chen C, DeCarli C, Erkinjuntti T, Ford GA, Kalaria RN, Pantoni L, Pasquier F, Roman GC, Wallin A, Sachdev P, Skoog I; VICCCS group., Ben-Shlomo Y, Passmore AP, Love S, Kehoe PG. The Vascular Impairment of Cognition Classification Consensus Study. Alzheimers Dement. 2016 Dec 10.
• Staekenborg SS, Pijnenburg YA, Lemstra AW, Scheltens P, Vd Flier WM. Dementia and Rapid Mortality: Who is at Risk? J Alzheimers Dis. 2016 Apr 19;53(1):135-42.
• Steenwijk MD, Geurts JJ, Daams M, Tijms BM, Wink AM, Balk LJ, Tewarie PK, Uitdehaag BM, Barkhof F, Vrenken H, Pouwels PJ. Cortical atrophy patterns in multiple sclerosis are non-random and clinically relevant. Brain. 2016 Jan;139(Pt 1):115-26.
• Ten Kate M, Sanz-Arigita EJ, Tijms BM, Wink AM, Clerigue M, Garcia-Sebastian M, Izagirre A, Ecay-Torres M, Estanga A, Villanua J, Vrenken H, Visser PJ, Martinez-Lage P, Barkhof F. Impact of APOE-ɛ4 and family history of dementia on gray matter atrophy in cognitively healthy middle-aged adults. Neurobiol Aging. 2016 Feb;38:14-20.
• Teunissen CE, Parnetti L. New CSF biomarkers on the block. EMBO Mol Med. 2016 Oct 4;8(10):1118-1119.
• Teunissen CE, Durieux-Lu S, Blankenstein MA, Oude Voshaar RC, Comijs HC. The inflammatory marker GDF-15 is not independently associated with late-life depression. J Psychosom Res. 2016 Apr;83:46-9.
• Teunissen CE, Elias N, Koel-Simmelink MJ, Durieux-Lu S, Malekzadeh A, Pham TV, Piersma SR, Beccari T, Meeter LH, Dopper EG, van Swieten JC, Jimenez CR, Pijnenburg YA. Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics. Alzheimers Dement (Amst). 2016 Jan 19;2:86-94.
• Tijms BM, ten Kate M, Wink AM, Visser PJ, Ecay M, Clerigue M, Estanga A, Garcia Sebastian M, Izagirre A, Villanua J, Martinez Lage P, van der Flier WM, Scheltens P, Sanz Arigita E, Barkhof F. Gray matter network disruptions and amyloid beta in cognitively normal adults. Neurobiol Aging. 2016 Jan;37:154-60.
• Tsolaki M, Papaliagkas V, Frisoni G, Jones R, Touchon J, Spiru L, Vellas B, Verhey F, Winblad B, Visser PJ. MCI Patients in Europe: Medication and Comorbidities. The DESCRIPA Study. Curr Alzheimer Res. 2016;13(12):1407-1413.
• Van der Flier WM. Clinical heterogeneity in familial Alzheimer’s disease. Lancet Neurol. 2016 Dec;15(13):1296-1298.
• van der Zande JJ, Booij J, Scheltens P, Raijmakers PG, Lemstra AW. [(123)]FP-CIT SPECT scans initially rated as normal became abnormal over time in patients with probable dementia with Lewy bodies. Eur J Nucl Med Mol Imaging. 2016 Jun;43(6):1060-6.
• van Duinkerken E, Ijzerman RG, Klein M, Moll AC, Snoek FJ, Scheltens P, Pouwels PJ, Barkhof F, Diamant M, Tijms BM. Disrupted subject-specific gray matter network properties and cognitive dysfunction in type 1 diabetes patients with and without proliferative retinopathy. Hum Brain Mapp. 2016 Mar;37(3):1194-208.
• van Rooden S, Buijs M, van Vliet ME, Versluis MJ, Webb AG, Oleksik AM, van de Wiel L, Middelkoop HA, Blauw GJ, Weverling-Rynsburger AW, Goos JD, van der Flier WM, Koene T, Scheltens P, Barkhof F, van de Rest O, Slagboom PE, van Buchem MA, van der Grond J. Cortical phase changes measured using 7-T MRI in subjects with subjective cognitive impairment, and their association with cognitive function. NMR Biomed. 2016 Sep;29(9):1289-94.
• van Steenoven I, Aarsland D, Weintraub D, Londos E, Blanc F, van der Flier WM, Teunissen CE, Mollenhauer B, Fladby T, Kramberger MG, Bonanni L, Lemstra AW; European DLB consortium. Cerebrospinal Fluid Alzheimer’s Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort. J Alzheimers Dis. 2016 Aug 18;54(1):287-95.
• van Straaten EC, de Waal H, Lansbergen MM, Scheltens P, Maestu F, Nowak R, Hillebrand A, Stam CJ. Magnetoencephalography for the Detection of Intervention Effects of a Specific Nutrient Combination in Patients with Mild Alzheimer’s Disease: Results from an Exploratory Double-Blind, Randomized, Controlled Study. Front Neurol. 2016 Oct 17;7:161.
• van Waalwijk van Doorn LJ, Koel-Simmelink MJ, Haußmann U, Klafki H, Struyfs H, Linning P, Knölker HJ, Twaalfhoven H, Kuiperij HB, Engelborghs S, Scheltens P, Verbeek MM, Vanmechelen E, Wiltfang J, Teunissen CE. Validation of soluble amyloid-β precursor protein assays as diagnostic CSF biomarkers for neurodegenerative diseases. J Neurochem. 2016 Apr;137(1):112-21.
• Vandenberghe R, Rinne JO, Boada M, Katayama S, Scheltens P, Vellas B, Tuchman M, Gass A, Fiebach JB, Hill D, Lobello K, Li D, McRae T, Lucas P, Evans I, Booth K, Luscan G, Wyman BT, Hua L, Yang L, Brashear HR, Black RS; Bapineuzumab 3000 and 3001 Clinical Study Investigators. Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials. Alzheimers Res Ther. 2016 May 12;8(1):18.
• Verfaillie SC, Tijms B, Versteeg A, Benedictus MR, Bouwman FH, Scheltens P, Barkhof F, Vrenken H, van der Flier WM. Thinner temporal and parietal cortex is related to incident clinical progression to dementia in patients with subjective cognitive decline. Alzheimers Dement (Amst). 2016 Nov 19;5:43-52.
• Vermunt L, Visser PJ, Muller M. . Ned Tijdschr Geneeskd. 2016;160(0):D442. Dutch.
• Vijverberg EG, Wattjes MP, Dols A, Krudop WA, Möller C, Peters A, Kerssens CJ, Gossink F, Prins ND, Stek ML, Scheltens P, van Berckel BN, Barkhof F, Pijnenburg YA. Diagnostic Accuracy of MRI and Additional [18F]FDG-PET for Behavioral Variant Frontotemporal Dementia in Patients with Late Onset Behavioral Changes. J Alzheimers Dis. 2016 Jun 30;53(4):1287-97.
• Vijverberg EG, Dols A, Krudop WA, Peters A, Kerssens CJ, van Berckel BN, Wattjes MP, Barkhof F, Gossink F, Prins ND, Stek ML, Scheltens P, Pijnenburg YA. Diagnostic Accuracy of the Frontotemporal Dementia Consensus Criteria in the Late-Onset Frontal Lobe Syndrome. Dement Geriatr Cogn Disord. 2016;41(3-4):210-9.
• Viswanathan A, Greenberg SM, Scheltens P. Role of Vascular Disease in Alzheimer-Like Progressive Cognitive Impairment. Stroke. 2016 Feb;47(2):577-80.
• Vos SJ, Gordon BA, Su Y, Visser PJ, Holtzman DM, Morris JC, Fagan AM, Benzinger TL. NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. Neurobiol Aging. 2016 Aug;44:1-8.
• Willemse EA, Durieux-Lu S, van der Flier WM, Pijnenburg YA, de Jonge R, Teunissen CE. Stability of Progranulin Under Pre-Analytical Conditions in Serum and Cerebrospinal Fluid. J Alzheimers Dis. 2016 Apr 21;53(1):107-16.
• Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, Cedazo-Minguez A, Dubois B, Edvardsson D, Feldman H, Fratiglioni L, Frisoni GB, Gauthier S, Georges J, Graff C, Iqbal K, Jessen F, Johansson G, Jönsson L, Kivipelto M, Knapp M, Mangialasche F, Melis R, Nordberg A, Rikkert MO, Qiu C, Sakmar TP, Scheltens P, Schneider LS, Sperling R, Tjernberg LO, Waldemar G, Wimo A, Zetterberg H. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol. 2016 Apr;15(5):455-532.
• Wu YH, de Rotrou J, Sikkes SA, Rigaud AS, Plichart M. Clinical utility of the K-T cancellation test in a memory clinic population. J Clin Exp Neuropsychol. 2016 Dec;38(10):1094-102.
• Yi HA, Möller C, Dieleman N, Bouwman FH, Barkhof F, Scheltens P, van der Flier WM, Vrenken H. Relation between subcortical grey matter atrophy and conversion from mild cognitive impairment to Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2016 Apr;87(4):425-32.
• Yu M, Gouw AA, Hillebrand A, Tijms BM, Stam CJ, van Straaten EC, Pijnenburg YA. Different functional connectivity and network topology in behavioral variant of frontotemporal dementia and Alzheimer’s disease: an EEG study. Neurobiol Aging. 2016 Jun;42:150-62.
• Zwan MD, Rinne JO, Hasselbalch SG, Nordberg A, Lleó A, Herukka SK, Soininen H, Law I, Bahl JM, Carter SF, Fortea J, Blesa R, Teunissen CE, Bouwman FH, van Berckel BN, Visser PJ. Use of amyloid-PET to determine cutpoints for CSF markers: A multicenter study. Neurology. 2016 Jan 5;86(1):50-8.
• Zwan MD, Villemagne VL, Doré V, Buckley R, Bourgeat P, Veljanoski R, Salvado O, Williams R, Margison L, Rembach A, Macaulay SL, Martins R, Ames D, van der Flier WM, Ellis KA, Scheltens P, Masters CL, Rowe CC. Subjective Memory Complaints in APOEɛ4 Carriers are Associated with High Amyloid-β Burden. J Alzheimers Dis. 2016;49(4):1115-22.

• De Beer M, Leeuwis A, Pijnenburg Y. Een patiënt met visuele problemen: eerste uiting van neurodegeneratieve aandoening. Ned Tijdschr Geneeskd. 2015;159
• Möller, C., Pijnenburg, Y.A., van der Flier, W.M., Versteeg, A., Tijms, B., de Munck, J.C., Hafkemeijer, A., Rombouts, S.A., van der Grond, J., van Swieten, J., Dopper, E., Scheltens, P., Barkhof, F., Vrenken, H., Wink, A.M. Alzheimer Disease and Behavioral Variant Frontotemporal Dementia: Automatic Classification Based on Cortical Atrophy for Single-Subject Diagnosis. Radiology. 2015 Dec 11:150220.
• Zwan, M.D., Villemagne, V.L., Doré, V., Buckley, R., Bourgeat, P., Veljanoski, R., Salvado, O., Williams, R., Margison, L., Rembach, A., Macaulay, S.L., Martins, R., Ames, D., van der Flier, W.M., Ellis, K.A., Scheltens, P., Masters, C.L., Rowe, C.C. Subjective Memory Complaints in APOEɛ4 Carriers are Associated with High Amyloid-β Burden. Journal of Alzheimer’s Disease 2015 Nov 25;49(4):1115-22.
• Möller, C., Hafkemeijer, A., Pijnenburg, Y.A., Rombouts, S.A., van der Grond, J., Dopper, E., van Swieten, J., Versteeg, A., Pouwels, P.J., Barkhof, F., Scheltens, P., Vrenken, H., van der Flier, W.M. Joint assessment of white matter integrity, cortical and subcortical atrophy to distinguish AD from behavioral variant FTD: A two-center study. Neuroimage: Clinical 2015 Sep 9;9:418-29.
• Rhodius-Meester, H.F., Koikkalainen, J., Mattila, J., Teunissen, C.E., Barkhof, F., Lemstra, A.W., Scheltens, P., Lötjönen, J., van der Flier, W.M. Integrating Biomarkers for Underlying Alzheimer’s Disease in Mild Cognitive Impairment in Daily Practice: Comparison of a Clinical Decision Support System with Individual Biomarkers. Journal of Alzheimer’s Disease 2015 Nov 13;50(1):261-70.
• Abheiden, C.N., van Doornik, R., Aukes, A.M., van der Flier, W.M., Scheltens, P., de Groot, C.J. Hypertensive Disorders of Pregnancy Appear Not to Be Associated with Alzheimer’s Disease Later in Life.Dementia and Geriatric Cognitive Disorders Extra 2015 Sep 30;5(3):375-85.
• Reijs, B.L., Teunissen, C.E., Goncharenko, N., Betsou, F., Blennow, K., Baldeiras, I., Brosseron, F., Cavedo, E., Fladby, T., Froelich, L., Gabryelewicz, T., Gurvit, H., Kapaki, E., Koson, P., Kulic, L., Lehmann, S., Lewczuk, P., Lleó, A., Maetzler, W., de Mendonça, A., Miller, A.M., Molinuevo, J.L., Mollenhauer, B., Parnetti, L., Rot, U., Schneider, A., Simonsen, A.H., Tagliavini, F., Tsolaki, M., Verbeek, M.M., Verhey, F.R., Zboch, M., Winblad, B., Scheltens, P., Zetterberg, H., Visser, P.J. The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. Frontiers in Neurology 2015 Oct 15;6:216.
• Roca, M., López-Navarro, E., Monzón, S., Vives, M, Garcia-Toro, M., Garcia-Campayo, J., Harrison, J. & Gili, M (2015) Cognitive impairment in remitted and non-remitted depressive patients: A follow-up comparison between first and recurrent episodes. Eur Neuropsychopharmacol 25: 1991-8.
• Rosenberger, A.F., Hilhorst, R., Coart, E., García Barrado, L., Naji, F., Rozemuller, A.J., van der Flier, W.M., Scheltens, P., Hoozemans, J.J., van der Vies, S.M. Protein Kinase Activity Decreases with Higher Braak Stages of Alzheimer’s Disease Pathology. Journal of Alzheimer’s Disease 2015 Oct 27;49(4):927-43.
• Dubois, B., Padovani, A., Scheltens, P., Rossi, A., Dell’Agnello, G. Timely Diagnosis for Alzheimer’s Disease: A Literature Review on Benefits and Challenges. Journal of Alzheimer’s Disease 2015 Oct 17;49(3):617-31.
• Hafkemeijer, A., Möller, C., Dopper, E.G., Jiskoot, L.C., Schouten, T.M., van Swieten, J.C., van der Flier, W.M., Vrenken, H., Pijnenburg, Y.A., Barkhof, F., Scheltens, P., van der Grond, J., Rombouts, S.A. Resting state functional connectivity differences between behavioral variant frontotemporal dementia and Alzheimer’s disease. Frontiers in Human Neuroscience 2015 Sep 8;9:474.
• Adriaanse, S.M., Wink, A.M., Tijms, B.M., Ossenkoppele, R., Verfaillie, S.C., Lammertsma, A.A., Boellaard, R., Scheltens, P., van Berckel, B.N., Barkhof, F. The Association of Glucose Metabolism and Eigenvector Centrality in Alzheimer’s Disease. Brain Connect 2016 Feb;6(1):1-8.
• van Harten, A.C., Mulders, J., Scheltens, P., van der Flier, W.M., Oudejans, C.B. Differential Expression of microRNA in Cerebrospinal Fluid as a Potential Novel Biomarker for Alzheimer’s Disease. Journal of Alzheimer’s Disease 2015;47(1):243-52.
• Duits, F.H., Hernandez-Guillamon, M., Montaner, J., Goos, J.D., Montañola, A., Wattjes, M.P., Barkhof, F., Scheltens, P., Teunissen, C.E., van der Flier, W.M. Matrix Metalloproteinases in Alzheimer’s Disease and Concurrent Cerebral Microbleeds. Journal of Alzheimer’s Disease 2015;48(3):711-20.
• Kester, M.I., Teunissen, C.E., Sutphen, C., Herries, E.M., Ladenson, J.H., Xiong, C.,Scheltens, P., van der Flier, W.M., Morris, J.C., Holtzman, D.M., Fagan, A.M. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer’s disease in a memory clinic cohort. Alzheimer’s Research Therapy 2015 Sep 17;7(1):59.
• Duits, F.H., Martinez-Lage, P., Paquet, C., Engelborghs, S., Lleó, A., Hausner, L., Molinuevo, J.L., Stomrud, E., Farotti, L., Ramakers, I.H., Tsolaki, M., Skarsgård, C., Åstrand, R., Wallin, A., Vyhnalek, M., Holmber-Clausen, M., Forlenza, O.V., Ghezzi, L., Ingelsson, M., Hoff, E.I., Roks, G., de Mendonça, A., Papma, J.M., Izagirre, A., Taga, M., Struyfs, H., Alcolea, D.A., Frölich, L., Balasa, M., Minthon, L., Twisk, J.W., Persson, S., Zetterberg, H., van der Flier, W.M., Teunissen, C.E., Scheltens, P., Blennow, K. Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. Alzheimer’s & Dementia 2016 Feb;12(2):154-63.
• Kester, M.I., Teunissen, C.E., Crimmins, D.L., Herries, E.M., Ladenson, J.H., Scheltens, P., van der Flier, W.M., Morris, J.C., Holtzman, D.M., Fagan, A.M. Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease. JAMA Neurology 2015 Nov;72(11):1275-80.
• Morley, J.E., Morris, J.C., Berg-Weger, M., Borson, S., Carpenter, B.D., Del Campo, N., Dubois, B., Fargo, K., Fitten, L.J., Flaherty, J.H., Ganguli, M., Grossberg, G.T., Malmstrom, T.K., Petersen, R.D., Rodriguez, C., Saykin, A.J., Scheltens, P., Tangalos, E.G., Verghese, J., Wilcock, G., Winblad, B., Woo, J., Vellas, B. Brain health: the importance of recognizing cognitive impairment: an IAGG consensus conference. Journal of the American Medical Directors Association 2015 Sep 1;16(9):731-9.
• Engels, M.M., Stam, C.J., van der Flier, W.M., Scheltens, P., de Waal, H., van Straaten, E.C. Declining functional connectivity and changing hub locations in Alzheimer’s disease: an EEG study. BMC Neurology 2015 Aug 20;15:145.
• Ossenkoppele, R., Cohn-Sheehy, B.I., La Joie, R., Vogel, J.W., Möller, C., Lehmann, M., van Berckel, B.N., Seeley, W.W., Pijnenburg, Y.A., Gorno-Tempini, M.L., Kramer, J.H., Barkhof, F., Rosen, H.J., van der Flier, W.M., Jagust, W.J., Miller, B.L., Scheltens, P., Rabinovici, G.D. Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer’s disease.Human Brain Mapping 2015 Nov;36(11):4421-37.
• Toledo, J.B., Zetterberg, H., van Harten, A.C., Glodzik, L., Martinez-Lage, P., Bocchio-Chiavetto, L., Rami, L., Hansson, O., Sperling, R., Engelborghs, S., Osorio, R.S., Vanderstichele, H., Vandijck, M., Hampel, H., Teipl, S., Moghekar, A., Albert, M., Hu, W.T., Monge Argilés, J.A., Gorostidi, A., Teunissen, C.E., De Deyn, P.P., Hyman, B.T., Molinuevo, J.L., Frisoni, G.B., Linazasoro, G., de Leon, M.J., van der Flier, W.M.,Scheltens, P., Blennow, K., Shaw, L.M., Trojanowski, J.Q.; Alzheimer’s Disease Neuroimaging Initiative. Alzheimer’s disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain 2015 Sep;138(Pt 9):2701-15.
• Rijpma, A., Meulenbroek, O., van Hees, A.M., Sijben, J.W., Vellas, B., Shah, R.C., Bennett, D.A., Scheltens, P., Olde Rikkert, M.G. Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer’s disease. Alzheimer’s Research Therapy 2015 Jul 24;7(1):51.
• van Dellen, E., de Waal, H., van der Flier, W.M., Lemstra, A.W., Slooter, A.J., Smits, L.L., van Straaten, E.C., Stam, C.J., Scheltens, P. Loss of EEG Network Efficiency Is Related to Cognitive Impairment in Dementia With Lewy Bodies.Movement Disorders Journal 2015 Nov;30(13):1785-93.
• Benedictus, M.R., van Harten, A.C., Leeuwis, A.E., Koene, T., Scheltens, P., Barkhof, F., Prins, N.D., van der Flier, W.M. White Matter Hyperintensities Relate to Clinical Progression in Subjective Cognitive Decline. Stroke 2015 Sep;46(9):2661-4.
• Ossenkoppele, R., Pijnenburg, Y.A., Perry, D.C., Cohn-Sheehy, B.I., Scheltens, N.M., Vogel, J.W., Kramer, J.H., van der Vlies, A.E., Joie, R.L., Rosen, H.J., van der Flier, W.M., Grinberg, L.T., Rozemuller, A.J., Huang, E.J., van Berckel, B.N., Miller, B.L., Barkhof, F., Jagust, W.J., Scheltens, P., Seeley, W.W., Rabinovici, G.D. The behavioural/dysexecutive variant of Alzheimer’s disease: clinical, neuroimaging and pathological features. Brain 2015 Sep;138(Pt 9):2732-49.
• Chouliaras, L., Kenis, G., Visser, P.J., Scheltens, P., Tsolaki, M., Jones, R.W., Kehoe, P.G., Graff, C., Girtler, N.G., Wallin, Å.K., Rikkert, M.O., Spiru, L., Elias-Sonnenschein, L.S., Ramakers, I.H., Pishva, E., van Os, J., Steinbusch, H.W., Verhey, F.R., van den Hove, D.L., Rutten, B.P. DNMT3A moderates cognitive decline in subjects with mild cognitive impairment: replicated evidence from two mild cognitive impairment cohorts. Epigenomics 2015;7(4):533-7.
• Krudop, W.A., Bosman, S., Geurts, J.J., Sikkes, S.A., Verwey, N.A., Stek, M.L., Scheltens, P., Rozemuller, A.J., Pijnenburg, Y.A. Clinico-Pathological Correlations of the Frontal Lobe Syndrome: Results of a Large Brain Bank Study. Dementia and Geriatric Cognitive Disorders 2015;40(3-4):121-9.
• Binnewijzend, M.A., Benedictus, M.R., Kuijer, J.P., van der Flier, W.M., Teunissen, C.E., Prins, N.D., Wattjes, M.P., van Berckel, B.N., Scheltens, P., Barkhof, F. Cerebral perfusion in the predementia stages of Alzheimer’s disease. European Radiology 2016 Feb;26(2):506-14.
• Ossenkoppele, R., Mattsson, N., Teunissen, C.E., Barkhof, F., Pijnenburg, Y., Scheltens, P., van der Flier, W.M., Rabinovici, G.D. Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer’s disease. Neurobiology of Aging 2015 Aug;36(8):2340-7.
• Ossenkoppele, R., Jansen, W.J., Rabinovici, G.D., Knol, D.L., van der Flier, W.M., van Berckel, B.N., Scheltens, P., Visser, P.J.; Amyloid PET Study Group, Verfaillie, S.C., Zwan, M.D., Adriaanse, S.M., Lammertsma, A.A., Barkhof, F., Jagust, W.J., Miller, B.L., Rosen, H.J., Landau, S.M., Villemagne, V.L., Rowe, C.C., Lee, D.Y., Na, D.L., Seo, S.W., Sarazin, M., Roe, C.M., Sabri, O., Barthel, H., Koglin, N., Hodges, J., Leyton, C.E., Vandenberghe, R., van Laere, K., Drzezga, A., Forster, S., Grimmer, T., Sánchez-Juan, P., Carril, J.M., Mok, V., Camus, V., Klunk, W.E., Cohen, A.D., Meyer, P.T., Hellwig, S., Newberg, A., Frederiksen, K.S., Fleisher, A.S., Mintun, M.A., Wolk, D.A., Nordberg, A., Rinne, J.O., Chételat, G., Lleo, A., Blesa, R., Fortea, J., Madsen, K., Rodrigue, K.M., Brooks, D.J. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. Journal of the American Medical Association 2015 May 19;313(19):1939-49.
• Jansen, W.J., Ossenkoppele, R., Knol, D.L., Tijms, B.M., Scheltens, P., Verhey, F.R., Visser, P.J.; Amyloid Biomarker Study Group, Aalten, P., Aarsland, D., Alcolea, D., Alexander, M., Almdahl, I.S., Arnold, S.E., Baldeiras, I., Barthel, H., van Berckel, B.N., Bibeau, K., Blennow, K., Brooks, D.J., van Buchem, M.A., Camus, V., Cavedo, E., Chen, K., Chetelat, G., Cohen, A.D., Drzezga, A., Engelborghs, S., Fagan, A.M., Fladby, T., Fleisher, A.S., van der Flier, W.M., Ford, L., Förster, S., Fortea, J., Foskett, N., Frederiksen, K.S., Freund-Levi, Y., Frisoni, G.B., Froelich, L., Gabryelewicz, T., Gill, K.D., Gkatzima, O., Gómez-Tortosa, E., Gordon, M.F., Grimmer, T., Hampel, H., Hausner, L., Hellwig, S., Herukka, S.K., Hildebrandt, H., Ishihara, L., Ivanoiu, A., Jagust, W.J., Johannsen, P., Kandimalla, R., Kapaki, E., Klimkowicz-Mrowiec, A., Klunk, W.E., Köhler, S., Koglin, N., Kornhuber, J., Kramberger, M.G., Van Laere, K., Landau, S.M., Lee, D.Y., de Leon, M., Lisetti, V., Lleó, A., Madsen, K., Maier, W., Marcusson, J., Mattsson, N., de Mendonça, A., Meulenbroek, O., Meyer, P.T., Mintun, M.A., Mok, V., Molinuevo, J.L., Møllergård, H.M., Morris, J.C., Mroczko, B., Van der Mussele, S., Na, D.L., Newberg, A., Nordberg, A., Nordlund, A., Novak, G.P., Paraskevas, G.P., Parnetti, L., Perera, G., Peters, O., Popp, J., Prabhakar, S., Rabinovici, G.D., Ramakers, I.H., Rami, L., Resende de Oliveira, C., Rinne, J.O., Rodrigue, K.M., Rodríguez-Rodríguez, E., Roe, C.M., Rot, U., Rowe, C.C., Rüther, E., Sabri, O., Sanchez-Juan, P., Santana, I., Sarazin, M., Schröder, J., Schütte, C., Seo, S.W., Soetewey, F., Soininen, H., Spiru, L., Struyfs, H., Teunissen, C.E., Tsolaki, M., Vandenberghe, R., Verbeek, M.M., Villemagne, V.L., Vos, S.J., van Waalwijk van Doorn, L.J., Waldemar, G., Wallin, A., Wallin, Å.K., Wiltfang, J., Wolk, D.A., Zboch, M., Zetterberg, H. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. Journal of the AMA. 2015 May 19;313(19):1924-38.
• Krudop, W.A., Kerssens, C.J., Dols, A., Prins, N.D., Möller, C., Schouws, S., van der Flier, W.M., Scheltens, P., Sikkes, S., Stek, M.L., Pijnenburg, Y.A. Identifying bvFTD Within the Wide Spectrum of Late Onset Frontal Lobe Syndrome: A Clinical Approach. The American Journal of Geriatric Psychiatry 2015 Oct;23(10):1056-66.
• Yi, H.A., Möller, C., Dieleman, N., Bouwman, F.H., Barkhof, F., Scheltens, P., van der Flier, W.M., Vrenken, H. Relation between subcortical grey matter atrophy and conversion from mild cognitive impairment to Alzheimer’s disease. Journal of Neurology, Neurosurgery & Psychiatry 2015 Apr 22.
• Verfaillie, S.C., Adriaanse, S.M., Binnewijzend, M.A., Benedictus, M.R., Ossenkoppele, R., Wattjes, M.P., Pijnenburg, Y.A., van der Flier, W.M., Lammertsma, A.A., Kuijer, J.P., Boellaard, R., Scheltens, P., van Berckel, B.N., Barkhof, F. Cerebral perfusion and glucose metabolism in Alzheimer’s disease and frontotemporal dementia: two sides of the same coin?European Radiology 2015 Oct;25(10):3050-9.
• Smits, L.L., Pijnenburg, Y.A., van der Vlies, A.E., Koedam, E.L., Bouwman, F.H., Reuling, I.E., Scheltens, P., van der Flier, W.M. Early onset APOE E4-negative Alzheimer’s disease patients show faster cognitive decline on non-memory domains. European Neuropsychopharmacology 2015 Jul;25(7):1010-7.
• Coart, E., Barrado, L.G., Duits, F.H., Scheltens, P., van der Flier, W.M., Teunissen, C.E., van der Vies, S.M., Burzykowski, T.; Alzheimer’s Disease Neuroimaging Initiative. Correcting for the Absence of a Gold Standard Improves Diagnostic Accuracy of Biomarkers in Alzheimer’s Disease.Journal of Alzheimer’s Disease 2015;46(4):889-99.
• van der Lee, S.J., Holstege, H., Wong, T.H., Jakobsdottir, J., Bis, J.C., Chouraki, V., van Rooij, J.G., Grove, M.L., Smith, A.V., Amin, N., Choi, S.H., Beiser, A.S., Garcia, M.E., van IJcken, W.F., Pijnenburg, Y.A., Louwersheimer, E., Brouwer, R.W., van den Hout, M.C., Oole, E., Eirkisdottir, G., Levy, D., Rotter, J.I., Emilsson, V., O’Donnell, C.J., Aspelund, T., Uitterlinden, A.G., Launer, L.J., Hofman, A., Boerwinkle, E., Psaty, B.M., DeStefano, A.L., Scheltens, P., Seshadri, S., van Swieten, J.C., Gudnason, V., van der Flier, W.M., Ikram, M.A., van Duijn, C.M. PLD3 variants in population studies. Nature 2015 Apr 2;520(7545):E2-3.
• Schmidt, R., Hofer, E., Bouwman, F.H., Buerger, K., Cordonnier, C., Fladby, T., Galimberti, D., Georges, J., Heneka, M.T., Hort, J., Laczó, J., Molinuevo, J.L., O’Brien, J.T., Religa, D., Scheltens, P., Schott, J.M., Sorbi, S. EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer’s disease. European Journal of Neurology 2015 Jun;22(6):889-98.
• Benedictus, M.R., Prins, N.D., Goos, J.D., Scheltens, P., Barkhof, F., van der Flier, W.M. Microbleeds, Mortality, and Stroke in Alzheimer Disease: The MISTRAL Study. JAMA Neurology 2015 May;72(5):539-45.
• Scheltens, N.M., Galindo-Garre, F., Pijnenburg, Y.A., van der Vlies, A.E., Smits, L.L., Koene, T., Teunissen, C.E., Barkhof, F., Wattjes, M.P., Scheltens, P., van der Flier, W.M. The identification of cognitive subtypes in Alzheimer’s disease dementia using latent class analysis. Journal of Neurology, Neurosurgery & Psychiatry 2016 Mar;87(3):235-43.
• Exalto, L.G., van der Flier, W.M., van Boheemen, C.J., Kappelle, L.J., Vrenken, H., Teunissen, C., Koene, T., Scheltens, P., Biessels, G.J. The metabolic syndrome in a memory clinic population: relation with clinical profile and prognosis. Journal of the Neurological Sciences 2015 Apr 15;351(1-2):18-23.
• Vos, S.J., Verhey, F., Frölich, L., Kornhuber, J., Wiltfang, J., Maier, W., Peters, O., Rüther, E., Nobili, F., Morbelli, S., Frisoni, G.B., Drzezga, A., Didic, M., van Berckel, B.N., Simmons, A., Soininen, H., Kłoszewska, I., Mecocci, P., Tsolaki, M., Vellas, B., Lovestone, S., Muscio, C., Herukka, S.K., Salmon, E., Bastin, C., Wallin, A., Nordlund, A., de Mendonça, A., Silva, D., Santana, I., Lemos, R., Engelborghs, S., Van der Mussele, S.; Alzheimer’s Disease Neuroimaging Initiative, Freund-Levi, Y., Wallin, Å.K., Hampel, H., van der Flier, W., Scheltens, P., Visser, P.J. Prevalence and prognosis of Alzheimer’s disease at the mild cognitive impairment stage. Brain 2015 May;138(Pt 5):1327-38.
• Prins, N.D., Scheltens, P. White matter hyperintensities, cognitive impairment and dementia: an update. Nature Reviews Neurology 2015 Mar;11(3):157-65.
• Louwersheimer, E., Ramirez, A., Cruchaga, C., Becker, T., Kornhuber, J., Peters, O., Heilmann, S., Wiltfang, J., Jessen, F., Visser, P.J., Scheltens, P., Pijnenburg, Y.A., Teunissen, C.E., Barkhof, F., van Swieten, J.C., Holstege, H., Van der Flier, W.M.; Alzheimer’s Disease Neuroimaging Initiative and Dementia Competence Network. Influence of genetic variants in SORL1 gene on the manifestation of Alzheimer’s disease. Neurobiology of Aging 2015 Mar;36(3):1605.e13-20.
• Bron, E.E., Smits, M., van der Flier, W.M., Vrenken, H., Barkhof, F., Scheltens, P., Papma, J.M., Steketee, R.M., Méndez Orellana, C., Meijboom, R., Pinto, M., Meireles, J.R., Garrett, C., Bastos-Leite, A.J., Abdulkadir, A., Ronneberger, O., Amoroso, N., Bellotti, R., Cárdenas-Peña, D., Álvarez-Meza, A.M., Dolph, C.V., Iftekharuddin, K.M., Eskildsen, S.F., Coupé, P., Fonov, V.S., Franke, K., Gaser, C., Ledig, C., Guerrero, R., Tong, T., Gray, K.R., Moradi, E., Tohka, J., Routier, A., Durrleman, S., Sarica, A., Di Fatta, G., Sensi, F., Chincarini, A., Smith, G.M., Stoyanov, Z.V., Sørensen, L., Nielsen, M., Tangaro, S., Inglese, P., Wachinger, C., Reuter, M., van Swieten, J.C., Niessen, W.J., Klein, S.; Alzheimer’s Disease Neuroimaging Initiative. Standardized evaluation of algorithms for computer-aided diagnosis of dementia based on structural MRI: the CADDementia challenge.Neuroimage 2015 May 1;111:562-79.
• Prestia, A., Caroli, A., Wade, S.K., van der Flier, W.M., Ossenkoppele, R., Van Berckel, B., Barkhof, F., Teunissen, C.E., Wall, A., Carter, S.F., Schöll, M., Choo, I.H., Nordberg, A., Scheltens, P., Frisoni, G.B. Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics. Alzheimer’s & Dementia 2015 Oct;11(10):1191-201.

• Gossink FT, Dols A, Kerssens CJ, Krudop WA, Kerklaan BJ, Scheltens P, Stek ML, Pijnenburg YA. Psychiatric diagnoses underlying the phenocopy syndrome of behavioural variant frontotemporal dementia. Journal of Neurology, Neurosurgery & Psychiatry 2016 Jan;87(1):64-8.
• Koster N, Knol DL, Uitdehaag BM, Scheltens P, Sikkes SA. The sensitivity to change over time of the Amsterdam IADL Questionnaire(©). Alzheimer’s & Dementia 2015 Oct;11(10):1231-40.
• Caroli A, Prestia A, Galluzzi S, Ferrari C, van der Flier WM, Ossenkoppele R, Van Berckel B, Barkhof F, Teunissen C, Wall AE, Carter SF, Schöll M, Choo IH, Grimmer T, Redolfi A, Nordberg A, Scheltens P, Drzezga A, Frisoni GB; Alzheimer’s Disease Neuroimaging Initiative. Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression.Neurology 2015 Feb 3;84(5):508-15.
• Jochemsen HM, Muller M, Bots ML, Scheltens P, Vincken KL, Mali WP, van der Graaf Y, Geerlings MI; SMART Study Group. Arterial stiffness and progression of structural brain changes: The SMART-MR study. Neurology 2015 Feb 3;84(5):448-55.
• Jongbloed W, Bruggink KA, Kester MI, Visser PJ, Scheltens P, Blankenstein MA, Verbeek MM, Teunissen CE, Veerhuis R. Amyloid-β oligomers relate to cognitive decline in Alzheimer’s disease. Journal of Alzheimer’s Disease 2015;45(1):35-43.
• Kvartsberg H, Duits FH, Ingelsson M, Andreasen N, Öhrfelt A, Andersson K, Brinkmalm G, Lannfelt L, Minthon L, Hansson O, Andreasson U, Teunissen CE, Scheltens P, Van der Flier WM, Zetterberg H, Portelius E, Blennow K. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer’s disease. Alzheimer’s & Dementia 2015 Oct;11(10):1180-90.
• Hall A, Mattila J, Koikkalainen J, Lötjonen J, Wolz R, Scheltens P, Frisoni G, Tsolaki M, Nobili F, Freund-Levi Y, Minthon L, Frölich L, Hampel H, Visser PJ, Soininen H. Predicting progression from cognitive impairment to Alzheimer’s disease with the Disease State Index. Current Alzheimer Research 2015;12(1):69-79.
• Hamel R, Köhler S, Sistermans N, Koene T, Pijnenburg Y, van der Flier W,Scheltens P, Aalten P, Verhey F, Visser PJ, Ramakers I. The trajectory of cognitive decline in the pre-dementia phase in memory clinic visitors: findings from the 4C-MCI study. Psychological Medicine 2015 May;45(7):1509-19.
• Frederiksen KS, Verdelho A, Madureira S, Bäzner H, O’Brien JT, Fazekas F,Scheltens P, Schmidt R, Wallin A, Wahlund LO, Erkinjunttii T, Poggesi A, Pantoni L, Inzitari D, Waldemar G; LADIS Study. Physical activity in the elderly is associated with improved executive function and processing speed: the LADIS Study. International Journal of Geriatric Psychiatry 2015 Jul;30(7):744-50.
• Teunissen CE, van der Flier WM, Scheltens P, Duits A, Wijnstok N, Nijpels G, Dekker JM, Blankenstein RM, Heijboer AC. Serum leptin is not altered nor related to cognitive decline in Alzheimer’s disease. Journal of Alzheimer’s Disease 2015;44(3):809-13.
• Möller C, Dieleman N, van der Flier WM, Versteeg A, Pijnenburg Y, ScheltensP, Barkhof F, Vrenken H. More atrophy of deep gray matter structures in frontotemporal dementia compared to Alzheimer’s disease.Journal of Alzheimer’s Disease 2015;44(2):635-47.
• Olde Rikkert MG, Verhey FR, Blesa R, von Arnim CA, Bongers A, Harrison J, Sijben J, Scarpini E, Vandewoude MF, Vellas B, Witkamp R, Kamphuis PJ,Scheltens P. Tolerability and safety of Souvenaid in patients with mild Alzheimer’s disease: results of multi-center, 24-week, open-label extension study. Journal of Alzheimer’s Disease 2015;44(2):471-80.
• Frisoni GB, Jack CR Jr, Bocchetta M, Bauer C, Frederiksen KS, Liu Y, Preboske G, Swihart T, Blair M, Cavedo E, Grothe MJ, Lanfredi M, Martinez O, Nishikawa M, Portegies M, Stoub T, Ward C, Apostolova LG, Ganzola R, Wolf D, Barkhof F, Bartzokis G, DeCarli C, Csernansky JG, deToledo-Morrell L, Geerlings MI, Kaye J, Killiany RJ, Lehéricy S, Matsuda H, O’Brien J, Silbert LC, Scheltens P, Soininen H, Teipel S, Waldemar G, Fellgiebel A, Barnes J, Firbank M, Gerritsen L, Henneman W, Malykhin N, Pruessner JC, Wang L, Watson C, Wolf H, deLeon M, Pantel J, Ferrari C, Bosco P, Pasqualetti P, Duchesne S, Duvernoy H, Boccardi M; EADC-ADNI Working Group on The Harmonized Protocol for Manual Hippocampal Volumetry and for the Alzheimer’s Disease Neuroimaging Initiative. The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: evidence of validity. Alzheimer’s & Dementia 2015 Feb;11(2):111-25.
• Jonker FA, Jonker C, Scheltens P, Scherder EJ. The role of the orbitofrontal cortex in cognition and behavior. Reviews in the Neurosciences 2015;26(1):1-11.
• Smits LL, van Harten AC, Pijnenburg YA, Koedam EL, Bouwman FH, Sistermans N, Reuling IE, Prins ND, Lemstra AW, Scheltens P, van der Flier WM. Trajectories of cognitive decline in different types of dementia.Psychological Medicine 2015 Apr;45(5):1051-9.
• Douglas CM, Scheltens P. Rethinking biobanking and translational medicine in the Netherlands: how the research process stands to matter for patient care. European Journal of Human Genetics 2015 Jun;23(6):736-8.
• Jochemsen HM, van der Flier WM, Ashby EL, Teunissen CE, Jones RE, Wattjes MP, Scheltens P, Geerlings MI, Kehoe PG, Muller M. Angiotensin-converting enzyme in cerebrospinal fluid and risk of brain atrophy. Journal of Alzheimer’s Disease 2015;44(1):153-62.
• Duits FH, Prins ND, Lemstra AW, Pijnenburg YA, Bouwman FH, Teunissen CE, Scheltens P, van der Flier WM. Diagnostic impact of CSF biomarkers for Alzheimer’s disease in a tertiary memory clinic. Alzheimer’s & Dementia 2015 May;11(5):523-32.
• Bertens D, Knol DL, Scheltens P, Visser PJ; Alzheimer’s Disease Neuroimaging Initiative. Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer’s disease. Alzheimer’s & Dementia 2015 May;11(5):511-22.
• van Rooden S, Doan NT, Versluis MJ, Goos JD, Webb AG, Oleksik AM, van der Flier WM, Scheltens P, Barkhof F, Weverling-Rynsburger AW, Blauw GJ, Reiber JH, van Buchem MA, Milles J, van der Grond J. 7T T₂*-weighted magnetic resonance imaging reveals cortical phase differences between early- and late-onset Alzheimer’s disease. Neurobiology of Aging 2015 Jan;36(1):20-6.
• Joling KJ, van Marwijk HW, Veldhuijzen AE, van der Horst HE, Scheltens P, Smit F, van Hout HP. The two-year incidence of depression and anxiety disorders in spousal caregivers of persons with dementia: who is at the greatest risk? American Journal of Geriatric Psychiatry 2015 Mar;23(3):293-303.
• Hooghiemstra AM, Eggermont LH, Scheltens P, van der Flier WM, Scherder EJ. The rest-activity rhythm and physical activity in early-onset dementia.Alzheimer Disease and Associated Disorders 2015 Jan-Mar;29(1):45-9.
• Jongbloed W, van Dijk KD, Mulder SD, van de Berg WD, Blankenstein MA, van der Flier W, Veerhuis R. Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer’s Disease. Journal of Alzheimer’s Disease 2015 Jun;46(4):1103-10.
• Rabin LA, Smart CM, Crane PK, Amariglio RE, Berman LM, Boada M, Buckley RF, Chételat G, Dubois B, Ellis KA, Gifford KA, Jefferson AL, Jessen F, Katz MJ, Lipton RB, Luck T, Maruff P, Mielke MM, Molinuevo JL, Naeem F, Perrotin A, Petersen RC, Rami L, Reisberg B, Rentz DM, Riedel-Heller SG, Risacher SL, Rodriguez O, Sachdev PS, Saykin AJ, Slavin MJ, Snitz BE, Sperling RA, Tandetnik C, van der Flier WM, Wagner M, Wolfsgruber S, Sikkes SA.Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. Journal of Alzheimer’s Disease 2015 Sep 24;48
• Benedictus MR, Hochart A, Rossi C, Boulouis G, Hénon H, van der Flier WM, Cordonnier C. Prognostic Factors for Cognitive Decline After Intracerebral Hemorrhage. Stroke 2015 Oct;46(10):2773-8.
• Barnes J, Dickerson BC, Frost C, Jiskoot LC, Wolk D, van der Flier WM. Alzheimer’s disease first symptoms are age dependent: Evidence from the NACC dataset. Alzheimer’s & Dementia 2015 Nov;11(11):1349-57.
• Willemse EA, Koel-Simmelink MJ, Durieux-Lu S, van der Flier WM, Teunissen CE. Standard biobanking conditions prevent evaporation of body fluid samples. Clinica Chimica Acta 2015 Mar 10;442:141-5.
• Olde Rikkert MG, van Exel E, Knol W, Lemstra AW, Roks G, Verhey FR. .Nederlands Tijdschrift voor Geneeskde. 2015;159:A8671. Review. Dutch.
• Millenaar JK, de Vugt ME, Bakker C, van Vliet D, Pijnenburg YA, Koopmans RT, Verhey FR. The Impact of Young Onset Dementia on Informal Caregivers Compared with Late Onset Dementia: Results from the NeedYD Study. American Journal of Geriatric Psychiatry 2015 Jul 17. pii: S1064-7481(15)00209-2.
• de Beer M, Leeuwis A, Pijnenburg Y. . Nederlands Tijdschrift voor Geneeskde. 2015;159:A8878. Dutch.
• Krudop WA, Pijnenburg YA. Historical evolution of the frontal lobe syndrome. Psychopathology 2015;48(4):222-9.
• Ten Kate M, Sanz-Arigita EJ, Tijms BM, Wink AM, Clerigue M, Garcia-Sebastian M, Izagirre A, Ecay-Torres M, Estanga A, Villanua J, Vrenken H,Visser PJ, Martinez-Lage P, Barkhof F. Impact of APOE-ɛ4 and family history of dementia on gray matter atrophy in cognitively healthy middle-aged adults. Neurobiology of Aging 2016 Feb;38:14-20.
• Zwan MD, Rinne JO, Hasselbalch SG, Nordberg A, Lleó A, Herukka SK, Soininen H, Law I, Bahl JM, Carter SF, Fortea J, Blesa R, Teunissen CE, Bouwman FH, van Berckel BN, Visser PJ. Use of amyloid-PET to determine cutpoints for CSF markers: A multicenter study. Neurology 2016 Jan 5;86(1):50-8.
• Jansen WJ, Ossenkoppele R, Visser PJ. Amyloid Pathology, Cognitive Impairment, and Alzheimer Disease Risk–Reply. JAMA 2015 Sep 15;314(11):1177-8.
• Tang EY, Harrison SL, Errington L, Gordon MF, Visser PJ, Novak G, Dufouil C, Brayne C, Robinson L, Launer LJ, Stephan BC. Current Developments in Dementia Risk Prediction Modelling: An Updated Systematic Review. PLoS One 2015 Sep 3;10(9):e0136181.
• Jovicich, J., Minati, L., Marizzoni, M., Marchitelli, R., Sala-Llonch, R., Bartrés-Faz, D., Arnold, J., Benninghoff, J., Fiedler, U., Roccatagliata, L., Picco, A., Nobili, F., Blin, O., Bombois, S., Lopes, R., Bordet, R., Sein, J., Ranjeva, J.P., Didic, M., Gros-Dagnac, H., Payoux, P., Zoccatelli, G., Alessandrini, F., Beltramello, A., Bargalló, N., Ferretti, A., Caulo, M., Aiello, M., Cavaliere, C., Soricelli, A., Parnetti, L., Tarducci, R., Floridi, P., Tsolaki, M., Constantinidis, M., Drevelegas, A., Rossini, P.M., Marra, C., Schönknecht, P., Hensch, T., Hoffmann, K.T., Kuijer, J.P., Visser, P.J., Barkhof, F., Frisoni, G.B.; PharmaCog Consortium. Longitudinal reproducibility of default-mode network connectivity in healthy elderly participants: A multicentric resting-state fMRI study. Neuroimage 2016 Jan 1;124(Pt A):442-54.
• Frisoni, G.B., Visser, P.J. Biomarkers for Alzheimer’s disease: a controversial topic. Lancet Neurology 2015 Aug;14(8):781-3.
• Marizzoni, M., Antelmi, L., Bosch, B., Bartrés-Faz, D., Müller, B.W., Wiltfang, J., Fiedler, U., Roccatagliata, L., Picco, A., Nobili, F., Blin, O., Bombois, S., Lopes, R., Sein, J., Ranjeva, J.P., Didic, M., Gros-Dagnac, H., Payoux, P., Zoccatelli, G., Alessandrini, F., Beltramello, A., Bargalló, N., Ferretti, A., Caulo, M., Aiello, M., Cavaliere, C., Soricelli, A., Salvadori, N., Parnetti, L., Tarducci, R., Floridi, P., Tsolaki, M., Constantinidis, M., Drevelegas, A., Rossini, P.M., Marra, C., Hoffmann, K.T., Hensch, T., Schönknecht, P., Kuijer, J.P., Visser, P.J., Barkhof, F., Bordet, R., Frisoni, G.B., Jovicich, J.; PharmaCog Consortium. Longitudinal reproducibility of automatically segmented hippocampal subfields: A multisite European 3T study on healthy elderly. Human Brain Mapping 2015 Sep;36(9):3516-27.
• Ramakers, I.H., Honings, S.T., Ponds, R.W., Aalten, P., Sebastian, K., Verhey, F.R.,Visser, P.J. The Effect of Psychological Distress and Personality Traits on Cognitive Performances and the Risk of Dementia in Patients with Mild Cognitive Impairment. Journal of Alzheimer’s Disease 2015;46(3):805-12.
• Vaudano, E., Vannieuwenhuyse, B., Van Der Geyten, S., van der Lei, J., Visser, P.J., Streffer, J., Ritchie, C., McHale, D., Lovestone, S., Hofmann-Apitius, M., Truyen, L., Goldman, M. Boosting translational research on Alzheimer’s disease in Europe: The Innovative Medicine Initiative AD research platform. Alzheimer’s & Dementia 2015 Sep;11(9):1121-2.
• Lleó, A., Cavedo, E., Parnetti, L., Vanderstichele, H., Herukka, S.K., Andreasen, N., Ghidoni, R., Lewczuk, P., Jeromin, A., Winblad, B., Tsolaki, M., Mroczko, B., Visser, P.J., Santana, I., Svenningsson, P., Blennow, K., Aarsland, D., Molinuevo, J.L., Zetterberg, H., Mollenhauer, B. Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nature Reviews Neurology 2015 Jan;11(1):41-55.
• Hall, A., Muñoz-Ruiz, M,. Mattila, J., Koikkalainen, J., Tsolaki, M., Mecocci, P., Kloszewska, I., Vellas, B., Lovestone, S., Visser, P.J., Lötjonen, J., Soininen, H.; Alzheimer Disease Neuroimaging Initiative; AddNeuroMed consortium; DESCRIPA and Kuopio L-MCI. Generalizability of the disease state index prediction model for identifying patients progressing from mild cognitive impairment to Alzheimer’s disease. Journal of Alzheimer’s Disease 2015;44(1):79-92.
• Bocchetta, M., Galluzzi, S., Kehoe, P.G., Aguera, E., Bernabei, R., Bullock, R., Ceccaldi, M., Dartigues, J.F., de Mendonça, A., Didic, M., Eriksdotter, M., Félician, O., Frölich, L., Gertz, H.J., Hallikainen, M., Hasselbalch, S.G., Hausner, L., Heuser, I., Jessen, F., Jones, R.W., Kurz, A., Lawlor, B., Lleo, A., Martinez-Lage, P., Mecocci, P., Mehrabian, S., Monsch, A., Nobili, F., Nordberg, A., Rikkert, M.O., Orgogozo, J.M., Pasquier, F., Peters, O., Salmon, E., Sánchez-Castellano, C., Santana, I., Sarazin, M., Traykov, L., Tsolaki, M., Visser, P.J., Wallin, Å.K., Wilcock, G., Wilkinson, D., Wolf, H., Yener, G., Zekry, D., Frisoni, G.B. The use of biomarkers for the etiologic diagnosis of MCI in Europe: an EADC survey. Alzheimer’s & Dementia 2015 Feb;11(2):195-206.e1.
• van Straaten, E.C., den Haan, J., de Waal, H., van der Flier, W.M., Barkhof, F., Prins, N.D., Stam, C.J. Disturbed phase relations in white matter hyperintensity based vascular dementia: an EEG directed connectivity study. Clinical Neurophysiology 2015 Mar;126(3):497-504.
• Wu, Y.H., Vidal, J.S., de Rotrou, J., Sikkes, S.A., Rigaud, A.S., Plichart, M. A Tablet-PC-Based Cancellation Test Assessing Executive Functions in Older Adults. American Journal of Geriatric Psychiatry 2015 Nov;23(11):1154-61.
• Jekel, K., Damian, M., Wattmo, C., Hausner, L., Bullock, R., Connelly, P.J., Dubois, B., Eriksdotter, M., Ewers, M., Graessel, E., Kramberger, M.G., Law, E., Mecocci, P., Molinuevo, J.L., Nygård, L., Olde-Rikkert, M.G., Orgogozo, J.M., Pasquier, F., Peres, K., Salmon, E., Sikkes, S.A., Sobow, T., Spiegel, R., Tsolaki, M., Winblad, B., Frölich, L. Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic review. Alzheimer’s Research & Therapy 2015 Mar 18;7(1):17.
• Pagani, M., De Carli, F., Morbelli, S., Öberg, J., Chincarini, A., Frisoni, G.B., Galluzzi, S., Perneczky, R., Drzezga, A., van Berckel, B.N., Ossenkoppele, R., Didic, M., Guedj, E., Brugnolo, A., Picco, A., Arnaldi, D., Ferrara, M., Buschiazzo, A., Sambuceti, G., Nobili, F. Volume of interest-based [18F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer’s disease from healthy controls. A European Alzheimer’s Disease Consortium (EADC) study. Neuroimage: Clinical 2014 Nov 18;7:34-42.
• Ossenkoppele, R., Schonhaut, D.R., Baker, S.L., O’Neil, J.P., Janabi, M., Ghosh, P.M., Santos, M., Miller, Z.A., Bettcher, B.M., Gorno-Tempini, M.L., Miller, B.L., Jagust, W.J., Rabinovici, G.D. Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy. Annals of Neurology 2015 Feb;77(2):338-42.
• Morbelli, S., Brugnolo, A., Bossert, I., Buschiazzo, A., Frisoni, G.B., Galluzzi, S., van Berckel, B.N., Ossenkoppele, R., Perneczky, R., Drzezga, A., Didic, M., Guedj, E., Sambuceti, G., Bottoni, G., Arnaldi, D., Picco, A., De Carli, F., Pagani, M., Nobili, F. Visual versus semi-quantitative analysis of 18F-FDG-PET in amnestic MCI: an European Alzheimer’s Disease Consortium (EADC) project. Journal of Alzheimer’s Disease 2015;44(3):815-26.
• Steenwijk, M.D., Geurts, J.J., Daams, M., Tijms, B.M., Wink, A.M., Balk, L.J., Tewarie, P.K., Uitdehaag, B.M., Barkhof, F., Vrenken, H., Pouwels, P.J. Cortical atrophy patterns in multiple sclerosis are non-random and clinically relevant. Brain 2016 Jan;139(Pt 1):115-26.
• Tijms, B.M., Sprooten, E., Job, D., Johnstone, E.C., Owens, D.G., Willshaw, D., Seriès, P., Lawrie, S.M. Grey matter networks in people at increased familial risk for schizophrenia. Schizophrenia Research 2015 Oct;168(1-2):1-8.

Internationale publicaties

• Benedictus, M.R., Binnewijzend, M.A., Kuijer, J.P., Steenwijk, M.D., Versteeg, A., Vrenken, H., Scheltens, P., Barkhof, F., van der Flier, W.M., Prins, N.D. Brain volume and white matter hyperintensities as determinants of cerebral blood flow in Alzheimer’s disease. Neurobiology of Aging 2014 Dec;35(12):2665-70.
• Bakker, C., de Vugt, M. E., van Vliet, D., Verhey, F. R. J., Pijnenburg, Y. A., Vernooij-Dassen, M. J. F. J., Koopmans, R. T. C. M. The relationship between unmet care needs in young-onset dementia and the course of neuropsychiatric symptoms: a two-year follow-up study. International Psychogeriatrics 2014 Dec;26(12):1991-2000.
• Bras, J., Guerreiro, R., Darwent, L., Parkkinen, L., Ansorge, O., Escott-Price, V., Hernandez, D.G., Nalls, M.A., Clark, L.N., Honig, L.S., Marder, K., van der Flier, W.M., Lemstra, A., Scheltens, P., Rogaeva, E., St George-Hyslop, P., Londos, E., Zetterberg, H., Ortega-Cubero, S., Pastor, P., Ferman, T.J., Graff-Radford, N.R., Ross, O.A., Barber, I., Braae, A., Brown, K., Morgan, K., Maetzler, W., Berg, D., Troakes, C., Al-Sarraj, S., Lashley, T., Compta, Y., Revesz, T., Lees, A., Cairns, N., Halliday, G.M., Mann, D., Pickering-Brown, S., Dickson, D.W., Singleton, A., Hardy, J. Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Human Molecular Genetics 2014 Dec 1;23(23):6139-46.
• Tewarie, P., Steenwijk, M. D., Tijms, B. M., Daams, M., Balk, L. J., Stam, C. J., Uitdehaag, B. M. J., Polman, C. H., Geurts, J. J. G., Barkhof, F., Pouwels, P. J. W., Vrenken, Hillebrand, H. A. Disruption of Structural and Functional Networks in Long-Standing Multiple Sclerosis. Human Brain Mapping 2014 Dec;35(12):5946-61.
• Bakker, C., de Vugt, M. E., van Vliet, D., Verhey, F., Pijnenburg, Y. A., Vernooij-Dassen, M. J. F. J., Koopmans, Unmet, R. T. C. M. Unmet needs and Health-Related Quality of Life in Young-Onset Dementia. American Journal of Geriatric Psychiatry 2014 Nov;22(11):1121-30.
• Möller, C., Dieleman, N., van der Flier, W.M., Versteeg, A., Pijnenburg, Y., Scheltens, P., Barkhof, F., Vrenken, H. More atrophy of deep gray matter structures in frontotemporal dementia compared to Alzheimer’s disease. Journal of Alzheimer’s Disease 2015;44(2):635-47.
• Cohn-Hokke, P. E., Wong, T. H., Rizzu, P., Breedveld, G., van der Flier, W. M., Scheltens, P., Baas, F., Heutink, P., Meijers-Heijboer, E. J., van Swieten, J. C., Pijnenburg, Y. A. L. Mutation frequency of PRKAR1B and the major familial dementia genes in a Dutch early onset dementia cohort. Journal of Neurology 2014 Nov;261(11):2085-92.
• Duits, F. H., Teunissen, C. E., Bouwman, F. H., Visser, P. J., Mattsson, N., Zetterberg, H., Blennow, K., Hansson, O., Minthon, L., Andreasen, N., Marcusson, J., Wallin, A., Rikkert, M. O., Tsolaki, M., Parnetti, L., Herukka, S. K., Hampel, H., De Leon, M. J., Schroder, J., Aarsland, D., Blankenstein, M. A., Scheltens, P., van der Flier, W. M. The cerebrospinal fluid “Alzheimer profile”: Easily said, but what does it mean? Alzheimer’s & Dementia 2014 Nov;10(6):713-23.
• Jessen, F., Amariglio, R. E., van Boxtel, M., Breteler, M., Ceccaldi, M., Chetelat, G., Dubois, B., Dufouil, C., Ellis, K. A., van der Flier, W. M., Glodzik, L., van Harten, A. C., De Leon, M. J., McHugh, P., Mielke, M. M., Molinuevo, J. L., Mosconi, L., Osorio, R. S., Perrotin, A., Petersen, R. C., Rabin, L. A., Rami, L., Reisberg, B., Rentz, D. M., Sachdev, P. S., de la Sayette, V., Saykin, A. J., Scheltens, P., Shulman, M. B., Slavin, M. J., Sperling, R. A., Stewart, R., Uspenskaya, O., Vellas, B., Visser, P. J., Wagner, M. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimer’s & Dementia 2014 Nov;10(6):844-52.
• Kerklaan, B. J., Van Berckel, B. N. M., Herholz, K., Dols, A., van der Flier, W. M., Scheltens, P., Pijnenburg, Y. A. L. The Added Value of 18-Fluorodeoxyglucose-Positron Emission Tomography in the Diagnosis of the Behavioral Variant of Frontotemporal Dementia. American Journal of Alzheimer’s Disease and other Dementias 2014 Nov;29(7):607-13.
• Ouwens, D. M., van Duinkerken, E., Schoonenboom, S. N. M., de Wiza, D. H., Klein, M., van Golen, L., Pouwels, P. J. W., Barkhof, F., Moll, A. C., Snoek, F. J., Teunissen, C. E., Scheltens, P., Diamant, M. Cerebrospinal fluid levels of Alzheimer’s disease biomarkers in middle-aged patients with type 1 diabetes. Diabetologia 2014 Oct;57(10):2208-14.
• Groeneveld, G. J. Examples of Go and No-Go Decisions After Rigorous Early Phase Drug Evaluation. Biological Psychiatry 2013 Sep-Okt;75(9):22S
• Binnewijzend, M. A. A., Kuijer, J. P. A., van der Flier, W. M., Benedictus, M. R., Moller, C. M., Pijnenburg, Y. A. L., Lemstra, A. W., Prins, N. D., Wattjes, M. P., Van Berckel, B. N. M., Scheltens, P., Barkhof, F. Distinct perfusion patterns in Alzheimer’s disease, frontotemporal dementia and dementia with Lewy bodies. European Radiology 2014 Sep;24(9):2326-33.
• Exalto, L. G., Quesenberry, C. P., Barnes, D., Kivipelto, M., Biessels, G. J., Whitmer, R. A. Midlife risk score for the prediction of dementia four decades later. Alzheimer’s & Dementia 2014 Sep;10(5):562-70.
• Dirven, L., Meijer, W., Sikkes, S. A. M., Reijneveld, J. C., Aaronson, N. K., Uitdehaag, B. M. J., Taphoorn, M. J. B. Development of A New Questionnaire to Measure Instrumental Activities of Daily Living (I-Adl) in Patients with Primary Brain Tumours: Results of Phase 1. Neuro-Oncology 2014 Sep;16
• Jongbloed, W., Herrebout, M. A. C., Blankenstein, M. A., Veerhuis, R. Quantification of clusterin in paired cerebrospinal fluid and plasma samples. Annals of Clinical Biochemistry 2014 Sep;51(5):557-67.
• Paap, J. V., Vernooij-Dassen, M., Droes, R. M., Radbruch, L., Vissers, K., Engels, Y. Consensus on quality indicators to assess the organisation of palliative cancer and dementia care applicable across national healthcare systems and selected by international experts. BMC Health Services Research 2014 Sep;14:396.
• Sommer, I. E., Roze, C. M., Linszen, M. M. J., Somers, M., van Zanten, G. A. Hearing loss; the neglected risk factor for psychosis. Schizophrenia Research 2014 Sep;158(1-3):266-7.
• Ossenkoppele, R., Madison, C., Oh, H., Wirth, M., Van Berckel, B. N. M., Jagust, W. J. Is Verbal Episodic Memory in Elderly with Amyloid Deposits Preserved Through Altered Neuronal Function? Cerebral Cortex 2014 Aug;24(8):2210-8.
• Seelen, M., Visser, A. E., Overste, D. J., Kim, H. J., Palud, A., Wong, T. H., van Swieten, J. C., Scheltens, P., Voermans, N. C., Baas, F., de Jong, J. M. B. V., van der Kooi, A. J., de Visser, M., Veldink, J. H., Taylor, J. P., Van Es, M. A., van den Berg, L. H. No mutations in hnRNPA1 and hnRNPA2B1 in Dutch patients with amyotrophic lateral sclerosis, frontotemporal dementia, and inclusion body myopathy. Neurobiology of Aging 2014 Aug;35(8):1956.
• Zwan, M. D., Ossenkoppele, R., Tolboom, N., Beunders, A. J. M., Kloet, R. W., Adriaanse, S. M., Boellaard, R., Windhorst, A. D., Raijmakers, P., Adams, H., Lammertsma, A. A., Scheltens, P., van der Flier, W. M., Van Berckel, B. N. M. Comparison of Simplified Parametric Methods for Visual Interpretation of C-11-Pittsburgh Compound-B PET Images. Journal of Nuclear Medicine 2014 Aug;55(8):1305-7.
• Sachdev, P., Kalaria, R., O’Brien, J., Skoog, I., Alladi, S., Black, S. E., Blacker, D., Blazer, D. G., Chen, C., Chui, H., Ganguli, M., Jellinger, K., Jeste, D. V., Pasquier, F., Paulsen, J., Prins, N., Rockwood, K., Roman, G., Scheltens, P. Diagnostic Criteria for Vascular Cognitive Disorders A VASCOG Statement.Alzheimer Disease & Associated Disorders 2014 Jul-Sep;28(3):206-18
• Adriaanse, S. M., Binnewijzend, M. A. A., Ossenkoppele, R., Tijms, B. M., van der Flier, W. M., Koene, T., Smits, L. L., Wink, A. M., Scheltens, P., Van Berckel, B. N. M., Barkhof, F. Widespread Disruption of Functional Brain Organization in Early-Onset Alzheimer’s Disease. Plos One 2014 Jul;9(7):e102995.
• Boelaarts, L., Scheltens, P., de Jonghe, J. Using Magnetic Resonance Imaging in Diagnosing Dementia: A Dutch Outpatient Memory Clinics Survey.Dementia and Geriatric Cognitive Disorders 2014 Jul;38(5-6):281-5.
• Chincarini, A., Bosco, P., Gemme, G., Esposito, M., Rei, L., Squarcia, S., Bellotti, R., Minthon, L., Frisoni, G., Scheltens, P., Frolich, L., Soininen, H., Visser, P. J., Nobili, F. Automatic temporal lobe atrophy assessment in prodromal AD: Data from the DESCRIPA study. Alzheimer’s & Dementia 2014 Jul;10(4):456-67.
• Del Campo, M., Hoozemans, J. J. M., Dekkers, L. L., Rozemuller, A. J., Korth, C., Muller-Schiffmann, A., Scheltens, P., Blankenstein, M. A., Jimenez, C. R., Veerhuis, R., Teunissen, C. E. BRI2-BRICHOS is increased in human amyloid plaques in early stages of Alzheimer’s disease. Neurobiology of Aging 2014 Jul;35(7):1596-604.
• Kester, M. I., Goos, J. D. C., Teunissen, C. E., Benedictus, M. R., Bouwman, F. H., Wattjes, M. P., Barkhof, F., Scheltens, P., van der Flier, W. M. Associations Between Cerebral Small-Vessel Disease and Alzheimer Disease Pathology as Measured by Cerebrospinal Fluid Biomarkers. JAMA Neurology 2014 Jul;71(7):855-62.
• Kochunov, P., Jahanshad, N., Sprooten, E., Nichols, T. E., Mandl, R. C., Almasy, L., Booth, T., Brouwer, R. M., Curran, J. E., de Zubicaray, G. I., Dimitrova, R., Duggirala, R., Fox, P. T., Hong, L. E., Landman, B. A., Lemaitre, H., Lopez, L. M., Martin, N. G., McMahon, K. L., Mitchell, B. D., Olvera, R. L., Peterson, C. P., Starr, J. M., Sussmann, J. E., Toga, A. W., Wardlaw, J. M., Wright, M. J., Wright, S. N., Bastin, M. E., McIntosh, A. M., Boomsma, D. I., Kahn, R. S., den Braber, A., de Geus, E. J. C., Deary, I. J., Pol, H. E. H., Williamson, D. E., Blangero, J., van’t Ent, D., Thompson, P. M., Glahn, D. C. Multi-site study of additive genetic effects on fractional anisotropy of cerebral white matter: Comparing meta and megaanalytical approaches for data pooling. Neuroimage 2014 Jul;95:136-50.
• Krudop, W. A., Kerssens, C. J., Dols, A., Prins, N. D., Moller, C., Schouws, S., Barkhof, F., Van Berckel, B. N. M., Teunissen, C. E., van der Flier, W. M., Scheltens, P., Stek, M. L., Pijnenburg, Y. A. L. Building a New Paradigm for the Early Recognition of Behavioral Variant Frontotemporal Dementia: Late Onset Frontal Lobe Syndrome Study. American Journal of Geriatric Psychiatry 2014 Jul;22(7):735-40.
• Prins, N. D., van der Flier, W. A., Knol, D. L., Fox, N. C., Brashear, H. R., Nye, J. S., Barkhof, F., Scheltens, P. The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial. Alzheimer’s Research & Therapy 2014 Jul;6(4):47.
• Van Mierlo, L. D., Meiland, F. J. M., Van Hout, H. P. J., Droes, R. M. Towards personalized integrated dementia care: a qualitative study into the implementation of different models of case management. BMC Geriatrics 2014 Jul;14:84.
• Adriaanse, S. M., van Dijk, K. R. A., Ossenkoppele, R., Reuter, M., Tolboom, N., Zwan, M. D., Yaqub, M., Boellaard, R., Windhorst, A. D., van der Flier, W. M., Scheltens, P., Lammertsma, A. A., Barkhof, F., Van Berckel, B. N. M. The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimer’s disease. European Journal of Nuclear Medicine and Molecular Imaging 2014 Jun;41(6):1190-8.
• Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., Dekosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., Cappa, S., Crutch, S., Engelborghs, S., Frisoni, G. B., Fox, N. C., Galasko, D., Habert, M. O., Jicha, G. A., Nordberg, A., Pasquier, F., Rabinovici, G., Robert, P., Rowe, C., Salloway, S., Sarazin, M., Epelbaum, S., de Souza, L. C., Vellas, B., Visser, P. J., Schneider, L., Stern, Y., Scheltens, P., Cummings, J. L. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurology 2014 Jun;13(6):614-29
• Harper, L., Barkhof, F., Scheltens, P., Schott, J. M., Fox, N. C. An algorithmic approach to structural imaging in dementia. Journal of Neurology, Neurosurgery & Psychiatry 2014 Jun;85(6):692-8.
• Poggesi, A., Gouw, A., van der Flier, W., Pracucci, G., Chabriat, H., Erkinjuntti, T., Fazekas, F., Ferro, J. M., Blahak, C., Langhorne, P., O’Brien, J., Schmidt, R., Visser, M. C., Wahlund, L. O., Waldemar, G., Wallin, A., Scheltens, P., Inzitari, D., Pantoni, L. Neurological abnormalities predict disability: the LADIS (Leukoaraiosis And DISability) study. Journal of Neurology 2014 Jun;261(6):1160-9.
• Vos, S. J. B., Visser, P. J., Verhey, F., Aalten, P., Knol, D., Ramakers, I., Scheltens, P., Rikkert, M. G. M. O., Verbeek, M. M., Teunissen, C. E. Variability of CSF Alzheimer’s Disease Biomarkers: Implications for Clinical Practice. Plos One 2014 Jun;9(6):e100784.
• Binnewijzend, M. A. A., Adriaanse, S. M., van der Flier, W. M., Teunissen, C. E., de Munck, J. C., Stam, C. J., Scheltens, P., Van Berckel, B. N. M., Barkhof, F., Wink, A. M. Brain network alterations in Alzheimer’s disease measured by Eigenvector centrality in fMRI are related to cognition and CSF biomarkers. Human Brain Mapping 2014 May;35(5):2383-93.
• Hartmann, T., van Wijk, N., Wurtman, R. J., Rikkert, M. G. M. O., Sijben, J. W. C., Soininen, H., Vellas, B., Scheltens, P. A Nutritional Approach to Ameliorate Altered Phospholipid Metabolism in Alzheimer’s Disease. Journal of Alzheimer’s Disease 2014 May;41(3):715-7.
• Jochemsen, H. M., Teunissen, C. E., Ashby, E. L., van der Flier, W. M., Jones, R. E., Geerlings, M. I., Scheltens, P., Kehoe, P. G., Muller, M. The association of angiotensin-converting enzyme with biomarkers for Alzheimer’s disease.Alzheimer’s Research & Therapy 2014 May;6(3):27.
• Meiland, F. J. M., Hattink, B. J. J., Overmars-Marx, T., de Boer, M. E., Jedlitschka, A., Ebben, P. W. G., Stalpers-Croeze, I. I. N. W., Flick, S., van der Leeuw, J., Karkowski, I. P., Droes, R. M. Participation of end users in the design of assistive technology for people with mild to severe cognitive problems; the European Rosetta project. International Psychogeriatrics 2014 May;26(5):769-79.
• Mulder, E. R., de Jong, R. A., Knol, D. L., van Schijndel, R. A., Cover, K. S., Visser, P. J., Barkhof, F., Vrenken, H. Hippocampal volume change measurement: Quantitative assessment of the reproducibility of expert manual outlining and the automated methods. FreeSurfer and FIRST. Neuroimage 2014 May;92:169-81.
• Ossenkoppele, R., van der Flier, W. M., Verfaillie, S. C. J., Vrenken, H., Versteeg, A., van Schijndel, R. A., Sikkes, S. A., Twisk, J., Adriaanse, S. M., Zwan, M. D., Boellaard, R., Windhorst, A. D., Barkhof, F., Scheltens, P., Lammertsma, A. A., Van Berckel, B. N. M. Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions. Neurology 2014 May;82(20):1768-75.
• van der Lee, J., Bakker, T. J. E. M., Duivenvoorden, H. J., Droes, R. M. Multivariate models of subjective caregiver burden in dementia: A systematic review. Ageing Research Reviews 2014 May;15:76-93.
• Wong, T. H., Chiu, W. Z., Breedveld, G. J., Li, K. W., Verkerk, A. J. M. H., Hondius, D., Hukema, R. K., Seelaar, H., Frick, P., Severijnen, L. A., Lammers, G. J., Lebbink, J. H. G., van Duinen, S. G., Kamphorst, W., Rozemuller, A. J., Bakker, E. B., Neumann, M., Willemsen, R., Bonifati, V., Smit, A. B., van Swieten, J. PRKAR1B mutation associated with a new neurodegenerative disorder with unique pathology. Brain 2014 May;137:1361-73.
• Bertens, D., Knol, D.L., Scheltens, P., Visser, P.J. Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer’s disease. Alzheimer’s & Dementia 2015 May;11(5):511-22.
• Duits, F.H., Prins, N.D., Lemstra, A.W., Pijnenburg, Y.A., Bouwman, F.H., Teunissen, C.E., Scheltens, P., van der Flier, W.M. Diagnostic impact of CSF biomarkers for Alzheimer’s disease in a tertiary memory clinic.Alzheimer’s & Dementia 2015 May;11(5):523-32.
• Smits, L.L., van Harten, A.C., Pijnenburg, Y.A., Koedam, E.L., Bouwman, F.H., Sistermans, N., Reuling, I.E., Prins, N.D., Lemstra, A.W., Scheltens, P., van der Flier, W.M. Trajectories of cognitive decline in different types of dementia. Psychological Medicine 2015 Apr;45(5):1051-9.
• Holstege, H., Pfeiffer, W., Sie, D., Hulsman, M., Nicholas, T. J., Lee, C. C., Ross, T., Lin, J., Miller, M. A., Ylstra, B., Meijers-Heijboer, H., Brugman, M. H., Staal, F. J. T., Holstege, G., Reinders, M. J. T., Harkins, T. T., Levy, S., Sistermansl, E. A. Somatic mutations found in the healthy blood compartment of a 115-yr-old woman demonstrate oligoclonal hematopoiesis. Genome Research 2014 Apr;24(5):733-42.
• Mulder, S. D., Nielsen, H. M., Blankenstein, M. A., Eikelenboom, P., Veerhuis, R. Apolipoproteins E and J interfere with amyloid-beta uptake by primary human astrocytes and microglia in vitro. Glia 2014 Apr;62(4):493-503.
• Oosterveld, S. M., Kessels, R. P. C., Hamel, R., Ramakers, I. H. G. B., Aalten, P., Verhey, F. R. J., Sistermans, N., Smits, L. L., Pijnenburg, Y. A., van der Flier, W. M., Rikkert, M. G. M. O., Melis, R. J. F. The Influence of Co-Morbidity and Frailty on the Clinical Manifestation of Patients with Alzheimer’s Disease. Journal of alzheimers disease 2014 Apr;42(2):501-9.
• Oudega, M. L., van Exel, E., Stek, M. L., Wattjes, M. P., van der Flier, W. M., Comijs, H. C., Dols, A., Scheltens, P., Barkhof, F., Eikelenboom, P., van den Heuvel, O. A. The structure of the geriatric depressed brain and response to electroconvulsive therapy. Psychiatry Research-Neuroimaging 2014 Apr;222(1-2):1-9.
• Vrenken, H., Vos, E. K., van der Flier, W. M., Sluimer, I. C., Cover, K. S., Knol, D. L., Barkhof, F. Validation of the Automated Method VIENA: An Accurate, Precise, and Robust Measure of Ventricular Enlargement. Human Brain Mapping 2014 Apr;35(4):1101-10.
• Adriaanse, S. M., Sanz-Arigita, E. J., Binnewijzend, M. A. A., Ossenkoppele, R., Tolboom, N., van Assema, D. M. E., Wink, A. M., Boellaard, R., Yaqub, M., Windhorst, A. D., van der Flier, W. M., Scheltens, P., Lammertsma, A. A., Rombouts, S. A. R. B., Barkhof, F., Van Berckel, B. N. M. Amyloid and its association with default network integrity in Alzheimer’s disease. Human Brain Mapping 2014 Mar;35(3):779-91.
• Gallagher, M. D., Suh, E. R., Grossman, M., Elman, L., McCluskey, L., van Swieten, J. C., Al-Sarraj, S., Neumann, M., Gelpi, E., Ghetti, B., Rohrer, J. D., Halliday, G., Van Broeckhoven, C., Seilhean, D., Shaw, P. J., Frosch, M. P., Alafuzoff, I., Antonell, A., Bogdanovic, N., Brooks, W., Cairns, N. J., Cooper-Knock, J., Cotman, C., Cras, P., Cruts, M., De Deyn, P. P., DeCarli, C., Dobson-Stone, C., Engelborghs, S., Fox, N., Galasko, D., Gearing, M., Gijselinck, I., Grafman, J., Hartikainen, P., Hatanpaa, K. J., Highley, J. R., Hodges, J., Hulette, C., Ince, P. G., Jin, L. W., Kirby, J., Kofler, J., Kril, J., Kwok, J. B. J., Levey, A., Lieberman, A., Llado, A., Martin, J. J., Masliah, E., McDermott, C. J., McKee, A., McLean, C., Mead, S., Miller, C. A., Miller, J., Munoz, D. G., Murrell, J., Paulson, H., Piguet, O., Rossor, M., Sanchez-Valle, R., Sano, M., Schneider, J., Silbert, L. C., Spina, S., van der Zee, J., Van Langenhove, T., Warren, J., Wharton, S. B., White, C. L., Woltjer, R. L., Trojanowski, J. Q., Lee, V. M. Y., Van Deerlin, V., Chen-Plotkin, A. S. TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. Acta Neuropathologica 2014 Mar;127(3):407-18.
• Smits, L. L., Flapper, M., Sistermans, N., Pijnenburg, Y. A. L., Scheltens, P., van der Flier, W. M. Apraxia in Mild Cognitive Impairment and Alzheimer’s Disease: Validity and Reliability of the Van Heugten Test for Apraxia.Dementia and Geriatric Cognitive Disorders 2014 Mar;38(1-2):55-64.
• Straver, R., Sistermans, E. A., Holstege, H., Visser, A., Oudejans, C. B. M., Reinders, M. J. T. WISECONDOR: detection of fetal aberrations from shallow sequencing maternal plasma based on a within-sample comparison scheme. Nucleic Acids Research 2014 Mar;42(5):e31.
• van de Pol, L. A., Scheltens, P. Medial temporal lobe atrophy scores translated to clinical practice: Editorial comment on ‘Influence of age, disease onset and ApoE4 on visual medial temporal lobe atrophy cut-offs’.Journal of Internal Medicine 2014 Mar;275(3):331
• Hooghiemstra, A.M., Eggermont, L.H., Scheltens, P., van der Flier, W.M., Scherder, E.J. The rest-activity rhythm and physical activity in early-onset dementia. Alzheimer Dis Assoc Disord. 2015 Jan-Mar;29(1):45-9.
• Caroli, A., Prestia, A., Galluzzi, S., Ferrari, C., van der Flier, W. M., Ossenkoppele, R., Van Berckel, B., Barkhof, F., Teunissen, C. E., Wall, A., Carter, S. F., Scholl, M., Choo, I. H., Grimmer, T., Nordberg, A., Scheltens, P., Drzezga, A., Frisoni, G. B. Mild cognitive impairment with suspected non AD pathology (SNAP): prediction of progression to dementia. European Journal of Neurology 2014 Feb;21:19
• Moller, C., van der Flier, W. M., Versteeg, A., Benedictus, M. R., Wattjes, M. P., Koedam, E. L. G. M., Scheltens, P., Barkhof, F., Vrenken, H. Quantitative regional validation of the visual rating scale for posterior cortical atrophy.European Radiology 2014 Feb;24(2):397-404.
• Oudega, M. L., van Exel, E., Wattjes, M. P., Comijs, H. C., Scheltens, P., Barkhof, F., Eikelenboom, P., de Craen, A. J. M., Beekman, A. T. F., Stek, M. L. White Matter Hyperintensities and Cognitive Impairment During Electroconvulsive Therapy in Severely Depressed Elderly Patients. American Journal of Geriatric Psychiatry 2014 Feb;22(2):157-66.
• Zonneveld, H. I., Goos, J. D. C., Wattjes, M. P., Prins, N. D., Scheltens, P., van der Flier, W. M., Kuijer, J. P. A., Muller, M., Barkhof, F. Prevalence of cortical superficial siderosis in a memory clinic population. Neurology 2014 Feb;82(8):698-704.
• Zwan, M., van Harten, A., Ossenkoppele, R., Bouwman, F., Teunissen, C., Adriaanse, S., Lammertsma, A., Scheltens, P., Van Berckel, B., van der Flier, W. Concordance Between Cerebrospinal Fluid Biomarkers and PIB PET in a Memory Clinic Cohort. Journal of Alzheimer’s Disease 2014 Feb;41(3):801-7.
• Exalto, L. G., van der Flier, W. M., Scheltens, P., Vrenken, H., Biessels, G. J. Dysglycemia, brain volume and vascular lesions on MRI in a memory clinic population. Journal of Diabetes and its Complications 2014 Jan-Feb;28(1):85-90.
• de Waal, H., Stam, C. J., Lansbergen, M. M., Wieggers, R. L., Kamphuis, P. J. G. H., Scheltens, P., Maestu, F., van Straaten, E. C. W. The Effect of Souvenaid on Functional Brain Network Organisation in Patients with Mild Alzheimer’s Disease: A Randomised Controlled Study. Plos One 2014 Jan;9(1):e86558.
• Rikkert, M. G. M. O., Verhey, F. R., Sijben, J. W. C., Bouwman, F. H., Dautzenberg, P. L. J., Lansink, M., Sipers, W. M. W., van Asselt, D. Z. B., van Hees, A. M. J., Stevens, M., Vellas, B., Scheltens, P. Differences in Nutritional Status Between Very Mild Alzheimer’s Disease Patients and Healthy Controls. Journal of Alzheimer’s Disease 2014 Jan;41(1):261-71.
• van der Flier, W. M., Pijnenburg, Y. A. L., Prins, N., Lemstra, A. W., Bouwman, F. H., Teunissen, C. E., Van Berckel, B. N. M., Stam, C. J., Barkhof, F., Visser, P. J., van Egmond, E., Scheltens, P. Optimizing Patient Care and Research: The Amsterdam Dementia Cohort. Journal of Alzheimer’s Disease 2014 Jan;41(1):313-27.
• van Rooden, S., Goos, J. D. C., van Opstal, A. M., Versluis, M. J., Webb, A. G., Blauw, G. J., van der Flier, W. M., Scheltens, P., Barkhof, F., van Buchem, M. A., van der Grond, J. Increased Number of Microinfarcts in Alzheimer Disease at 7-T MR Imaging. Radiology 2014 Jan;270(1):205-11.
• Yakhia, M., Konig, A., van der Flier, W. M., Friedman, L., Robert, P. H., David, R. Actigraphic Motor Activity in Mild Cognitive Impairment Patients Carrying Out Short Functional Activity Tasks: Comparison between Mild Cognitive Impairment with and without Depressive Symptoms. Journal of Alzheimer’s Disease 2014 Jan;40(4):869-75.
• van Buchem, M. A., Biessels, G. J., la Rocca, H. P. B., de Craen, A. J. M., van der Flier, W. M., Ikram, M. A., Kappelle, L. J., Koudstaal, P. J., Mooijaart, S. P., Niessen, W., van Oostenbrugge, R., de Roos, A., van Rossum, A. C., Daemen, M. J. A. P. The Heart-Brain Connection: A Multidisciplinary Approach Targeting a Missing Link in the Pathophysiology of Vascular Cognitive Impairment. Journal of Alzheimer’s Disease 2014;42:S443-S451.

Vakpublicaties:

• van Hout, H. P. J., Macneil Vroomen, J. L., Van Mierlo, L. D., Meiland, F. J. M., Moll van Charante, E. P., Joling, K. J., van den Dungen, P., Droes, R. M., van der Horst, H. E., de Rooij, S. E. J. A.Comparing case management care models for people with dementia and their caregivers: the design of the COMPAS study. Tijdschrift voor gerontologie en geriatrie 2014;45(2):105-16.

Dissertaties:

• Binnewijzend M.A.A. Functional and perfusion MRI in dementia
  Vrije Universiteit Amsterdam 21 maart 2014.
  Promotoren: F. Barkhof, Ph. Scheltens, copromotor: J.P.A Kuijer
• de Waal H. Understanding heterogeneity in Alzheimer’s disease: A neurophysiological perspective.
  Vrije Universiteit Amsterdam 25 april 2014.
  Promotoren: Ph. Scheltens, C.J. Stam, copromotoren: W.M. van der Flier, E.C.W. van Straaten.
• Jongbloed W. Neurodegeneration: Biochemical signals from the brain
  Vrije Universiteit Amsterdam 8 mei 2014
  Promotoren: M.A. Blankenstein, Ph. Scheltens, copromotor: R. Veerhuis
• Poortvliet-Koedam E.L.G.E. Early-onset dementia: Unravelling the clinical phenotypes.
  Vrije Universiteit Amsterdam 28 mei 2014.
  Promotoren: Ph. Scheltens, copromotoren: Y.A.L Pijnenburg, M.P. Wattjes
• van Harten A.C. The road less traveled. CSF biomarkers for Alzheimer’s disease: predicting earliest cognitive decline and exploring microrna as a novel biomarker source.
  Vrije Universiteit Amsterdam 7 november 2014.
  Promotoren: Ph. Scheltens, C.B.M Oudejans, copromotoren: W.M. van der Flier, C.E. Teunissen
• Hooghiemstra A. Early-onset dementia: with exercise in mind
  Vrije Universiteit Amsterdam 3 december 2014
  Promotoren: E.J.A Scherder, Ph. Scheltens, copromotor: L.H.P Eggermont

Internationale publicaties:

• Bakker, C., de Vugt, M. E., van Vliet, D., Verhey, F. R. J., Pijnenburg, Y. A., Vernooij-Dassen, M. J. F. J., Koopmans, R. T. C. M. The Use of Formal and Informal Care in Early Onset Dementia: Results From the NeedYD Study. American journal of geriatric psychiatry 2013;21(1):37-45. doi:10.1016/j.jagp.2012.10.004
• Bakker, C., de Vugt, M. E., van Vliet, D., Verhey, F. R. J., Pijnenburg, Y. A., Vernooij-Dassen, M. J. F. J., Koopmans, R. T. C. M. Predictors of the Time to Institutionalization in Young- Versus Late-Onset Dementia: Results From the Needs in Young Onset Dementia (NeedYD) Study. Journal of the american medical directors association 2013;14(4):248-53. doi:10.1016/j.jamda.2012.09.011
• Barkhof, F., Daams, M., Scheltens, P., Brashear, H. R., Arrighi, H. M., Bechten, A., Morris, K., McGovern, M., Wattjes, M. P. An MRI rating scale for amyloid-related imaging abnormalities with edema or effusion. AJNR American journal of neuroradiology 2013;34(8):1550-5. doi:10.3174/ajnr.A3475
• Benedictus, M. R., Goos, J. D., Binnewijzend, M. A. A., Muller, M., Barkhof, F., Scheltens, P., Prins, N. D., van der Flier, W. M. Specific risk factors for microbleeds and white matter hyperintensities in Alzheimer’s disease. Neurobiology of aging 2013;34(11):2488-94. doi:10.1016/j.neurobiolaging.2013.04.023
• Binnewijzend, M. A., Kuijer, J. P., Benedictus, M. R., van der Flier, W. M., Wink, A. M., Wattjes, M. P., van Berckel, B. N., Scheltens, P., Barkhof, F. Cerebral Blood Flow Measured with 3D Pseudocontinuous Arterial Spin-labeling MR Imaging in Alzheimer Disease and Mild Cognitive Impairment: A Marker for Disease Severity. Radiology 2013;267(1):221-30. Doi:10.1148/radiol.12120928
• Boom, M., Olofsen, E., Neukirchen, M., Fussen, R., Hay, J., Groeneveld, G. J., Aarts, L., Sarton, E., Dahan, A. Fentanyl Utility Function: A Risk-Benefit Composite of Pain Relief and Breathing Responses. Anesthesiology 2013;119(3):663-74. Doi:10.1097/ALN.0b013e31829ce4cb
• Bruggink, K. A., Jongbloed, W., Biemans, E. A. L. M., Veerhuis, R., Claassen, J. A. H. R., Kuiperij, H. B., Verbeek, M. M. Amyloid-beta oligomer detection by ELISA in cerebrospinal fluid and brain tissue. Analytical biochemistry 2013;433(2):112-20. Doi:10.1016/j.ab.2012.09.014
• Clerx, L., Jacobs, H., I, Burgmans, S., Gronenschild, E., Uylings, H., Echavarri, C., Visser, P., Verhey, F., Aalten, P. Sensitivity of Different MRI-Techniques to Assess Gray Matter Atrophy Patterns in Alzheimer’s Disease is Region-Specific. Current alzheimer research 2013;10(9):940-51. WpR, VUmc NCA-NB
• Clerx, L., van Rossum, I. A., Burns, L., Knol, D. L., Scheltens, P., Verhey, F., Aalten, P., Lapuerta, P., van de Pol, L., van Schijndel, R., de Jong, R., Barkhof, F., Wolz, R., Rueckert, D., Bocchetta, M., Tsolaki, M., Nobili, F., Wahlund, L. O., Minthon, L., Frolich, L., Hampel, H., Soininen, H., Visser, P. J. Measurements of medial temporal lobe atrophy for prediction of Alzheimer’s disease in subjects with mild cognitive impairment. Neurobiology of aging 2013;34(8):2003-13. Doi:10.1016/j.neurobiolaging.2013.02.002
• Crutch, S. J., Schott, J. M., Rabinovici, G. D., Boeve, B. F., Cappa, S. F., Dickerson, B. C., Dubois, B., Graff-Radford, N. R., Krolak-Salmon, P., Lehmann, M., Mendez, M. F., Pijnenburg, Y. A. L., Ryan, N. S., Scheltens, P., Shakespeare, T., Tang-Wai, D. F., van der Flier, W. M., Bain, L., Carrillo, M. C., Fox, N. C. Shining a light on posterior cortical atrophy. Alzheimer’s & dementia : the journal of the Alzheimer’s Association 2013;9(4):463-5. Doi:10.1016/j.jalz.2012.11.004
• Cummings, J. L., Dubois, B., Molinuevo, J. L., Scheltens, P. International Work Group Criteria for the Diagnosis of Alzheimer Disease. Medical clinics of north america 2013;97(3):363-+. Doi:10.1016/j.mcna.2013.01.001
• Damian, M., Hausner, L., Jekel, K., Richter, M., Froelich, L., Almkvist, O., Boada, M., Bullock, R., De Deyn, P. P., Frisoni, G. B., Hampel, H., Jones, R. W., Kehoe, P., Lenoir, H., Minthon, L., Olde Rikkert, M. G. M., Rodriguez, G., Scheltens, P., Soininen, H., Spiru, L., Touchon, J., Tsolaki, M., Vellas, B., Verhey, F. R. J., Winblad, B., Wahlund, L. O., Wilcock, G., Visser, P. J. Single-domain amnestic mild cognitive impairment identified by cluster analysis predicts Alzheimer’s disease in the european prospective DESCRIPA study. Dementia and geriatric cognitive disorders 2013;36(1-2):1-19. Doi:10.1159/000348354
• de Haan, W., Mott, K., van Straaten, E. C. W., Scheltens, P., Stam, C. J. Activity Dependent Degeneration Explains Hub Vulnerability in Alzheimer’s Disease. Plos computational biology 2012;8(8):e1002582. Doi:10.1371/journal.pcbi.1002582
• de Waal, H., Stam, C. J., de Haan, W., van Straaten, E. C. W., Blankenstein, M. A., Scheltens, P., van der Flier, W. M. Alzheimer’s disease patients not carrying the apolipoprotein E epsilon4 allele show more severe slowing of oscillatory brain activity. Neurobiology of aging 2013;34(9):2158-63. Doi:10.1016/j.neurobiolaging.2013.03.007
• Duits, F. H., Kester, M. I., Scheffer, P. G., Blankenstein, M. A., Scheltens, P., Teunissen, C. E., van der Flier, W. M. Increase in Cerebrospinal Fluid F2-Isoprostanes is Related to Cognitive Decline in APOE epsilon4 Carriers. Journal of Alzheimer’s disease : JAD 2013;36(3):563-70. Doi:10.3233/JAD-122227
• Elias-Sonnenschein, L. S., Helisalmi, S., Natunen, T., Hall, A., Paajanen, T., Herukka, S. K., Laitinen, M., Remes, A. M., Koivisto, A. M., Mattila, K. M., Lehtimaki, T., Verhey, F. R. J., Visser, P. J., Soininen, H., Hiltunen, M. Genetic Loci Associated with Alzheimer’s Disease and Cerebrospinal Fluid Biomarkers in a Finnish Case-Control Cohort. PloS one 2013;8(4). Doi:10.1371/journal.pone.0059676
• Frisoni, G. B., Bocchetta, M., Chetelat, G., Rabinovici, G. D., de Leon, M. J., Kaye, J., Reiman, E. M., Scheltens, P., Barkhof, F., Black, S. E., Brooks, D. J., Carrillo, M. C., Fox, N. C., Herholz, K., Nordberg, A., Jack, C. R. J., Jagust, W. J., Johnson, K. A., Rowe, C. C., Sperling, R. A., Thies, W., Wahlund, L. O., Weiner, M. W., Pasqualetti, P., DeCarli, C. Imaging markers for Alzheimer disease: which vs how. Neurology 2013;81(5):487-500. Doi:10.1212/WNL.0b013e31829d86e8
• Galasko, D., Golde, T. E., Scheltens, P. Progress in Alzheimer’s disease research circa 2013: Is the glass half empty or half full? Alzheimers research & therapy 2013;5(3):26. Doi:10.1186/alzrt180
• Hooshmand, B., Polvikoski, T., Kivipelto, M., Tanskanen, M., Myllykangas, L., Erkinjuntti, T., Makela, M., Oinas, M., Paetau, A., Scheltens, P., van Straaten, E. C., Sulkava, R., Solomon, A. Plasma homocysteine, Alzheimer and cerebrovascular pathology: a population-based autopsy study. Brain 2013;136:2707-16. Doi:10.1093/brain/awt206
• IJsselstijn, L., Papma, J. M., Dekker, L. J., Calame, W., Stingl, C., Koudstaal, P. J., Prins, N. D., Smitt, P. A., Luider, T. M. Serum proteomics in amnestic mild cognitive impairment. Proteomics 2013;13(16):2526-33. Doi:10.1002/pmic.201200190
• Jacobs, H. I., Visser, P. J., Van Boxtel, M. P., Frisoni, G. B., Tsolaki, M., Papapostolou, P., Nobili, F., Wahlund, L. O., Minthon, L., Frolich, L., Hampel, H., Soininen, H., van de Pol, L., Scheltens, P., Tan, F. E., Jolles, J., Verhey, F. R. The association between white matter hyperintensities and executive decline in mild cognitive impairment is network dependent. Neurobiology of aging 2012;33(1):201. Doi:10.1016/j.neurobiolaging.2010.07.015
• Jochemsen, H. M., Kloppenborg, R. P., de Groot, L. C. P. G., Kampman, E., Mali, W. P. T. M., van der Graaf, Y., Geerlings, M. I. Homocysteine, progression of ventricular enlargement, and cognitive decline: The Second Manifestations of ARTerial disease-Magnetic Resonance study. Alzheimers & dementia 2013;9(3):302-9. Doi:10.1016/j.jalz.2011.11.008
• Jochemsen, H. M., Muller, M., Visseren, F. L., Scheltens, P., Vincken, K. L., Mali, W. P., van der Graaf, Y., Geerlings, M. I. Blood Pressure and Progression of Brain Atrophy The SMART-MR Study. JAMA neurology 2013;70(8):1046-53. Doi:10.1001/jamaneurol.2013.217
• Jokinen, H., Schmidt, R., Ropele, S., Fazekas, F., Gouw, A. A., Barkhof, F., Scheltens, P., Madureira, S., Verdelho, A., Ferro, J. M., Wallin, A., Poggesi, A., Inzitari, D., Pantoni, L., Erkinjuntti, T. Diffusion changes predict cognitive and functional outcome: The LADIS study. Annals of neurology 2013;73(5):576-83. Doi:10.1002/ana.23802
• Joling, K. J., Bosmans, J. E., van Marwijk, H. W. J., van der Horst, H. E., Scheltens, P., Vroomen, J. L. M., van Hout, H. P. J. The cost-effectiveness of a family meetings intervention to prevent depression and anxiety in family caregivers of patients with dementia: a randomized trial. Trials 2013;14:305. Doi:10.1186/1745-6215-14-305
• Jongbloed, W., Kester, M. I., van der Flier, W. M., Veerhuis, R., Scheltens, P., Blankenstein, M. A., Teunissen, C. E. Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer’s disease study. Alzheimers & dementia 2013;9(3):276-83. Doi:10.1016/j.jalz.2012.01.004
• Koedam, E. L. G. E., van der Vlies, A. E., van der Flier, W. M., Verwey, N. A., Koene, T., Scheltens, P., Blankenstein, M. A., Pijnenburg, Y. A. L. Cognitive correlates of cerebrospinal fluid biomarkers in frontotemporal dementia. Alzheimers & dementia 2013;9(3):269-75. Doi:10.1016/j.jalz.2011.12.007
• Kohler, S., Hamel, R., Sistermans, N., Koene, T., Pijnenburg, Y. A. L., van der Flier, W. M., Scheltens, P., Visser, P. J., Aalten, P., Verhey, F. R. J., Ramakers, I. Progression to dementia in memory clinic patients without dementia: a latent profile analysis. Neurology 2013;81(15):1342-9. Doi:10.1212/WNL.0b013e3182a82536
• Kooij, C.H. Van der, Dröes, R.M., Lange, J. de, Ettema, T.P., Cools, H., Tilburg, VanThe implementation of integrated emotion-oriented care; did it actually change the attitude, skills and time spending of trained caregivers? Dementia: The International Journal of Social Research and Practice, 09/2013,12(5):536-550
• Kreisel, S. H., Blahak, C., Bazner, H., Inzitari, D., Pantoni, L., Poggesi, A., Chabriat, H., Erkinjuntti, T., Fazekas, F., Ferro, J. M., Langhorne, P., O’Brien, J., Scheltens, P., Visser, M. C., Wahlund, L. O., Waldemar, G., Wallin, A., Hennerici, M. G. Deterioration of Gait and Balance over Time: The Effects of Age-Related White Matter Change – The LADIS Study. Cerebrovascular diseases 2013;35(6):544-53. Doi:10.1159/000350725
• Lehmann, M., Koedam, E. L., Barnes, J., Bartlett, J. W., Barkhof, F., Wattjes, M. P., Schott, J. M., Scheltens, P., Fox, N. C. Visual ratings of atrophy in MCI: prediction of conversion and relationship with CSF biomarkers. Neurobiology of aging 2013;34(1):73-82. Doi:10.1016/j.neurobiolaging.2012.03.010
• Meesters, P. D., Comijs, H. C., Droes, R. M., de Haan, L., Smit, J. H., Eikelenboom, P., Beekman, A. T. F., Stek, M. L. The Care Needs of Elderly Patients With Schizophrenia Spectrum Disorders. American journal of geriatric psychiatry 2013;21(2):129-37. Doi:10.1016/j.jagp.2012.10.008
• Moleiro, C., Madureira, S., Verdelho, A., Ferro, J. M., Poggesi, A., Chabriat, H., Erkinjuntti, T., Fazekas, F., Hennerici, M., O’Brien, J., Pantoni, L., Salvadori, E., Scheltens, P., Visser, M. C., Wahlund, L. O., Waldemar, G., Wallin, A., Inzitari, D. Confirmatory factor analysis of the Neuropsychological Assessment Battery of the LADIS study: A longitudinal analysis. Journal of clinical and experimental neuropsychology 2013;35(3):269-78. Doi:10.1080/13803395.2013.770822
• Molinuevo, J. L., Cummings, J. L., Dubois, B., Scheltens, P. Preface. Medical clinics of north america 2013;97(3):XIII-XIXV. Doi:10.1016/j.mcna.2013.01.003
• Möller, C., Vrenken, H., Jiskoot, L., Versteeg, A., Barkhof, F., Scheltens, P., van der Flier, W. M. Different patterns of gray matter atrophy in early- and late-onset Alzheimer’s disease. Neurobiology of aging 2013;34(8):2014-22. Doi:10.1016/j.neurobiolaging.2013.02.013
• Morbelli, S., Perneczky, R., Drzezga, A., Frisoni, G. B., Caroli, A., van Berckel, B. N. M., Ossenkoppele, R., Guedj, E., Didic, M., Brugnolo, A., Naseri, M., Sambuceti, G., Pagani, M., Nobili, F. Metabolic Networks Underlying Cognitive Reserve in Prodromal Alzheimer Disease: A European Alzheimer Disease Consortium Project. Journal of nuclear medicine 2013;54(6):894-902. Doi:10.2967/jnumed.112.113928
• Muller, M., Jochemsen, H., Visseren, F., Grool, A., Launer, L., van der Graaf, Y., Geerlings, M., I. Low blood pressure and antihypertensive treatment are independently associated with physical and mental health status in patients with arterial disease: the SMART study. Journal of internal medicine 2013;274(3):241-51. Doi:10.1111/joim.12069
• Okroglic, S., Widmann, C. N., Urbach, H., Scheltens, P., Heneka, M. T. Clinical Symptoms and Risk Factors in Cerebral Microangiopathy Patients. PloS one 2013;8(2). Doi:10.1371/journal.pone.0053455
• Ossenkoppele, R., Prins, N. D., Pijnenburg, Y. A., Lemstra, A. W., van der Flier, W. M., Adriaanse, S. F., Windhorst, A. D., Handels, R. L., Wolfs, C. A., Aalten, P., Verhey, F. R., Verbeek, M. M., van Buchem, M. A., Hoekstra, O. S., Lammertsma, A. A., Scheltens, P., van Berckel, B. N. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers & dementia 2013;9(4):414-21. Doi:10.1016/j.jalz.2012.07.003
• Ossenkoppele, R., Prins, N. D., van Berckel, B. N. M. Amyloid imaging in clinical trials. Alzheimers research & therapy 2013;5(4):36. Doi:10.1186/1758-9193-5-36
• Ossenkoppele, R., van der Flier, W. M., Zwan, M. D., Adriaanse, S. F., Boellaard, R., Windhorst, A. D., Barkhof, F., Lammertsma, A. A., Scheltens, P., van Berckel, B. N. M. Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia. Neurology 2013;80(4):359-65. WpR, VUmc NCA-NB
• Palm, W. M., Ferrarini, L., van der Flier, W. M., Westendorp, R. G., Bollen, E. L., Middelkoop, H. A., Milles, J. R., van der Grond, J., van Buchem, M. A. Cerebral atrophy in elderly with subjective memory complaints. Journal of magnetic resonance imaging 2013;38(2):358-64. Doi:10.1002/jmri.23977
• Papma, J. M., Seelaar, H., de Koning, I., Hasan, D., Reijs, A., Valkema, R., Prins, N. D., van Swieten, J. C. Episodic Memory Impairment in Frontotemporal Dementia; A Tc-99m-HMPAO SPECT Study. Current alzheimer research 2013;10(3):332-9. WpR, VUmc NCA-NB
• Poggesi, A., Gouw, A., van der Flier, W., Pracucci, G., Chabriat, H., Erkinjuntti, T., Fazekas, F., Ferro, J. M., Hennerici, M., Langhorne, P., O’Brien, J. T., Visser, M. C., Wahlund, L. O., Waldemar, G., Wallin, A., Scheltens, P., Inzitari, D., Pantoni, L. Cerebral white matter changes are associated with abnormalities on neurological examination in non-disabled elderly: the LADIS study. Journal of neurology 2013;260(4):1014-21. Doi:10.1007/s00415-012-6748-3
• Poil, S. S., de Haan, W., van der Flier, W. M., Mansvelder, H. D., Scheltens, P., Linkenkaer-Hansen, K. Integrative EEG biomarkers predict progression to Alzheimer’s disease at the MCI stage. Frontiers in aging neuroscience 2013;5:UNSP. Doi:10.3389/fnagi.2013.00058
• Prestia, A., Caroli, A., van der Flier, W. M., Ossenkoppele, R., van Berckel, B., Barkhof, F., Teunissen, C. E., Wall, A. E., Carter, S. F., Scholl, M., Choo, I. H., Nordberg, A., Scheltens, P., Frisoni, G. B. Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology 2013;80(11):1048-56. Doi:10.1212/WNL.0b013e3182872830
• Prins, N. D., van der Flier, W. M., Brashear, H. R., Knol, D. L., van De Pol, L. A., Barkhof, F., Scheltens, P. Predictors of progression from mild cognitive impairment to dementia in the placebo-arm of a clinical trial population. Journal of Alzheimer’s disease : JAD 2013;36(1):79-85. Doi:10.3233/JAD-122233
• Ramakers, I. H. G. B., Verhey, F. R. J., Scheltens, P., Hampel, H., Soininen, H., Aalten, P., Rikkert, M. O., Verbeek, M. M., Spiru, L., Blennow, K., Trojanowski, J. Q., Shaw, L. M., Visser, P. J. Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment. Psychological medicine 2013;43(5):911-20. Doi:10.1017/S0033291712001870
• Ravenscroft, T. A., Baker, M. C., Rutherford, N. J., Neumann, M., Mackenzie, I. R., Josephs, K. A., Boeve, B. F., Petersen, R., Halliday, G. M., Kril, J., van Swieten, J. C., Seeley, W. W., Dickson, D. W., Rademakers, R. Mutations in protein N-arginine methyltransferases are not the cause of FTLD-FUS. Neurobiology of aging 2013;34(9):UNSP. Doi:10.1016/j.neurobiolaging.2013.04.004
• Scheltens, P. DEMENTIA Mild cognitive impairment-amyloid and beyond. Nature reviews neurology 2013;9(9):493-5. Doi:10.1038/nrneurol.2013.147
• Schuitemaker, A., Kropholler, M. A., Boellaard, R., van der Flier, W. M., Kloet, R. W., van der Doef, T. F., Knol, D. L., Windhorst, A. D., Luurtsema, G., Barkhof, F., Jonker, C., Lammertsma, A. A., Scheltens, P., van Berckel, B. N. M. Microglial activation in Alzheimer’s disease: an (R)-PK11195 positron emission tomography study. Neurobiology of aging 2013;34(1):128-36. Doi:10.1016/j.neurobiolaging.2012.04.021
• Sikkes, S. A. M., Knol, D. L., Pijnenburg, Y. A. L., de Lange-de Klerk, E., Uitdehaag, B. M. J., Scheltens, P. Validation of the Amsterdam IADL Questionnaire (c), a New Tool to Measure Instrumental Activities of Daily Living in Dementia. Neuroepidemiology 2013;41(1):35-41. Doi:10.1159/000346277
• Sikkes, S. A. M., Pijnenburg, Y. A. L., Knol, D. L., de Lange-de Klerk, E., Scheltens, P., Uitdehaag, B. M. J. Assessment of Instrumental Activities of Daily Living in Dementia: Diagnostic Value of the Amsterdam Instrumental Activities of Daily Living Questionnaire. Journal of geriatric psychiatry and neurology 2013;26(4):244-50. Doi:10.1177/0891988713509139
• Spies, P. E., Claassen, J. A. H. R., Peer, P. G. M., Blankenstein, M. A., Teunissen, C. E., Scheltens, P., van der Flier, W. M., Rikkert, M. G. M. O., Verbeek, M. M. A prediction model to calculate probability of Alzheimer’s disease using cerebrospinal fluid biomarkers. Alzheimers & dementia 2013;9(3):262-8. Doi:10.1016/j.jalz.2012.01.010
• Tijms, B. M., Möller, C., Vrenken, H., Wink, A. M., de Haan, W., van der Flier, W. M., Stam, C. J., Scheltens, P., Barkhof, F. Single-Subject Grey Matter Graphs in Alzheimer’s Disease. PloS one 2013;8(3). Doi:10.1371/journal.pone.0058921
• Tijms, B. M., Wink, A. M., de Haan, W., van der Flier, W. M., Stam, C. J., Scheltens, P., Barkhof, F. Alzheimer’s disease: connecting findings from graph theoretical studies of brain networks. Neurobiology of aging 2013;34(8):2023-36. Doi:10.1016/j.neurobiolaging.2013.02.020
• van Berckel, B. N., Ossenkoppele, R., Tolboom, N., Yaqub, M., Foster-Dingley, J. C., Windhorst, A. D., Scheltens, P., Lammertsma, A. A., Boellaard, R. Longitudinal Amyloid Imaging Using C-11-PiB: Methodologic Considerations. Journal of nuclear medicine 2013;54(9):1570-6. Doi:10.2967/jnumed.112.113654
• van de Glind, E. M. M., van Enst, W. A., van Munster, B. C., Olde Rikkert, M. G. M., Scheltens, P., Scholten, R. J. P. M., Hooft, L. Pharmacological treatment of dementia: a scoping review of systematic reviews. Dementia and geriatric cognitive disorders 2013;36(3-4):211-28. Doi:10.1159/000353892
• van der Vlies, A. E., Staekenborg, S. S., dmiraal-Behloul, F., Prins, N. D., Barkhof, F., Vrenken, H., Reiber, J. H. C., Scheltens, P., van der Flier, W. M. Associations between Magnetic Resonance Imaging Measures and Neuropsychological Impairment in Early and Late Onset Alzheimer’s Disease. Journal of alzheimers disease 2013;35(1):169-78. Doi:10.3233/JAD-121291
• van Harten, A. C., Smits, L. L., Teunissen, C. E., Visser, P. J., Koene, T., Blankenstein, M. A., Scheltens, P., van der Flier, W. M. Preclinical AD predicts decline in memory and executive functions in subjective complaints. Neurology 2013;81(16):1409-16. Doi:10.1212/WNL.0b013e3182a8418b
• van Harten, A. C., Visser, P. J., Pijnenburg, Y. A., Teunissen, C. E., Blankenstein, M. A., Scheltens, P., van der Flier, W. M. Cerebrospinal fluid A beta 42 is the best predictor of clinical progression in patients with subjective complaints. Alzheimers & dementia 2013;9(5):481-7. Doi:10.1016/j.jalz.2012.08.004
• van Swieten, J. C., Pijnenburg, Y. The role of the subgenual cingulate cortex in self-appraisal. Journal of neurology neurosurgery and psychiatry 2013;84(2):121. Doi:10.1136/jnnp-2012-303571
• van Vliet, D., de Vugt, M. E., Aalten, P., Bakker, C., Pijnenburg, Y. A. L., Vernooij-Dassen, M. J. F. J., Koopmans, R. T. C. M., Verhey, F. R. J. Prevalence of Neuropsychiatric Symptoms in Young-Onset Compared to Late-Onset Alzheimer’s Disease – Part 1: Findings of the Two-Year Longitudinal NeedYD-Study. Dementia and geriatric cognitive disorders 2012;34(5-6):319-27. Doi:10.1159/000342824
• van Vliet, D., de Vugt, M. E., Bakker, C., Pijnenburg, Y. A. L., Vernooij-Dassen, M. J. F. J., Koopmans, R. T. C. M., Verhey, F. R. J. Time to diagnosis in young-onset dementia as compared with late-onset dementia. Psychological medicine 2013;43(2):423-32. Doi:10.1017/S0033291712001122
• van Vliet, D., de Vugt, M. E., Koehler, S., Aalten, P., Bakker, C., Pijnenburg, Y. A., Vernooij-Dassen, M. J., Koopmans, R. T., Verhey, F. R. Awareness and Its Association With Affective Symptoms in Young-onset and Late-onset Alzheimer Disease: A Prospective Study. Alzheimer disease & associated disorders 2013;27(3):265-71. Doi:10.1097/WAD.0b013e31826cffa5
• Vellas, B., Carrillo, M. C., Sampaio, C., Brashear, H. R., Siemers, E., Hampel, H., Schneider, L. S., Weiner, M., Doody, R., Khachaturian, Z., Cedarbaum, J., Grundman, M., Broich, K., Giacobini, E., Dubois, B., Sperling, R., Wilcock, G. K., Fox, N. C., Scheltens, P., Touchon, J., Hendrix, S., Andrieu, S., Aisen, P. Designing drug trials for Alzheimer’s disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force. Alzheimer’s & dementia : the journal of the Alzheimer’s Association 2013;9(4):438-44. Doi:10.1016/j.jalz.2013.03.007
• Verdelho, A., Madureira, S., Moleiro, C., Ferro, J. M., O’Brien, J. T., Poggesi, A., Pantoni, L., Fazekas, F., Scheltens, P., Waldemar, G., Wallin, A., Erkinjuntti, T., Inzitari, D. Depressive symptoms predict cognitive decline and dementia in older people independently of cerebral white matter changes: the LADIS study. Journal of neurology, neurosurgery, and psychiatry 2013;84(11):1250-4. Doi:10.1136/jnnp-2012-304191
• Vermeiren, A. P. A., Bosma, H., Visser, P. J., Zeegers, M. P., Graff, C., Ewers, M., Frisoni, G. B., Frolich, L., Hampel, H., Jones, R. W., Kehoe, P. G., Lenoir, H., Minthon, L., Nobili, F. M., Rikkert, M. O., Rigaud, A. S., Scheltens, P., Soininen, H., Spiru, L., Tsolaki, M., Wahlund, L. O., Vellas, B., Wilcock, G., Elias-Sonnenschein, L. S., Verhey, F. R. J. The Association Between APOE epsilon 4 and Alzheimer-type Dementia Among Memory Clinic Patients is Confined to those with a Higher Education. The DESCRIPA Study. Journal of alzheimers disease 2013;35(2):241-6. Doi:10.3233/JAD-122182
• Verwey, N. A., Hoozemans, J. J., Korth, C., van Royen, M. R., Prikulis, I., Wouters, D., Twaalfhoven, H. A., van Haastert, E. S., Schenk, D., Scheltens, P., Rozemuller, A. J., Blankenstein, M. A., Veerhuis, R. Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid beta-peptide. Amyloid-journal of protein folding disorders 2013;20(3):179-87. Doi:10.3109/13506129.2013.797389
• Vos, S. J., Xiong, C., Visser, P. J., Jasielec, M. S., Hassenstab, J., Grant, E. A., Cairns, N. J., Morris, J. C., Holtzman, D. M., Fagan, A. M. Preclinical Alzheimer’s disease and its outcome: a longitudinal cohort study. Lancet neurology 2013;12(10):957-65. Doi:10.1016/S1474-4422(13)70194-7
• Vos, S. J. B., van Rossum, I. A., Verhey, F., Knol, D. L., Soininen, H., Wahlund, L. O., Hampel, H., Tsolaki, M., Minthon, L., Frisoni, G. B., Froelich, L., Nobili, F., van der Flier, W., Blennow, K., Wolz, R., Scheltens, P., Visser, P. J. Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Neurology 2013;80(12):1124-32. Doi:10.1212/WNL.0b013e318288690c
• Zarei, M., Beckmann, C. F., Binnewijzend, M. A., Schoonheim, M. M., Oghabian, M. A., Sanz-Arigita, E. J., Scheltens, P., Matthews, P. M., Barkhof, F. Functional segmentation of the hippocampus in the healthy human brain and in Alzheimer’s disease. Neuroimage 2013;66:28-35. Doi:10.1016/j.neuroimage.2012.10.071

Vakpublicaties:

• Gossink, F., Dols, A., Kerssens, C. J., Scheltens, P., Stek, M. L., Pijnenburg, Y. A. L. . Nederlands tijdschrift voor geneeskunde 2013;157(42):A6370. VP, VUmc NCA-NB
• Huber, E., Meiland, F., Stek, M., Dröes, R.M., Bootsma-vd Wiel, A. De overdracht van GGZ naar verpleeghuis. Continuiteit van zorg voor patiënten met dementie. Tijdschrift voor Ouderengeneeskunde, 2013, 04, 177-181
• Meesters, P.D., Comijs, C., Dröes, R.M., Haan, L.de, Smit, J. Eikelenboom, P., Beekman, A.T.F., Stek, M. Ouderen met schizoofrenie; zorgbehoeften en zorgvernieuwing. MGv, 68 (4) 2013,174-183.
• Scheltens, P., Twisk, J. W. R. . Nederlands tijdschrift voor geneeskunde 2013;157(0):A6721. VP, VUmc NCA-NB
• van der Flier, W. M., Ossenkoppele, R., van Berckel, B. N. M., Scheltens, P. Vroegdiagnostiek van de ziekte van Alzheimer: de rol van Positron Emissie Tomografie (PET). Tijdschrift voor gerontologie en geriatrie 2013;44(4):190-1. VP, VUmc NCA-NB.10.1007/s12439-013-0033-5
• Verberne, W. R., Snijders, T. J., Liem, K. S., Baakman, A. C., Veldhuijzen, D. S. . Nederlands tijdschrift voor geneeskunde 2013;157(5):A5434. VP, VUmc NCA-NB
• Verhey, F. R. J., Visser, P. J. . Nederlands tijdschrift voor geneeskunde 2013;157(11):A5596. VP, VUmc NCA-NB

Boekhoofdstukken :

• A.W. Lemstra, H. Seelaar, J.C. van Swieten. Primary Dementia Syndromes and Parkinsonism. In Oxford textbook of movement Disorders edited by DJ Burns, Oxford 2013

Dissertaties:

• Goos J.D.C. Microbleeds in dementia: Connecting the dots  Vrije Universiteit Amsterdam 6 februari 2013. Promotoren: Ph. Scheltens, F. Barkhof, copromotor: W.M. van der Flier
• Ossenkoppele R. Alzheimer PEThology Vrije Universiteit Amsterdam 8 mei 2013. Promotoren: Ph. Scheltens, A Lammertsma, copromotoren: B.N.M. van Berckel, W.M. van der Flier
• Jochemsen H. Brain under pressure. Influences of blood pressure and angiotensin-converting enzyme on the brain. Vrije Universiteit Amsterdam 4 oktober 2013. Promotoren: Ph. Scheltens, Y. van der Graaf, copromotoren: M. Muler, M.I. Geerlings /li>
• Van der Vlies A. Cognitive profiles in Alzheimer’s disease. Recognizing its many faces. Vrije Universiteit Amsterdam 27 november 2013. Promotor: Ph. Scheltens, copromotor: W.M. van der Flier
• Van Rossum I. Diagnosis and prognosis of Alzheimer’s disease in subjects with mild cognitive impairment.  Vrije Universiteit Amsterdam 28 november 2013. Promotor: Ph. Scheltens, copromotor: P.J. Visser

Internationale wetenschappelijke publicaties:

• Albert MS, Dekosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging and Alzheimer’s Association workgroup. Alzheimers Dement 2011;7:270-279.
• Bateman RJ, Aisen PS, de Strooper B, Fox NC, Lemere CA, Ringman JM, Salloway S, Sperling RA, Windisch M, Xiong C. Autosomal-dominant Alzheimer’s disease: a review and proposal for the prevention of Alzheimer’s disease. Alzheimers Res Ther 2011;3(1):1-13.
• Brodaty H, Breteler MMB, Dekosky ST, Dorenlot P, Fratiglioni L, Hock C, Kenigsberg P-A, Scheltens P, de Strooper B. The world of dementia beyond 2020. J Am Geriatr Soc 2011;59:923-927.
• Cardoso MJ, Clarkson MJ, Ridgway GR, Modat M, Fox NC, Ourselin S,and The Alzheimer’s Disease Neuroimaging Initiative. LoAd: A locally adaptive cortical segmentation algorithm. Neuroimage 2011;56:1386-1397.
• Chiang GC, Insel PS, Tosun D, Schuff N, Truran-Sacrey D, Raptentsetsang ST, Thompson PM, Reiman EM, Jack CR Jr, Fox NC, Jagust WJ, Harvey DJ, Beckett LA, Gamst A, Aisen PS, Petersen RC, Weiner MW, for the Alzheimer’s Disease Neuroimaging Initiative. Impact of apolipoprotein ɛ4-cerebrospinal fluid beta-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment. Alzheimers Dement 2011;7:514-520.
• Clarkson MJ, Cardoso MJ, Ridgway GR, Modat M, Leung KK, Rohrer JD, Fox NC, Ourselin S. A comparison of voxel and surface based cortical thickness estimation methods. Neuroimage 2011;57:856-865.
• Cordonnier C, van der Flier WM. Brain microbleeds and Alzheimer’s disease: innocent observation or key player? Brain 2011;134:335-344.
• Echávarri C, Aalten P, Uylings HBM, Jacobs HIL, Visser PJ, Gronenschild EHBM, Verhey FRJ, Burgmans S. Atrophy in the parahippocampal gyrus as an early biomarker of Alzheimer’s disease. Brain Struct Funct 2011;215:265-271.
• Elias-Sonnenschein LS, Viechtbauer W, Ramakers IHGB, Verhey FRJ, Visser PJ. Predictive value of APOE-ε4 allele for progression from MCI to AD-type dementia: a meta-analysis.  J Neurol Neurosurg Psychiatry 2011;82:1149-1156.
• van der Flier WM, Pijnenburg YAL Fox NC, Scheltens P. Early-onset versus late-onset Alzheimer’s disease: the case of the missing APOE ε4 allele. Lancet Neurol 2011;10:280-288.
• Feldman FH, Scheltens Ph, Dubois B, on behalf of the International Working Group for New Research Criteria for AD.  New lexicon and criteria for the diagnosis of Alzheimer’s disease – Authors’ reply. Lancet Neurol 2011;11:300-301.
• Fonteijn HM, Clarkson MJ, Modat M, Barnes J, Lehmann M, Ourselin S, Fox NC, Alexander DC.  An event-based disease progression model and its application to familial Alzheimer’s disease. Inf Process Med Imaging 2011;22:748-759.
• Fox NC, Ridgway GR, Schott JM.Algorithms, atrophy and Alzheimer’s disease. Cautionary tales for clinical trials. Neuroimage 2011;57:15-18.
• Gao FQ, Swartz RH, Scheltens P, Leibovitch FS, Kiss A, Honjo K, Black SE. Complexity of MRI white matter hyperintensity assessments in relation to cognition in aging and dementia from the sunnybrook dementia study. J Alzheimers Dis 2011;26:379-388.
• Goos JDC, van der Flier WM, Knol DL, Pouwels PJW, Scheltens P, Barkhof F, Wattjes MP. Clinical Relevance of Improved Microbleed Detection by Susceptibility-Weighted Magnetic Resonance Imaging. Stroke 2011;42:1894-1900.
• Gouw AA, Seewann A, van der Flier WM, Barkhof F, Rozemuller AM, Scheltens P, Geurts JJG. Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry 2011;82:126-135.
• Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, K B, Carrillo M, Fox NC, Frisoni GB, Isaac M, Lovestone S, Nordberg A, Prvulovic D, Sampaio C, Scheltens P, Weiner M, Winblad B, Coley N, Vellas B, for the Oxford Task Force Group. Biomarkers for Alzheimer’s disease therapeutic trials. Prog Neurobiol 2011;95:579-593.
• van Harten AC, Kester MI, Visser PJ, Blankenstein MA, Pijnenburg YAL, van der Flier WM, Scheltens P. Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. Clin Chem Lab Med 2011;49:353-366.
• Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Jones N, Stretton A, Thomas C, Richards A, Ivanov D, Widdowson C, Chapman J, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Beaumont H, Warden D, Wilcock G, Love S, Kehoe PG, Hooper NM, Vardy ER, Hardy J, Mead S, Fox NC,  et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet 2011;43:429-436.
• Jack CR Jr, Barkhof F, Bernstein MA, Cantillon M, Cole PE, Decarli C, Dubois B, Duchesne S, Fox NC, Frisoni GB, Hampel H, Hill DL, Johnson K, Mangin JF, Scheltens P, Schwarz AJ, Sperling R, Suhy J, Thompson PM, Weiner M, Foster NL. Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer’s disease. Alzheimers Dement 2011;7:474-485.
• Jansen C, Parchi P, Jelles B, Gouw AA, Beunders G, van Spaendonk RML, van de Kamp JM, Lemstra AW, Capellari S, Rozemuller AJM. The first case of fatal familial insomnia (FFI) in the Netherlands: a patient from Egyptian descent with concurrent 4 repeat tau deposits.  Neuropathol Appl Neurobiol 2011;37:549-553.
• Jokinen H, Gouw AA, Madureira S, Ylikoski R, van Straaten ECW, van der Flier WM, Barkhof F, Scheltens P, Fazekas F, Schmidt R, Verdelho A, Ferro JM, Pantoni L, Inzitari D, Erkinjuntti T, On behalf of the LADIS Study Group. Incident lacunes influence cognitive decline: The LADIS study. Neurology 2011;76:1872-1878.
• de Jong-Hagelstein M, van de Sandt-Koenderman WME, Prins ND, Dippel DWJ, Koudstaal PJ, Visch-Brink EG. Efficacy of early cognitive-linguistic treatment and communicative treatment in aphasia after stroke: a randomised controlled trial (RATS-2). J Neurol Neurosurg Psychiatry 2011;82:399-404.
• Kamphuis PJGH, Verhey FRJ, Olde Rikkert MGM, Twisk JWR, Swinkels SHN, Scheltens P. Effect of a medical food on body mass index and activities of daily living in patients with Alzheimer’s disease: secondary analyses from a randomized, controlled trial. J Nutr Health Aging 2011;15:672-676.
• Kamphuis PJGH, Verhey FRJ, Olde Rikkert MGM, Twisk JWR, Swinkels SHN, Scheltens P. Efficacy of a medical food on cognition in Alzheimer’s disease: results from secondary analyses of a randomized, controlled trial. J Nutr Health Aging 2011;15:720-724.
• Kester MI, Verwey NA, van Elk EJ, Blankenstein MA, Scheltens P, van der Flier WM. Progression from MCI to AD: Predictive value of CSF Abeta42 is modified by APOE genotype. Neurobiol Aging 2011;32:1372-1378.
• Kim S, Swaminathan S, Shen L, Risacher SL, Nho K, Foroud T, Shaw LM, Trojanowski JQ, Potkin SG, Huentelman MJ, Craig DW, DeChairo BM, Aisen PS, Petersen RC, Weiner MW, Saykin AJ, for the Alzheimer’s Disease Neuroimaging Initiative. (waaronder o.a. Fox N.) Genome-wide association study of CSF biomarkers Aβ1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology 2011;76:69-79.
• Knight WD, Okello AA, Ryan NS, Turkheimer FE, Rodríguez Martinez de Llano S, Edison P, Douglas J, Fox NC, Brooks DJ, Rossor MN. Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. Brain 2011;134:293-300.
• Koedam ELGE, Lehmann M, van der Flier WM, Scheltens P, Pijnenburg YAL, Fox N, Barkhof F, Wattjes MP. Visual assessment of posterior atrophy development of a MRI rating scale. Eur Radiol 2011;21:2618-2625.
• Lashley T, Rohrer JD, Bandopadhyay R, Fry C, Ahmed Z, Isaacs AM, Brelstaff JH, Borroni B, Warren JD, Troakes C, King A, Al-Saraj S, Newcombe J, Quinn N, Ostergaard K, Schøder HD, Bojsen-Møller M, Braendgaard H, Fox NC, Rossor MN, Lees AJ, Holton JL, Revesz T. A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies. Brain 2011;134:2548-2564.
• Lehmann M, Barnes J, Ridgway GR, Wattam-Bell J, Warrington EK, Fox NC, Crutch SJ.  Basic visual function and cortical thickness patterns in posterior cortical atrophy. Cereb Cortex 2011;21:2122-2132.
• Lehmann M, Crutch SJ, Ridgway GR, Ridha BH, Barnes J, Warrington EK, Rossor MN, Fox NC. Cortical thickness and voxel-based morphometry in posterior cortical atrophy and typical Alzheimer’s disease. Neurobiol Aging 2011;32:1466-1476.
• Leung KK, Barnes J, Modat M, Ridgway GR, Bartlett JW, Fox NC, Ourselin S, and the Alzheimer’s Disease Neuroimaging Initiative. Brain MAPS: An automated, accurate and robust brain extraction technique using a template library. Neuroimage 2011;55:1091-1108.
• McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimers Dement 2011;7:263-269.
• Mahoney CJ, Rohrer JD, Goll JC, Fox NC, Rossor MN, Warren JD. Structural neuroanatomy of tinnitus and hyperacusis in semantic dementia. J Neurol Neurosurg Psychiatry 2011;82:1274-1278.
• Maruta C, Guerreiro M, de Mendonça A, Hort J, Scheltens P. The use of neuropsychological tests across Europe: the need for a consensus in the use of assessment tools for dementia. Eur J Neurol 2011;18:279-286.
• Norberg J, Graff C, Almkvist O, Ewers M, Frisoni GB, Frölich L, Hampel H, Jones RW, Kehoe PG, Lenoir H, Minthon L, Nobili F, Olde Rikkert M, Rigaud A-S, Scheltens P, Soininen H, Spiru L, Tsolaki M, Wahlund L-O, Vellas B, Wilcock G, Elias-Sonnenschein LS, Verhey FRJ, Visser PJ. Regional differences in effects of APOE ε4 on cognitive impairment in non-demented subjects. Dement Geriatr Cogn Disord 2011;32:135-142.
• O’Brien J, Scheltens P. Clinical use of neuroimaging in dementia: an international perspective. Int Psychogeriatr 2011;23(suppl 2):S3-S5.
• Ossenkoppele R, Tolboom N, Pijnenburg YA, Lammertsma AA, Scheltens P, van Berckel BNM.  Afbeelden van amyloïdplaques in de hersenen met PET. Ned Tijdschr Geneeskd 2011;155:A2981.
• Ossenkoppele R, van Berckel BNM, Tolboom N, PijnenburgYA, Prins ND, Lemstra AW, Lammertsma AA, Scheltens Ph. Moleculaire beeldvorming bij de ziekte van Alzheimer. Tschr Neurol Neurochir 2011;112:201-208.
• Ossenkoppele R, van Berckel BNM, Prins ND. Amyloid imaging in prodromal Alzheimer’s disease. Alzheimers Res Ther 2011;3(5):26.
• Oudega ML, van Exel E, Wattjes MP, Comijs HC, Scheltens P, Barkhof F, Eikelenboom P, de Craen AJM, Beekman ATF, Stek ML. White matter hyperintensities, medial temporal lobe atrophy, cortical atrophy, and response to electroconvulsive therapy in severely depressed elderly patients.  J Clin Psychiatry 2011;72:104-112.
• Pievani M, de Haan W, Wu T, Seeley WW, Frisoni GB. Functional network disruption in the degenerative dementias. Lancet Neurol 2011;10:829-843.
• van de Pol L, Gertz H-J, Scheltens P, Wolf H. Hippocampal atrophy in subcortical vascular dementia. Neurodegener Dis 2011;8:465-469.
• Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EGP, Onyike CU, Hillis AE, Josephs KA, Boeve BF, Kertesz A, Seeley WW, Rankin KP, Johnson JK, Gorno-Tempini ML, Rosen H, Prioleau-Latham CE, Lee A, Kipps CM, Lillo P, Piguet O, Rohrer JD, Rossor MN, Warren JD, Fox NC, Galasko D, Salmon DP, Black SE, Mesulam M, Weintraub S, Dickerson BC, Diehl-Schmid J, Pasquier F, Deramecourt V, Lebert F, Pijnenburg Y, Chow TW, Manes F, Grafman J, Cappa SF, Freedman M, Grossman M, Miller BL. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain  2011;134:2456-2477.
• Rohrer JD, Lashley T, Holton J, Revesz T, Urwin H, Isaacs AM, Fox NC, Rossor MN, Warren J. The clinical and neuroanatomical phenotype of FUS associated frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry 2011;82:1405-1407.
• Rohrer JD, Lashley T, Schott JM, Warren JE, Mead S, Isaacs AM, Beck J, Hardy J, de Silva R, Warrington E, Troakes C, Al-Sarraj S, King A, Borroni B, Clarkson MJ, Ourselin S, Holton JL, Fox NC, Revesz T, Rossor MN, Warren JD. Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain 2011;134:2565-2581.
• Ryberg C, Rostrup E, Paulson OB, Barkhof F, Scheltens P, van Straaten ECW, van der Flier WM, Fazekas F, Schmidt R, Ferro JM, Baezner H, Erkinjuntti T, Jokinen H, Wahlund L-O, Poggesi A, Pantoni L, Inzitari D, Waldemar G, and on behalf of the LADIS study group. Corpus callosum atrophy as a predictor of age-related cognitive and motor impairment: A 3-year follow-up of the LADIS study cohort. J Neurol Sci 2011;307:100-105.
• Scheltens P, Rockwood K. How golden is the gold standard of neuropathology in dementia? Alzheimers Dement 2011;7:486-489.
• Scher AI, Xu Y, Korf ESC, Hartley SW, Witter MP, Scheltens P, White LR, Thompson PM, Toga AW, Valentino DJ, Launer LJ. Hippocampal morphometry in population-based incident Alzheimer’s disease and vascular dementia: the HAAS. J Neurol Neurosurg Psychiatry 2011;82:373-377.
• Scherder E, Eggermont L, Visscher C, Scheltens P, Swaab D. Understanding higher level gait disturbances in mild dementia in order to improve rehabilitation; ‘Last in – first out’. Neurosci Biobehav Rev 2011;35:699-714.
• Schmidt R, Schmidt H, Haybaeck J, Loitfelder M, Weis S, Cavalieri M, Seiler S, Enzinger C, Ropele S, Erkinjuntti T, Pantoni L, Scheltens P, Fazekas F, Jellinger K. Heterogeneity in age-related white matter changes. Acta Neuropathol 2011;122:171-178.
• Schott JM, Warren JD, Barkhof F, Rossor MN, Fox NC. Suspected early dementia. BMJ 2011;343:d5568:1-5.
• Sikkes SAM, Knol DL, van den Berg MT, de Lange-de Klerk ESM, Scheltens P, Klein M, Pijnenburg YAL, Uitdehaag, BMJ. An informant questionnaire for detecting Alzheimer’s disease: are some items better than others? J Int Neuropsychol Soc 2011;17:674-681.
• Sims R, Dwyer S, Harold D, Gerrish A, Hollingworth P, Chapman J, Jones N, Abraham R, Ivanov D, Pahwa JS, Moskvina V, Dowzell K, Thomas C, Stretton A, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuiness B, Todd S, Johnston JA, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Livingston G, Bass NJ, Gurling H, McQuillin A, Jones L, Holmans PA, O’Donovan M, Owen MJ, Williams J. No evidence that extended tracts of homozygosity are associated with Alzheimer’s disease. Am J Med Genet B Neuropsychiatr Genet 2011;156:764-771.
• Smits LL, Liedorp M, Koene T, Roos-Reuling IEW, Lemstra AW, Scheltens P, Stam CJ, van der Flier WM. EEG abnormalities are associated with different cgnitive profiles in Alzheimer’s disease. Dement Geriatr Cogn Disord 2011;31:1-6.
• Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, Thies W, Bednar MM, Black RS, Brashear HR, Grundman M, Siemers ER, Feldman HH, Schindler RJ. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimers Dement 2011;7:367-385.
• Tabrizi SJ, Scahill RI, Durr A, Roos RAC, Leavitt BR, Jones R, Landwehrmeyer GB, Fox NC, Johnson H, Hicks SL, Kennard C, Craufurd D, Frost C, Langbehn DR, Reilmann R, Stout JC, and the TRACK-HD investigators. Biological and clinical changes in premanifest and early stage Huntington’s disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 2011;10:31-421.
• Vellas B, Aisen PS, Sampaio C, Carrillo M, Scheltens P, Scherrer B, Frisoni GB, Weiner M, Schneider L, Gauthier S, Gispen-de Wied CC, Hendrix S, Feldman H, Cedarbaum J, Petersen R, Siemers E, Andrieu S, Prvulovic D, Touchon J, Hampel H. Prevention trials in Alzheimer’s disease: An EU-US task force report. Prog Neurobiol 2011;95:594-600.
• Verdelho A, Madureira S, Moleiro C, Santos CO, Ferro JM, Erkinjuntti T, Poggesi A, Pantoni L, Fazekas F, Scheltens P, Waldemar G, Wallin A, Inzitari D, and on behalf of the LADIS study(waaronder Scheltens P, van Straaten I, Gouw A, van der Flier W, Visser M). Self-perceived memory complaints predict progression to Alzheimer disease. The LADIS study. J Alzheimers Dis  2011;27:491-498.
• van Vliet D, de Vugt ME, Bakker C, Koopmans RTCM, Pijnenburg YAL, Vernooij-Dassen MJFJ, Verhey FR. Caregivers’ perspectives on the pre-diagnostic period in early onset dementia: a long and winding road. Int Psychogeriatr 2011;23:1393-1404.
• de Waal H, Stam CJ, Blankenstein MA, Pijnenburg YAL, Scheltens P, van der Flier WM. EEG abnormalities in early and late onset Alzheimer’s disease: understanding heterogeneity. J Neurol Neurosurg Psychiatry 2011;82:67-71.
• de Wilde MC, Kamphuis PJGH, Sijben JWC, Scheltens P. Utility of imaging for nutritional intervention studies in Alzheimer’s disease. Eur J Pharmacol 2011;668(suppl.1):S59-S69.
• Witlox J, Kalisvaart KJ, de Jonghe JFM, Verwey NA, van Stijn MFM, Houdijk APJ, Traast HS, Maclullich AMJ, van Gool WA, Eikelenboom P. Cerebrospinal fluid β-amyloid and tau are not associated with risk of delirium: a prospective cohort study in older adults with hip fracture. J Am Geriatr Soc 2011;59:1260-1267.
• Dröes, R.M., Van Mierlo, L.D., Meiland, F.J.M., Van der Roest, H.G. Memory problems in dementia: Adaptation and copingstrategies, and psychosocial treatments. Expert Reviews Neurotherapeutics, 2011,11(12)1769-1782.
• De Boer ME, Dröes RM, Jonker C, Eefsting JA, Hertogh CMPM. Advance directives for euthanasia in dementia: how are they dealt with in Dutch nursing homes? Experiences of physicians and relatives.Journal of the American Geriatrics Society 2011;59(6):989-96.
• Jansen APD, Van Hout HPJ, Nijpels G, Rijmen F, Dröes RM, Pot AM, Schellevis F, Van Marwijk HWJ, Stalman W. Effectiveness of case management among older adults with early symptoms of dementia and their primary informal caregivers: a randomised clinical trial. International Journal of Nursing Studies 2011 Aug;48(8):933-43.
• Meiland FJM, Jonker C, Dröes RM. Predictors of effective support in meeting centers for people with dementia and their carers,Nonpharmacological therapies in dementia2010; 1(3):251-270.
• Monfort JC, Villemur V, Lezy AM, Baron-Laforet S, Dröes RM. From paedophilia to gerontophilia. Lancet 2011; Vol. 377, Jan 22, 300. Van Mierlo LD, Meiland FJM, Dröes RM. Dementelcoach: effect of telephone coaching on carers of community dwelling people with dementia. Int Psychogeriatr. 2011 Oct 14:1-11.

Boek(hoofdstukken) en vakpublicaties:

• Barkhof F, Fox NC, Bastos-Leite AJ, Scheltens Ph. Neuroimaging in dementia. New York, Springer, 2011. 278 pp.
• van Exel E, Eikelenboom P, Comijs HC, Kurniawan C, Frölich M, Smit JH, Stek ML, Scheltens P, Eefsting JE, Westendorp  RGJ.  Het immuunsysteem en de ziekte van Alzheimer. Tijdschr Psychiatr 2011;53:637-643.
• Hort J, O’Brien JT, Gainotti G, Pirttila T, Popescu BO, Rektorova I, Sorbi S, Scheltens P. Alzheimer’s disease. In: Gilhus NE, Barnes M, Brainin M (eds), European handbook of neurological management. Oxford, John Wiley-Blackwell Publishing, 2011:269-281.
• Kerklaan BJ, Scheltens P, Schoonderwoerd GC, Killestein J, Rozemuller AJM, van der Knaap MS. ‘Adult polyglucosan body disease’: een weinig bekende maar herkenbare wittestofziekte. Tschr Neurol Neurochir 2011;112:25-31.
• Vos SJB, Visser PJ, Verhey FRJ. De rol van liquormarkers bij de vroege diagnostiek van de ziekte van Alzheimer. Tijdschr Psychiatr 2011;53:647-653.
• Dijk M van, Weert J van, Dröes RM. De Veder methode. Contact maken door middel van theater. Denkbeeld; Tijdschrift voor Psychogeriatrie, 23, 2011, 2-5.
• Mierlo L, Dröes RM. Dementelcoach; telefonische ondersteuning voor mantelzorgers van mensen met dementie. Vita Valley, Nieuwsbrief, juli 2011.

Dissertaties:

• Kester, MI. Biomarkers for Alzheimer’s pathology; monitoring, predicting and understanding the disease.
  Vrije Universiteit Amsterdam 14 januari 2011
  promotoren: Ph Scheltens, MA Blankenstein, copromotor: WM van der Flier
• Mulder SD. Amyloid associated proteins in Alzheimer’s disease.
  Vrije Universiteit Amsterdam 7 oktober 2011
  promotoren: MA Blankenstein. Ph Scheltens, copromotor: R Veerhuis
• Sikkes SAM. Measuring IADL in dementia.
  Vrije Universiteit Amsterdam 14 oktober 2011.
  promotoren: Ph Scheltens, BMJ Uitdehaag, copromotoren: YAL Pijnenburg, ESM de Lange-de Klerk
• Sluimer JD. Visualizing the shrinking brain: longitudinal MR studies in the spectrum of cognitive decline.
  Vrije Universiteit Amsterdam 28 april 2011.
  promotoren: F Barkhof, Ph Scheltens, copromotoren: WM van der Flier, H. Vrenken
• Van der Roest HG. Care needs in dementia and digital interactive information provisioning.
  Vrije Universiteit Amsterdam 12 oktober 2009
  Promotoren: RM Dröes, C Jonker, copromotoren: FJ Meiland, P. Scheltens

Internationale wetenschappelijke publicaties:

• Albert MS, Dekosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging and Alzheimer’s Association workgroup. Alzheimers Dement 2011;7:270-279.
• Bateman RJ, Aisen PS, de Strooper B, Fox NC, Lemere CA, Ringman JM, Salloway S, Sperling RA, Windisch M, Xiong C. Autosomal-dominant Alzheimer’s disease: a review and proposal for the prevention of Alzheimer’s disease. Alzheimers Res Ther 2011;3(1):1-13.
• Brodaty H, Breteler MMB, Dekosky ST, Dorenlot P, Fratiglioni L, Hock C, Kenigsberg P-A, Scheltens P, de Strooper B. The world of dementia beyond 2020. J Am Geriatr Soc 2011;59:923-927.
• Cardoso MJ, Clarkson MJ, Ridgway GR, Modat M, Fox NC, Ourselin S,and The Alzheimer’s Disease Neuroimaging Initiative. LoAd: A locally adaptive cortical segmentation algorithm. Neuroimage 2011;56:1386-1397.
• Chiang GC, Insel PS, Tosun D, Schuff N, Truran-Sacrey D, Raptentsetsang ST, Thompson PM, Reiman EM, Jack CR Jr, Fox NC, Jagust WJ, Harvey DJ, Beckett LA, Gamst A, Aisen PS, Petersen RC, Weiner MW, for the Alzheimer’s Disease Neuroimaging Initiative. Impact of apolipoprotein ɛ4-cerebrospinal fluid beta-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment. Alzheimers Dement 2011;7:514-520.
• Clarkson MJ, Cardoso MJ, Ridgway GR, Modat M, Leung KK, Rohrer JD, Fox NC, Ourselin S. A comparison of voxel and surface based cortical thickness estimation methods. Neuroimage 2011;57:856-865.
• Cordonnier C, van der Flier WM. Brain microbleeds and Alzheimer’s disease: innocent observation or key player? Brain 2011;134:335-344.
• Echávarri C, Aalten P, Uylings HBM, Jacobs HIL, Visser PJ, Gronenschild EHBM, Verhey FRJ, Burgmans S. Atrophy in the parahippocampal gyrus as an early biomarker of Alzheimer’s disease. Brain Struct Funct 2011;215:265-271.
• Elias-Sonnenschein LS, Viechtbauer W, Ramakers IHGB, Verhey FRJ, Visser PJ. Predictive value of APOE-ε4 allele for progression from MCI to AD-type dementia: a meta-analysis.  J Neurol Neurosurg Psychiatry 2011;82:1149-1156.
• van der Flier WM, Pijnenburg YAL Fox NC, Scheltens P. Early-onset versus late-onset Alzheimer’s disease: the case of the missing APOE ε4 allele. Lancet Neurol 2011;10:280-288.
• Feldman FH, Scheltens Ph, Dubois B, on behalf of the International Working Group for New Research Criteria for AD.  New lexicon and criteria for the diagnosis of Alzheimer’s disease – Authors’ reply. Lancet Neurol 2011;11:300-301.
• Fonteijn HM, Clarkson MJ, Modat M, Barnes J, Lehmann M, Ourselin S, Fox NC, Alexander DC.  An event-based disease progression model and its application to familial Alzheimer’s disease. Inf Process Med Imaging 2011;22:748-759.
• Fox NC, Ridgway GR, Schott JM.Algorithms, atrophy and Alzheimer’s disease. Cautionary tales for clinical trials. Neuroimage 2011;57:15-18.
• Gao FQ, Swartz RH, Scheltens P, Leibovitch FS, Kiss A, Honjo K, Black SE. Complexity of MRI white matter hyperintensity assessments in relation to cognition in aging and dementia from the sunnybrook dementia study. J Alzheimers Dis 2011;26:379-388.
• Goos JDC, van der Flier WM, Knol DL, Pouwels PJW, Scheltens P, Barkhof F, Wattjes MP. Clinical Relevance of Improved Microbleed Detection by Susceptibility-Weighted Magnetic Resonance Imaging. Stroke 2011;42:1894-1900.
• Gouw AA, Seewann A, van der Flier WM, Barkhof F, Rozemuller AM, Scheltens P, Geurts JJG. Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry 2011;82:126-135.
• Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, K B, Carrillo M, Fox NC, Frisoni GB, Isaac M, Lovestone S, Nordberg A, Prvulovic D, Sampaio C, Scheltens P, Weiner M, Winblad B, Coley N, Vellas B, for the Oxford Task Force Group. Biomarkers for Alzheimer’s disease therapeutic trials. Prog Neurobiol 2011;95:579-593.
• van Harten AC, Kester MI, Visser PJ, Blankenstein MA, Pijnenburg YAL, van der Flier WM, Scheltens P. Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. Clin Chem Lab Med 2011;49:353-366.
• Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Jones N, Stretton A, Thomas C, Richards A, Ivanov D, Widdowson C, Chapman J, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Beaumont H, Warden D, Wilcock G, Love S, Kehoe PG, Hooper NM, Vardy ER, Hardy J, Mead S, Fox NC,  et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet 2011;43:429-436.
• Jack CR Jr, Barkhof F, Bernstein MA, Cantillon M, Cole PE, Decarli C, Dubois B, Duchesne S, Fox NC, Frisoni GB, Hampel H, Hill DL, Johnson K, Mangin JF, Scheltens P, Schwarz AJ, Sperling R, Suhy J, Thompson PM, Weiner M, Foster NL. Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer’s disease. Alzheimers Dement 2011;7:474-485.
• Jansen C, Parchi P, Jelles B, Gouw AA, Beunders G, van Spaendonk RML, van de Kamp JM, Lemstra AW, Capellari S, Rozemuller AJM. The first case of fatal familial insomnia (FFI) in the Netherlands: a patient from Egyptian descent with concurrent 4 repeat tau deposits.  Neuropathol Appl Neurobiol 2011;37:549-553.
• Jokinen H, Gouw AA, Madureira S, Ylikoski R, van Straaten ECW, van der Flier WM, Barkhof F, Scheltens P, Fazekas F, Schmidt R, Verdelho A, Ferro JM, Pantoni L, Inzitari D, Erkinjuntti T, On behalf of the LADIS Study Group. Incident lacunes influence cognitive decline: The LADIS study. Neurology 2011;76:1872-1878.
• de Jong-Hagelstein M, van de Sandt-Koenderman WME, Prins ND, Dippel DWJ, Koudstaal PJ, Visch-Brink EG. Efficacy of early cognitive-linguistic treatment and communicative treatment in aphasia after stroke: a randomised controlled trial (RATS-2). J Neurol Neurosurg Psychiatry 2011;82:399-404.
• Kamphuis PJGH, Verhey FRJ, Olde Rikkert MGM, Twisk JWR, Swinkels SHN, Scheltens P. Effect of a medical food on body mass index and activities of daily living in patients with Alzheimer’s disease: secondary analyses from a randomized, controlled trial. J Nutr Health Aging 2011;15:672-676.
• Kamphuis PJGH, Verhey FRJ, Olde Rikkert MGM, Twisk JWR, Swinkels SHN, Scheltens P. Efficacy of a medical food on cognition in Alzheimer’s disease: results from secondary analyses of a randomized, controlled trial. J Nutr Health Aging 2011;15:720-724.
• Kester MI, Verwey NA, van Elk EJ, Blankenstein MA, Scheltens P, van der Flier WM. Progression from MCI to AD: Predictive value of CSF Abeta42 is modified by APOE genotype. Neurobiol Aging 2011;32:1372-1378.
• Kim S, Swaminathan S, Shen L, Risacher SL, Nho K, Foroud T, Shaw LM, Trojanowski JQ, Potkin SG, Huentelman MJ, Craig DW, DeChairo BM, Aisen PS, Petersen RC, Weiner MW, Saykin AJ, for the Alzheimer’s Disease Neuroimaging Initiative. (waaronder o.a. Fox N.) Genome-wide association study of CSF biomarkers Aβ1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology 2011;76:69-79.
• Knight WD, Okello AA, Ryan NS, Turkheimer FE, Rodríguez Martinez de Llano S, Edison P, Douglas J, Fox NC, Brooks DJ, Rossor MN. Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. Brain 2011;134:293-300.
• Koedam ELGE, Lehmann M, van der Flier WM, Scheltens P, Pijnenburg YAL, Fox N, Barkhof F, Wattjes MP. Visual assessment of posterior atrophy development of a MRI rating scale. Eur Radiol 2011;21:2618-2625.
• Lashley T, Rohrer JD, Bandopadhyay R, Fry C, Ahmed Z, Isaacs AM, Brelstaff JH, Borroni B, Warren JD, Troakes C, King A, Al-Saraj S, Newcombe J, Quinn N, Ostergaard K, Schøder HD, Bojsen-Møller M, Braendgaard H, Fox NC, Rossor MN, Lees AJ, Holton JL, Revesz T. A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies. Brain 2011;134:2548-2564.
• Lehmann M, Barnes J, Ridgway GR, Wattam-Bell J, Warrington EK, Fox NC, Crutch SJ.  Basic visual function and cortical thickness patterns in posterior cortical atrophy. Cereb Cortex 2011;21:2122-2132.
• Lehmann M, Crutch SJ, Ridgway GR, Ridha BH, Barnes J, Warrington EK, Rossor MN, Fox NC. Cortical thickness and voxel-based morphometry in posterior cortical atrophy and typical Alzheimer’s disease. Neurobiol Aging 2011;32:1466-1476.
• Leung KK, Barnes J, Modat M, Ridgway GR, Bartlett JW, Fox NC, Ourselin S, and the Alzheimer’s Disease Neuroimaging Initiative. Brain MAPS: An automated, accurate and robust brain extraction technique using a template library. Neuroimage 2011;55:1091-1108.
• McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimers Dement 2011;7:263-269.
• Mahoney CJ, Rohrer JD, Goll JC, Fox NC, Rossor MN, Warren JD. Structural neuroanatomy of tinnitus and hyperacusis in semantic dementia. J Neurol Neurosurg Psychiatry 2011;82:1274-1278.
• Maruta C, Guerreiro M, de Mendonça A, Hort J, Scheltens P. The use of neuropsychological tests across Europe: the need for a consensus in the use of assessment tools for dementia. Eur J Neurol 2011;18:279-286.
• Norberg J, Graff C, Almkvist O, Ewers M, Frisoni GB, Frölich L, Hampel H, Jones RW, Kehoe PG, Lenoir H, Minthon L, Nobili F, Olde Rikkert M, Rigaud A-S, Scheltens P, Soininen H, Spiru L, Tsolaki M, Wahlund L-O, Vellas B, Wilcock G, Elias-Sonnenschein LS, Verhey FRJ, Visser PJ. Regional differences in effects of APOE ε4 on cognitive impairment in non-demented subjects. Dement Geriatr Cogn Disord 2011;32:135-142.
• O’Brien J, Scheltens P. Clinical use of neuroimaging in dementia: an international perspective. Int Psychogeriatr 2011;23(suppl 2):S3-S5.
• Ossenkoppele R, Tolboom N, Pijnenburg YA, Lammertsma AA, Scheltens P, van Berckel BNM.  Afbeelden van amyloïdplaques in de hersenen met PET. Ned Tijdschr Geneeskd 2011;155:A2981.
• Ossenkoppele R, van Berckel BNM, Tolboom N, PijnenburgYA, Prins ND, Lemstra AW, Lammertsma AA, Scheltens Ph. Moleculaire beeldvorming bij de ziekte van Alzheimer. Tschr Neurol Neurochir 2011;112:201-208.
• Ossenkoppele R, van Berckel BNM, Prins ND. Amyloid imaging in prodromal Alzheimer’s disease. Alzheimers Res Ther 2011;3(5):26.
• Oudega ML, van Exel E, Wattjes MP, Comijs HC, Scheltens P, Barkhof F, Eikelenboom P, de Craen AJM, Beekman ATF, Stek ML. White matter hyperintensities, medial temporal lobe atrophy, cortical atrophy, and response to electroconvulsive therapy in severely depressed elderly patients.  J Clin Psychiatry 2011;72:104-112.
• Pievani M, de Haan W, Wu T, Seeley WW, Frisoni GB. Functional network disruption in the degenerative dementias. Lancet Neurol 2011;10:829-843.
• van de Pol L, Gertz H-J, Scheltens P, Wolf H. Hippocampal atrophy in subcortical vascular dementia. Neurodegener Dis 2011;8:465-469.
• Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EGP, Onyike CU, Hillis AE, Josephs KA, Boeve BF, Kertesz A, Seeley WW, Rankin KP, Johnson JK, Gorno-Tempini ML, Rosen H, Prioleau-Latham CE, Lee A, Kipps CM, Lillo P, Piguet O, Rohrer JD, Rossor MN, Warren JD, Fox NC, Galasko D, Salmon DP, Black SE, Mesulam M, Weintraub S, Dickerson BC, Diehl-Schmid J, Pasquier F, Deramecourt V, Lebert F, Pijnenburg Y, Chow TW, Manes F, Grafman J, Cappa SF, Freedman M, Grossman M, Miller BL. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain  2011;134:2456-2477.
• Rohrer JD, Lashley T, Holton J, Revesz T, Urwin H, Isaacs AM, Fox NC, Rossor MN, Warren J. The clinical and neuroanatomical phenotype of FUS associated frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry 2011;82:1405-1407.
• Rohrer JD, Lashley T, Schott JM, Warren JE, Mead S, Isaacs AM, Beck J, Hardy J, de Silva R, Warrington E, Troakes C, Al-Sarraj S, King A, Borroni B, Clarkson MJ, Ourselin S, Holton JL, Fox NC, Revesz T, Rossor MN, Warren JD. Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain 2011;134:2565-2581.
• Ryberg C, Rostrup E, Paulson OB, Barkhof F, Scheltens P, van Straaten ECW, van der Flier WM, Fazekas F, Schmidt R, Ferro JM, Baezner H, Erkinjuntti T, Jokinen H, Wahlund L-O, Poggesi A, Pantoni L, Inzitari D, Waldemar G, and on behalf of the LADIS study group. Corpus callosum atrophy as a predictor of age-related cognitive and motor impairment: A 3-year follow-up of the LADIS study cohort. J Neurol Sci 2011;307:100-105.
• Scheltens P, Rockwood K. How golden is the gold standard of neuropathology in dementia? Alzheimers Dement 2011;7:486-489.
• Scher AI, Xu Y, Korf ESC, Hartley SW, Witter MP, Scheltens P, White LR, Thompson PM, Toga AW, Valentino DJ, Launer LJ. Hippocampal morphometry in population-based incident Alzheimer’s disease and vascular dementia: the HAAS. J Neurol Neurosurg Psychiatry 2011;82:373-377.
• Scherder E, Eggermont L, Visscher C, Scheltens P, Swaab D. Understanding higher level gait disturbances in mild dementia in order to improve rehabilitation; ‘Last in – first out’. Neurosci Biobehav Rev 2011;35:699-714.
• Schmidt R, Schmidt H, Haybaeck J, Loitfelder M, Weis S, Cavalieri M, Seiler S, Enzinger C, Ropele S, Erkinjuntti T, Pantoni L, Scheltens P, Fazekas F, Jellinger K. Heterogeneity in age-related white matter changes. Acta Neuropathol 2011;122:171-178.
• Schott JM, Warren JD, Barkhof F, Rossor MN, Fox NC. Suspected early dementia. BMJ 2011;343:d5568:1-5.
• Sikkes SAM, Knol DL, van den Berg MT, de Lange-de Klerk ESM, Scheltens P, Klein M, Pijnenburg YAL, Uitdehaag, BMJ. An informant questionnaire for detecting Alzheimer’s disease: are some items better than others? J Int Neuropsychol Soc 2011;17:674-681.
• Sims R, Dwyer S, Harold D, Gerrish A, Hollingworth P, Chapman J, Jones N, Abraham R, Ivanov D, Pahwa JS, Moskvina V, Dowzell K, Thomas C, Stretton A, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuiness B, Todd S, Johnston JA, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Livingston G, Bass NJ, Gurling H, McQuillin A, Jones L, Holmans PA, O’Donovan M, Owen MJ, Williams J. No evidence that extended tracts of homozygosity are associated with Alzheimer’s disease. Am J Med Genet B Neuropsychiatr Genet 2011;156:764-771.
• Smits LL, Liedorp M, Koene T, Roos-Reuling IEW, Lemstra AW, Scheltens P, Stam CJ, van der Flier WM. EEG abnormalities are associated with different cgnitive profiles in Alzheimer’s disease. Dement Geriatr Cogn Disord 2011;31:1-6.
• Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, Thies W, Bednar MM, Black RS, Brashear HR, Grundman M, Siemers ER, Feldman HH, Schindler RJ. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimers Dement 2011;7:367-385.
• Tabrizi SJ, Scahill RI, Durr A, Roos RAC, Leavitt BR, Jones R, Landwehrmeyer GB, Fox NC, Johnson H, Hicks SL, Kennard C, Craufurd D, Frost C, Langbehn DR, Reilmann R, Stout JC, and the TRACK-HD investigators. Biological and clinical changes in premanifest and early stage Huntington’s disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 2011;10:31-421.
• Vellas B, Aisen PS, Sampaio C, Carrillo M, Scheltens P, Scherrer B, Frisoni GB, Weiner M, Schneider L, Gauthier S, Gispen-de Wied CC, Hendrix S, Feldman H, Cedarbaum J, Petersen R, Siemers E, Andrieu S, Prvulovic D, Touchon J, Hampel H. Prevention trials in Alzheimer’s disease: An EU-US task force report. Prog Neurobiol 2011;95:594-600.
• Verdelho A, Madureira S, Moleiro C, Santos CO, Ferro JM, Erkinjuntti T, Poggesi A, Pantoni L, Fazekas F, Scheltens P, Waldemar G, Wallin A, Inzitari D, and on behalf of the LADIS study(waaronder Scheltens P, van Straaten I, Gouw A, van der Flier W, Visser M). Self-perceived memory complaints predict progression to Alzheimer disease. The LADIS study. J Alzheimers Dis  2011;27:491-498.
• van Vliet D, de Vugt ME, Bakker C, Koopmans RTCM, Pijnenburg YAL, Vernooij-Dassen MJFJ, Verhey FR. Caregivers’ perspectives on the pre-diagnostic period in early onset dementia: a long and winding road. Int Psychogeriatr 2011;23:1393-1404.
• de Waal H, Stam CJ, Blankenstein MA, Pijnenburg YAL, Scheltens P, van der Flier WM. EEG abnormalities in early and late onset Alzheimer’s disease: understanding heterogeneity. J Neurol Neurosurg Psychiatry 2011;82:67-71.
• de Wilde MC, Kamphuis PJGH, Sijben JWC, Scheltens P. Utility of imaging for nutritional intervention studies in Alzheimer’s disease. Eur J Pharmacol 2011;668(suppl.1):S59-S69.
• Witlox J, Kalisvaart KJ, de Jonghe JFM, Verwey NA, van Stijn MFM, Houdijk APJ, Traast HS, Maclullich AMJ, van Gool WA, Eikelenboom P. Cerebrospinal fluid β-amyloid and tau are not associated with risk of delirium: a prospective cohort study in older adults with hip fracture. J Am Geriatr Soc 2011;59:1260-1267.
• Dröes, R.M., Van Mierlo, L.D., Meiland, F.J.M., Van der Roest, H.G. Memory problems in dementia: Adaptation and copingstrategies, and psychosocial treatments. Expert Reviews Neurotherapeutics, 2011,11(12)1769-1782.
• De Boer ME, Dröes RM, Jonker C, Eefsting JA, Hertogh CMPM. Advance directives for euthanasia in dementia: how are they dealt with in Dutch nursing homes? Experiences of physicians and relatives.Journal of the American Geriatrics Society 2011;59(6):989-96.
• Jansen APD, Van Hout HPJ, Nijpels G, Rijmen F, Dröes RM, Pot AM, Schellevis F, Van Marwijk HWJ, Stalman W. Effectiveness of case management among older adults with early symptoms of dementia and their primary informal caregivers: a randomised clinical trial. International Journal of Nursing Studies 2011 Aug;48(8):933-43.
• Meiland FJM, Jonker C, Dröes RM. Predictors of effective support in meeting centers for people with dementia and their carers,Nonpharmacological therapies in dementia2010; 1(3):251-270.
• Monfort JC, Villemur V, Lezy AM, Baron-Laforet S, Dröes RM. From paedophilia to gerontophilia. Lancet 2011; Vol. 377, Jan 22, 300. Van Mierlo LD, Meiland FJM, Dröes RM. Dementelcoach: effect of telephone coaching on carers of community dwelling people with dementia. Int Psychogeriatr. 2011 Oct 14:1-11.

Boek(hoofdstukken) en vakpublicaties:

• Barkhof F, Fox NC, Bastos-Leite AJ, Scheltens Ph. Neuroimaging in dementia. New York, Springer, 2011. 278 pp.
• van Exel E, Eikelenboom P, Comijs HC, Kurniawan C, Frölich M, Smit JH, Stek ML, Scheltens P, Eefsting JE, Westendorp  RGJ.  Het immuunsysteem en de ziekte van Alzheimer. Tijdschr Psychiatr 2011;53:637-643.
• Hort J, O’Brien JT, Gainotti G, Pirttila T, Popescu BO, Rektorova I, Sorbi S, Scheltens P. Alzheimer’s disease. In: Gilhus NE, Barnes M, Brainin M (eds), European handbook of neurological management. Oxford, John Wiley-Blackwell Publishing, 2011:269-281.
• Kerklaan BJ, Scheltens P, Schoonderwoerd GC, Killestein J, Rozemuller AJM, van der Knaap MS. ‘Adult polyglucosan body disease’: een weinig bekende maar herkenbare wittestofziekte. Tschr Neurol Neurochir 2011;112:25-31.
• Vos SJB, Visser PJ, Verhey FRJ. De rol van liquormarkers bij de vroege diagnostiek van de ziekte van Alzheimer. Tijdschr Psychiatr 2011;53:647-653.
• Dijk M van, Weert J van, Dröes RM. De Veder methode. Contact maken door middel van theater. Denkbeeld; Tijdschrift voor Psychogeriatrie, 23, 2011, 2-5.
• Mierlo L, Dröes RM. Dementelcoach; telefonische ondersteuning voor mantelzorgers van mensen met dementie. Vita Valley, Nieuwsbrief, juli 2011.

Dissertaties:

• Kester, MI. Biomarkers for Alzheimer’s pathology; monitoring, predicting and understanding the disease.
  Vrije Universiteit Amsterdam 14 januari 2011
  promotoren: Ph Scheltens, MA Blankenstein, copromotor: WM van der Flier
• Mulder SD. Amyloid associated proteins in Alzheimer’s disease.
  Vrije Universiteit Amsterdam 7 oktober 2011
  promotoren: MA Blankenstein. Ph Scheltens, copromotor: R Veerhuis
• Sikkes SAM. Measuring IADL in dementia.
  Vrije Universiteit Amsterdam 14 oktober 2011.
  promotoren: Ph Scheltens, BMJ Uitdehaag, copromotoren: YAL Pijnenburg, ESM de Lange-de Klerk
• Sluimer JD. Visualizing the shrinking brain: longitudinal MR studies in the spectrum of cognitive decline.
  Vrije Universiteit Amsterdam 28 april 2011.
  promotoren: F Barkhof, Ph Scheltens, copromotoren: WM van der Flier, H. Vrenken
• Van der Roest HG. Care needs in dementia and digital interactive information provisioning.
  Vrije Universiteit Amsterdam 12 oktober 2009
  Promotoren: RM Dröes, C Jonker, copromotoren: FJ Meiland, P. Scheltens

Internationale wetenschappelijk publicaties (peer reviewed):

• Archer HA, Kennedy J, Barnes J, Pepple T, Boyes R, Randlesome K, Clegg S, Leung KK, Ourselin S, Frost C, Rossor MN, Fox NC. Memory complaints and increased rates of brain atrophy: risk factors for mild cognitive impairment and Alzheimer’s disease. Int J Geriatr Psychiatry 2010;25:1119-1126.
• Babiloni C, Visser PJ, Frisoni G, De Deyn PP, Bresciani L, Jelic V, Nagels G, Rodriguez G, Rossini PM, Vecchio F, Colombo D, Verhey F, Wahlund L-O, Nobili F. Cortical sources of resting EEG rhythms in mild cognitive impairment and subjective memory complaint. Neurobiol Aging 2010;31:1787-1798.
• Barnes J, Mitchell LA, Kennedy J, Bastos-Leite AJ, Barker S, Lehmann M, Nordstrom RC, Frost C, Smith JR, Garde E, Rossor MN, Fox NC. Does registration of serial MRI improve diagnosis of dementia? Neuroradiology 2010;52:987-995.
• Barnes J, Ridgway GR, Bartlett J, Henley SMD, Lehmann M, Hobbs N, Clarkson MJ, Macmanus DG, Ourselin S, Fox NC.  Head size, age and gender adjustment in MRI studies: A necessary nuisance?  Neuroimage 2010;53:1244-1255.
• Bird CM, Chan D, Hartley T, Pijnenburg YA, Rossor MN, Burgess N. Topographical short-term memory differentiates Alzheimer’s disease from frontotemporal lobar degeneration. Hippocampus 2010;20:1154-1169.
• Bour AMJJ, Rasquin SMC, Baars L, van Boxtel MPJ, Visser PJ, Limburg M, Verhey FRJ. The effect of the APOE-ε4 allele and ACE-I/D polymorphism on cognition during a two-year follow-up in first-ever stroke patients. Dement Geriatr Cogn Disord 2010;29:534-542.
• Bouwman FH, Verwey NA, Klein M, Kok A, Blankenstein MA, Sluimer JD, Barkhof F,van der Flier WM, Scheltens P. New research criteria for the diagnosis of Alzheimer’s disease applied in a memory clinic population.  Dement Geriatr Cogn Disord 2010;30:1-7.
• Carmichael O, Schwarz C, Drucker D, Fletcher E, Harvey D, Beckett L, Jack CR Jr, Weiner M, DeCarli C, for the Alzheimer’s Disease Neuroimaging Initiative.(waaronder Visser PJ)Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. Arch Neurol 2010;67:1370-1378.
• Chouliaras L, Rutten BPF, Kenis G, Peerbooms O, Visser PJ, Verhey F, van Os J, Steinbusch HWM, van den Hove DLA. Epigenetic regulation in the pathophysiology of Alzheimer’s disease. Prog Neurobiol 2010;90:498-510.
• Clarkson MJ, Malone IB, Modat M, Leung KK, Ryan N, Alexander DC, Fox NC, Ourselin S. A framework for using diffusion weighted imaging to improve cortical parcellation. Med Image Comput Comput Assist Interv. 2010;13:534-541.
• Delaloye C, Moy G, de Bilbao F, Baudois S, Weber K, Hofer F, Paquier CR, Donati A, Canuto A, Giardini U, von Gunten A, Stancu RI, Lazeyras F, Millet P, Scheltens P, Giannakopoulos P, Gold G. Neuroanatomical and neuropsychological features of elderly euthymic depressed patients with early- and late-onset. J Neurol Sci 2010;299:19-23.
• Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O’Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol 2010;9:1118-1127.
• Evans MC, Barnes J, Nielsen C, Kim LG, Clegg SL, Blair M, Leung KK, Douiri A, Boyes RG, Ourselin S, Fox NC, and the Alzheimer’s Disease Neuroimaging Initiative.  Volume changes in Alzheimer’s disease and mild cognitive impairment: cognitive associations. Eur Radiol 2010;20:674-682.
• Exalto LG, van der Flier WM, Scheltens P, Biessels GJ. Glycemia and levels of cerebrospinal fluid amyloid and tau in patients attending a memory clinic.  J Am Geriatr Soc 2010;58:1318-1321.
• Fox N. Clinical advances in our understanding and classification of the dementias. J Neurol Neurosurg Psychiatry 2010;81(10):e3,006.
• Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease.  Nat Rev Neurol 2010;6:67-77.
• Goos JDC, Henneman WJP, Sluimer JD, Vrenken H, Sluimer IC, Barkhof F, Blankenstein MA, Scheltens PH, van der Flier WM. Incidence of cerebral microbleeds: A longitudinal study in a memory clinic population. Neurology 2010;74:1954-1960.
• Gordon E, Rohrer JD, Kim LG, Omar R, Rossor MN, Fox NC, Warren JD. Measuring disease progression in frontotemporal lobar degeneration: a clinical and MRI study. Neurology 2010:74: 666-673.
• Guerreiro RJ, Beck J, Gibbs JR, Santana I, Rossor MN, Schott JM, Nalls MA, Ribeiro H, Santiago B, Fox NC, Oliveira C, Collinge J, Mead S, Singleton A, Hardy J.  Genetic variability inCLU and its association with Alzheimer’s disease.  PLoS One 2010;5(3):e9510.
• Henley SMD, Ridgway GR, Scahill RI, Klöppel S, Tabrizi SJ, Fox NC, Kassubek J, for the EHDN Imaging Working Group. Pitfalls in the Use of Voxel-Based Morphometry as a Biomarker: Examples from Huntington Disease. AJNR Am J Neuroradiol 2010;31:711-719.
• Hobbs NZ, Barnes J, Frost C, Henley SMD, Wild EJ, Macdonald K, Barker RA, Scahill RI, Fox NC, Tabrizi SJ. Onset and progression of pathologic atrophy in Huntington disease: a longitudinal MR imaging study. AJNR Am J Neuroradiol 2010;31:1036-1041.
• Hobbs NZ, Henley SMD, Ridgway G, Wild EJ, Barker R, Scahill RI, Barnes J, Fox NC, Tabrizi SJ. The progression of regional atrophy in premanifest and early Huntington’s disease: a longitudinal voxel-based morphometry study. J Neurol Neurosurg Psychiatry 2010;81:756-763.
• Hort J, O’Brien JT, Gainotti G, Pirttila T, Popescu BO, Rektorova I, Sorbi S, Scheltens P, on Behalf of the EFNS Scientist Panel on Dementia. EFNS guidelines for the diagnosis and management of Alzheimer’s disease. Eur J Neurol 2010;17:1236-1248.
• Hort J, Bartos A, Pirttilä T, Scheltens P. Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe.  Eur J Neurol 2010;17:90-96.
• Hyare H, Wroe S, Siddique D, Webb T, Fox NC, Stevens J, Collinge J, Yousry T, Thornton JS. Brain-water diffusion coefficients reflect the severity of inherited prion disease. Neurology 2010;74:658-665.
• Jack CR Jr, Bernstein MA, Borowski BJ, Gunter JL, Fox NC, Thompson PM, Schuff N, Krueger G, Killiany RJ, DeCarli CS, Dale AM, Carmichael OW, Tosun D, Weiner MW and the Alzheimer’s Disease Neuroimaging Initiative.  Update on the magnetic resonance imaging core of the Alzheimer’s disease neuroimaging initiative.  Alzheimers Dement 2010;6:212-220.
• Joling KJ, van Hout HPJ, Schellevis FG, van der Horst HE, Scheltens P, Knol DL, van Marwijk HWJ. Incidence of depression and anxiety in the spouses of patients with dementia: a naturalistic cohort study of recorded morbidity with a 6-year follow-up. Am J Geriatr Psychiatry 2010;18:146-153.
• Jones L, Holmans PA, Hamshere ML, Harold D, Moskvina V, Ivanov D, Pocklington A, Abraham R, Hollingworth P, Sims R, Gerrish A, Pahwa JS, Jones N, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Mead S, Fox N, et al. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer’s disease. PLoS One 2010;5(11):e13950.
• Jonsson M, Zetterberg H, van Straaten E, Lind K, Syversen S, Edman A, Blennow K, Rosengren L, Pantoni L, Inzitari D, Wallin A. Cerebrospinal fluid biomarkers of white matter lesions – cross-sectional results from the LADIS study. Eur J Neurol 2010;17:377-382.
• Kamphuis PJGH, Scheltens P. Can nutrients prevent or delay onset of Alzheimer’s disease? J Alzheimers Dis 2010;20:765-775.
• Keihaninejad S, Heckemann RA, Fagiolo G, Symms MR, Hajnal JV, Hammers A, Alzheimer’s Disease Neuroimaging Initiative.(waaronder Fox NC) A robust method to estimate the intracranial volume across MRI field strengths (1.5T and 3T). Neuroimage 2010;50:1427-1437.
• Kester MI, Boelaarts L, Bouwman FH, Vogels RL, Groot ER, van Elk EJ, Blankenstein MA, van der Flier WM, Scheltens P. Diagnostic impact of CSF biomarkers in a local hospital memory clinic. Dement Geriatr Cogn Disord 2010;29:491-497.
• Kester MI, Verwey NA, van Elk EJ, Scheltens P, Blankenstein MA. Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer’s disease in patients with mild cognitive impairment. Neurobiol Aging 2010;31:539-540.
• Kester MI, van der Flier WM, Mandic G, Blankenstein MA, Scheltens P, Muller M. Joint effect of hypertension and APOE genotype on CSF biomarkers for Alzheimer’s disease.
• J Alzheimers Dis 2010;20:1083-1090.
• Keihaninejad S, Heckemann RA, Fagiolo G, Symms MR, Hajnal JV, Hammers A, Alzheimer’s Disease Neuroimaging Initiative (waaronder Fox N). A robust method to estimate the intracranial volume across MRI field strengths (1.5T and 3T). Neuroimage 2010;50:1427-1437.
• Koedam ELGE, Van der Flier WM, Barkhof F, Koene T, Scheltens P, Pijnenburg YAL. Clinical characteristics of patients with frontotemporal dementia with and without lobar atrophy on MRI. Alzheimer Dis Assoc Disord 2010;24:242-247.
• Koedam ELGE, Lauffer V, van der Vlies AE, van der Flier WM, Scheltens P, Pijnenburg YAL. Early- versus late-onset Alzheimer’s disease: more than age alone. J Alzheimers Dis 2010;19:1401-1408.
• Lehmann M, Douiri A, Kim LG, Modat M, Chan D, Ourselin S, Barnes J, Fox NC. Atrophy patterns in Alzheimer’s disease and semantic dementia: A comparison of FreeSurfer and manual volumetric measurements. Neuroimage 2010;49:2264-2274.
• Lehmann M, Rohrer JD, Clarkson MJ, Ridgway GR, Scahill RI, Modat M, Warren JD, Ourselin S, Barnes J, Rossor MN, Fox NC. Reduced cortical thickness in the posterior cingulate gyrus is characteristic of both typical and atypical Alzheimer’s disease. J Alzheimers Dis 2010;20:587-598.
• Leung KK, Barnes J, Ridgway GR, Bartlett JW, Clarkson MJ, Macdonald K, Schuff N, Fox NC, Ourselin S, and  the Alzheimer’s Disease Neuroimaging Initiative. Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer’s disease.  Neuroimage 2010;51:1345-1359.
• Leung KK, Shen KK, Barnes J, Ridgway GR, Clarkson MJ, Fripp J, Salvado O, Meriaudeau F, Fox NC, Bourgeat P, Ourselin S, Increasing power to predict mild cognitive impairment conversion to Alzheimer’s disease using hippocampal atrophy rate and statistical shape models. Med Image Comput Comput Assist Interv. 2010;13:125-132.
• Leung KK, Clarkson MJ, Bartlett JW, Clegg S, Jack CR Jr, Weiner MW, Fox NC, Ourselin S, and the Alzheimer’s Disease Neuroimaging Initiative. Robust atrophy rate measurement in Alzheimer’s disease using multi-site serial MRI: tissue-specifi c intensity normalisation and parameter selection.  Neuroimage 2010;50:516-523.
• Liedorp M, Stam CJ, van der Flier WM, Pijnenburg YAL, Scheltens Ph. Prevalence and clinical significance of epileptiform EEG discharges in a large memory clinic cohort. Dement Geriatr Cogn Disord 2010;29:432-437.
• Madureira S, Verdelho A, Moleiro C, Ferro JM, Erkinjuntti T, Jokinen H, Pantoni L, Fazekas F, van der Flier W, Visser M, Waldemar G, Wallin A, Hennerici M, Inzitari D. Neuropsychological predictors of dementia in a three-year follow-up period: data from the LADIS study. Dement Geriatr Cogn Disord 2010;29:325-334.
• Mihaescu R, Detmar SB, Cornel MC, van der Flier WM, Heutink P, Hol EM, Olde Rikkert MGM, van Duijn CM, Janssens ACJW. Translational research in genomics of Alzheimer’s disease: a review of current practice and future perspectives. J Alzheimers Dis 2010;20:967-980.
• Modat M, Ridgway GR, Taylor ZA, Lehmann M, Barnes J, Hawkes DJ, Fox NC, Ourselin S. Fast free-form deformation using graphics processing units.
• Comput Methods Programs Biomed 2010;98:278-184.
• Mulder C, Verwey NA, van der Flier WM, Bouwman FH, Kok A, van Elk EJ, Scheltens P, Blankenstein MA. Amyloid-β(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem 2010;56:248-253.
• Mulder SD, van der Flier WM, Verheijen JH, Mulder C, Scheltens P, Blankenstein MA, Hack CE, Veerhuis R. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology. J Alzheimers Dis 2010;20:253-260.
• Mulder SD, Hack CE, van der Flier WM, Scheltens P, Blankenstein MA, Veerhuis R. Evaluation of intrathecal serum amyloid P (SAP) and C-reactive protein (CRP) synthesis in Alzheimer’s disease with the use of index values. J Alzheimers Dis 2010;22:1073-1079.
• Oosterman JM, Vogels RLC, van Harten B, Gouw AA, Poggesi A, Scheltens P, Kessels RPC, Scherder EJA. Assessing mental flexibility: neuroanatomical and neuropsychological correlates of the trail making test in elderly people. Clin Neuropsychol 2010;24:203-219.
• Petzold A, Verwey NA, van Uffelen K, Blankenstein MA, Teunissen C. Batch prepared protein standards for cerebrospinal fluid (CSF) biomarkers for neurodegeneration. J Neurosci Methods 2010;193:296-299.
• Petzold A, Chapman MD, Schraen S, Verwey NA, Pasquier F, Bombois S, Brettschneider J, Fox NC, von Arnim CAF, Teunissen C, Pijnenburg Y, Riepe MW, Otto M, Tumani H, Scheltens P, Buee L, Rosso MN. An unbiased, staged, multi-center, validation strategy for Alzheimer’s disease CSF tau levels. Exp Neurol 2010;223:432-438.
• Polvikoski TM, van Straaten ECW, Barkhof F, Sulkava R, Aronen HJ, Niinistö L, Oinas M, Scheltens P, Erkinjuntti T, Kalaria RN. Frontal lobe white matter hyperintensities and neurofibrillary pathology in the oldest old. Neurology 2010;75:2071-2078.
• Prins ND, van Swieten JC. Alzheimer disease: MRI and CSF biomarkers in AD-accuracy and temporal change. Nat Rev Neurol 2010:6:650-651.
• Prins ND, Visser PJ, Scheltens P. Can novel therapeutics halt the amyloid cascade? Alzheimers Res Ther 2010;2(2):5.
• Ramakers IHGB, Visser PJ, Aalten P, Kester A, Jolles J, Verhey FRJ. Affective symptoms as predictors of Alzheimer’s disease in subjects with mild cognitive impairment: a 10-year follow-up study.  Psychol Med 2010;40:1193-1201.
• Ramakers IHGB, Visser PJ, Aalten P, Maes HL, Lansdaal HGM, Meijs CJC, Jolles J, Verhey FR. The predictive value of memory strategies for Alzheimer’s disease in subjects with mild cognitive impairment. Arch Clin Neuropsychol 2010;25:71-77.
• Reesink FE, Lemstra AW, van Dijk KD, Berendse HW, van de Berg WDJ, Klein M, Blankenstein MA, Scheltens P, Verbeek MM, van der Flier WM. CSF α-synuclein does not discriminate dementia with lewy bodies from Alzheimer’s disease. J Alzheimers Dis 2010;22:87-95.
• Richard E, Gouw AA, Scheltens P, van Gool WA. Vascular care in patients with Alzheimer disease with cerebrovascular lesions slows progression of white matter lesions on MRI. The evaluation of vascular care in Alzheimer’s disease (EVA) study. Stroke 2010;41:554-556.
• Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, de Liano SR, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9:363-372.
• Rohrer JD, Ridgway GR, Modat M, Ourselin S, Mead S, Fox NC, Rossor MN, Warren JD. Distinct profiles of brain atrophy in frontotemporal lobar degeneration caused by progranulin and tau mutations. Neuroimage 2010;53:1070-1076.
• Rossor MN, Fox NC, Mummery CJ, Schott JM, Warren JD. The diagnosis of young-onset dementia. Lancet Neurol 2010;9:793-806.
• van Rossum IA, ten Houten R. Alledaagse symptomen als uiting van MELAS. Ned Tijdschr Geneeskd 2010;154:A2168.
• van Rossum IA, Vos S, Handels R, Visser PJ. Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. J Alzheimers Dis 2010;20:881-891.
• Salloway SP, Black R, Sperling R, Fox N, Gilman S, Schenk D, Griundman Ml.  Reply from the authors: A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2010;74(24):2026-2027.
• Sanz-Arigita EJ, Schoonheim MM, Damoiseaux JS, Rombouts SARB, Maris E, Barkhof F, Scheltens P, Stam CJ. Loss of ‘small-world’ networks in Alzheimer’s disease: graph analysis of FMRI resting-state functional connectivity. PLoS One 2010;5(11):e13788.
• Scheltens P, Kamphuis PJGH, Verhey FRJ, Olde Rikkert MGM,  Wurtman RJ,  Wilkinson D, Twisk JWR, Kurz A. Efficacy of a medical food in mild Alzheimer’s disease: a randomized, controlled trial. Alzheimers Dement  2010;6:1-10
• Schmidt R, Ropele S, Ferro J, Madureira S, Verdelho A, Petrovic K, Gouw A, van der Flier WM, Enzinger C, Pantoni L, Inzitari D, Erkinjuntti T, Scheltens P, Wahlund LO, Waldemar G, Rostrup E, Wallin A, Barkhof F, Fazekas F, on behalf of the LADIS study group. Diffusion-weighted imaging and cognition in the leukoariosis and disability in the elderly study.  Stroke 2010;41:e402-e408.
• Schneider LS, Kennedy RE, Cutter GR, and the Alzheimer’s Disease Neuroimaging Initiative. (waaronder Fox N.)Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer’s disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimers Dement 2010;6:367-377.
• Schott JM, Bartlett JW, Fox NC, Barnes J, for the Alzheimer’s Disease Neuroimaging Initiative Investigators. Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1-42. Ann Neurol 2010;68:825-834.
• Schott JM, Bartlett JW, Barnes J, Leung KK, Ourselin S, Fox NC, for the Alzheimer’s Disease Neuroimaging Initiative Investigators. Reduced sample sizes for atrophy outcomes in Alzheimer’s disease trials: baseline adjustment. Neurobiol Aging 2010;31:1452-1462.
• Schott JM, Frost C, Macmanus DG, Ibrahim F, Waldman AD, Fox NC. Short echo time proton magnetic resonance spectroscopy in Alzheimer’s disease: a longitudinal multiple time point study. Brain 2010;133:3315-3322.
• Schuitemaker A, Dik MG, Veerhuis R, Scheltens P, Schoonenboom NSM, Hack CE, Blankenstein MA, Jonker C. Inflammatory markers in AD and MCI patients with different biomarker profiles-interpretation of serum and CSF levels. Neurobiol Aging 2010;31:1655.
• Shen L, Kim S, Risacher SL, Nho K, Swaminathan S, West JD, Foroud T, Pankratz N, Moore JH, Sloan CD, Huentelman MJ, Craig DW, Dechairo BM, Potkin SG, Jack CR Jr, Weiner MW, Saykin AJ and the Alzheimer’s Disease Neuroimaging Initiative.( waaronder Fox N ). Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort. Neuroimage 2010;53:1051-1063.
• Sikkes SAM, van den Berg MT, Knol DL, de Lange-de Klerk ESM, Scheltens P, Uitdehaag BMJ, Klein M, Pijnenburg YAL. How useful Is the IQCODE for discriminating between Alzheimer’s disease, mild cognitive impairment and subjective memory complaints? Dement Geriatr Cogn Disord 2010;30:411-416.
• Slats D, Spies PE, Sjögren MJC, Visser PJ, Verbeek MM, Rikkert MGM, Kehoe PG. CSF biomarker utilisation and ethical considerations of biomarker assisted diagnosis and research in dementia: perspectives from within the European Alzheimer’s Disease Consortium (EADC). J Neurol Neurosurg Psychiatry 2010;81:124-125.
• Sluimer JD, Bouwman FH, Vrenken H, Blankenstein MA, Barkhof F, van der Flier WM, Scheltens P. Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. Neurobiol Aging 2010;31:758-764.
• Smits LL, Liedorp M, Koene T, Roos-Reuling IEW, Lemstra AW, Scheltens P, Stam CJ, van der Flier WM. EEG abnormalities are associated with different cognitive profiles in Alzheimer’s disease. Dement Geriatr Cogn Disord 2010;31:1-6.
• Staekenborg SS, Su T, van Straaten ECW, Lane R, Scheltens P, Barkhof F, van der Flier WM. Behavioural and psychological symptoms in vascular dementia; differences between small and large vessel disease. J Neurol Neurosurg Psychiatry 2010;81:547-551.
• Staekenborg SS, de Waal H, Admiraal-Behloul F, Barkhof F, Reiber JHC, Scheltens P, Pijnenburg YAL, Vrenken H, van der Flier WM. Neurological signs in relation to white matter hyperintensity volumes in memory clinic patients.  Dement Geriatr Cogn Disord 2010;29:301-308.
• Teodorczuk A, Firbank MJ, Pantoni L, Poggesi A, Erkinjuntti T, Wallin A, Wahlund L-O, Scheltens P, Waldemar G, Schrotter G, Ferro JM, Chabriat H, Bazner H, Visser M, Inzitari D, O’Brien JT, on behalf of the LADIS Group. Relationship between baseline white-matter changes and development of late-life depressive symptoms: 3-year results from the LADIS study. Psychol Med 2010;40:603-610.
• Teunissen CE, Verwey NA, Kester MI, van Uffelen K, Blankenstein MA. Standardization of assay procedures for analysis of the CSF biomarkers amyloid β(1-42)), tau, and phosphorylated tau in Alzheimer’s disease: report of an International workshop.
• Int J Alzheimers Dis 2010; Article ID 635053:1-6.
• Tolboom N, Koedam ELGE, Schott JM, Yaqub M, Blankenstein MA, Barkhof F, Pijnenburg YAL, Lammertsma AA, Scheltens P, van Berckel BNM. Dementia mimicking Alzheimer’s disease owing to a tau mutation: CSF and PET findings.  Alzheimer Dis Assoc Disord 2010;24:303-307.
• Tolboom N, van der Flier WM, Boverhoff J, Yaqub M, Wattjes MP, Raijmakers PG, Barkhof F, Scheltens P, Herholz K, Lammertsma AA, van Berckel BNM. Molecular imaging in the diagnosis of Alzheimer’s disease: visual assessment of [11C]PIB and [18F]FDDNP PET images. J Neurol Neurosurg Psychiatry 2010;81:882-884.
• Tsolaki M, Papaliagkas V, Anogianakis G, Bernabei R, Emre M, Frolich L, Visser PJ, Michel J-P, Pirttila T, Olde Rikkert M, Soininen H, Sobow T, Vellas B, Verhey F, Winblad B and the European Alzheimer’s Disease Consortium. Consensus statement on dementia education and training in Europe. J Nutr Health Aging 2010;14:131-135.
• Verdelho A, Madureira S, Moleiro C, Ferro JM, Santos CO, Erkinjuntti T, Pantoni L, Fazekas F, Visser M, Waldemar G, Wallin A, Hennerici M, Inzitari D, on behalf of the LADIS Study. White matter changes and diabetes predict cognitive decline in the elderly: The LADIS Study. Neurology 2010;75:160-167.
• Verwey NA, Kester MI, van der Flier WM, Veerhuis R, Berkhof H, Twaalfhoven H, Blankenstein MA, Scheltens P, Pijnenburg YAL. Additional value of CSF amyloid-β40 levels in the differentiation between FTLD and control subjects. J Alzheimers Dis 2010;20:445-452.
• VITATOPS Trial Study Group (waaronder Eikelenboom JW, Koedam E). B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial.  Lancet Neurol 2010;9:855-865.
• Vounou M, Nichols TE, Montana G and the  Alzheimer’s Disease Neuroimaging Initiative (waaronder Fox N). Discovering genetic associations with high-dimensional neuroimaging phenotypes: A sparse reduced-rank regression approach. Neuroimage 2010;53:1147-1159.
• Wild EJ, Henley SMD, Hobbs NZ, Frost C, MacManus DG, Barker RA, Fox NC, Tabrizi SJ. Rate and acceleration of whole-brain atrophy in premanifest and early Huntington’s disease. Mov Disord 2010;25:888-895.
• Wolk DA, Dickerson BC and the Alzheimer’s Disease Neuroimaging Initiative, (waaronder Fox NC) Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer’s disease. Proc Natl Acad Sci U S A 2010;107:10256-10261.
• Yaqub M, Tolboom N, van Berckel BNM, Scheltens P, Lammertsma AA, Boellaard R. Simplified parametric methods for [18F]FDDNP studies. Neuroimage 2010;49:433-441.
• Boer ME de, Hertogh C.MPM, Dröes RM, Jonker C, Eefsting JA. Advance directives in dementia: issues on validity and effectiveness. International Psychogeriatrics, 2010 Mar;22(2):201-8.
• Boer ME, Dröes RM, Jonker C, Eefsting JA, Hertogh CM. Advance directives for euthanasia in dementia: Do law-based opportunities lead to more euthanasia? Health Policy 2010;98:256-262.
• Bouman AIE, Ettema TP, Wetzels RB, Beek APA. van, de Lange J, Dröes RM. Qualidem: Evaluation of a Dementia-specific Quality of Life Instrument for Persons with Dementia in residential settings; Scalability and Reliability of Subscales used in four Dutch Field Surveys. International Journal of Geriatric Psychiatry 2011 Jul;26(7):711-22.
• Dröes RM. Mierlo LD van, Roest HG van der, Meiland FJM. Focus and effectiveness of psychosocial interventions for people with dementia in institutional care settings from the perspective of coping with the disease. Non-pharmacological therapies in dementia, 2010;1(2):139-161.
• Meiland FJM, Reinersmann A, Sävenstedt S, Bergvall-Kåreborn B, Hettinga M, Craig D, Andersson AL, Dröes RM. User-participatory development of assistive technology for people with dementia – from needs to functional requirements. First results of the COGKNOW project. Non-pharmacological therapies in dementia 2010;1(1):71-91.
• Roest HG van der, Meiland FJ, Jonker C, Dröes RM. User evaluation of the DEM-DISC. Aging and Mental Health, 2010;14(4):461-70.
• Van Mierlo LD, Van der Roest HG, Meiland FJM, Dröes RM. Personalized Dementia Care; proven effectiveness of psychosocial interventions in subgroups. Ageing Res Rev. 2010 Apr;9(2):163-83.

Boek(hoofdstukken) en vakpublicaties:

• Boss HM, van den Berg-Vos RM, Scheltens P, Weinstein HC.  Stand van zaken. Vasculaire cognitieve beperking.Ned Tijdschr Geneeskd 2010;154:A1907
• Gouw, A.A. Proefschriftbespreking: Schade aan kleine hersenvaten op MRI: klinische uitingen en onderligende pathologie.  Tschr Neurol Neurochir 2010;111:180-182.
• Keulen MA, Uijterwaal MH, Engels MAH, Koene T, Scheltens Ph, Pijnenburg YAL. Taaldiagnostiek bij patiënten met semantische dementie en progressieve niet-vloeiende afasie. Stem-,Spraak- en Taalpathologie 2010;16:239-254.
• Lemstra E, Eikelenboom P, van Gool P. Cholinerge deficiëtie en cognitie.
• In: van der Mast R, Heeren T, Kat M, et al. (red.), Handboek ouderen-psychiatrie; 3e dr. Utrecht, de Tijdstroom,2010:511-518.
• Scheltens Ph. Nog steeds geen pil voor Alzheimer. Ned Tijdschr Geneeskd 2010;154:A1885.
• Boer ME de, Dröes RM, Jonker C, Eefsting JA, Hertogh CMPM. De beleving van beginnende dementie en het gevreesde lijden. Tijdschrift voor Gerontologie en Geriatrie 2010; 41(5): 194-203.
• Craig D, Meiland FJM, Passmore AP, Dröes RM. Prevalence and clinical features of dementia. In: Mulvenna MD, Nugent CD. (Eds.), Supporting People with Dementia Using Pervasive Health Technologies, Series: Advanced Information and Knowledge Processing, London, Springer-Verlag, 2010, Chapter 2, 15-22.
• Dröes RM. Omgaan met dementie het psychosociale perspectief. Tijdschrift voor Ouderen-geneeskunde, 2010, 35(5)197-199.
• Dröes RM. Omgaan met dementie het psychosociale perspectief. Samenvatting oratie.  CaRe-bulletin CaRré, aug 2010.
• Dröes RM, Bentvelzen SCL, Meiland F, Craig D. Dementia-related and other factors to be taken into account when developing ICT-support for people with dementia – Lessons from field trials, In: Mulvenna MD, Nugent CD. (Eds), Supporting People with Dementia Using Pervasive Health Technologies, Series: Advanced Information and Knowledge Processing, London, Springer-Verlag, 2010; Chapter 8, 113-130.
• Gerritsen DL, Dröes RM, Ettema TP, Boelens E, Bos J, Meihuizen L, de Lange J, Schölzel-Dorenbos CJ, Hoogeveen F. Quality of life in dementia, opinions among people with dementia, their professional caregivers, and in literature. Tijdschr Gerontol Geriatr. 2010 Dec;41(6):241-55.
• Lauriks S, Reinersmann A, Roest H.G. van der, Meiland FJM, Davies RJ, Moelaert F, Mulvenna MD, Nugent CD, Dröes RM. Review of ICT-based services for identified unmet needs in people with dementia, In: Mulvenna MD, Nugent CD. (Eds), Supporting People with Dementia Using Pervasive Health Technologies, Series: Advanced Information and Knowledge Processing, London, Springer-Verlag, 2010; Chapter 4, 37-62.
• Martin S, Bengtsson JE, Dröes RM. Assistive technologies and issues relating to privacy, ethics and security. In: Mulvenna MD, Nugent CD. (Eds), Supporting People with Dementia Using Pervasive Health Technologies, Series: Advanced Information and Knowledge Processing, London, Springer-Verlag, 2010; Chapter 5, 63-78.
• Meiland F, Dröes RM, Sävenstedt S, Bergvall-Kåreborn B, Andersson AL. Identifying User Needs and the Participative Design Process, In: Mulvenna MD, Nugent CD. (Eds), Supporting People with Dementia Using Pervasive Health Technologies, Series: Advanced Information and Knowledge Processing, London, Springer-Verlag, 2010; Chapter 6, 79-100.
• Meiland F, Dröes RM, Sävenstedt S. Measuring the impact of Cognitive Prosthetics on the daily life of people with dementia and their carers In: Mulvenna MD, Nugent CD. (Eds), Supporting People with Dementia Using Pervasive Health Technologies, Series: Advanced Information and Knowledge Processing, London, Springer-Verlag, 2010; Chapter 14, 207-220.
• Mierlo L. & Dröes RM. Dementelcoach; telefonische ondersteuning voor mantelzorgers van mensen met dementie. Vita Valley, Nieuwsbrief, juli 2011.
• Mulvenna MD, Nugent C, Moelaert F, Craig D, Dröes RM, Bengtsson J. Supporting People with Dementia Using Pervasive Healthcare Technologies, In: Mulvenna MD, Nugent, CD. (Eds.), Supporting People with Dementia Using Pervasive Health Technologies, Series: Advanced Information and Knowledge Processing, London, Springer-Verlag, 2010; Chapter 1, 3-14.
• Mulvenna MD, Moelaert F, Meiland F, Sävenstedt S, Hettinga M, Craig D, Bengtsson JE, Dröes RM, Martin S. Designing and Evaluating a Cognitive Prosthetic for People with Mild Dementia. In: Brinkman WP, Neerincx M, (Eds), Caring Technology for the Future: Proceedings of the European Conference on Cognitive Ergonomics, 389 pp, Mediamatica, 2010;11-18.
• Roest HG van der, Meiland FJM, Dröes RM. Proefschrift: Zorgbehoeften bij dementie en digitale, gepersonaliseerde informatievoorziening voor dementiezorg. Verpleegkunde 2010;(3):25-31
• Sävenstedt S, Meiland F, Dröes RM, Moelaert F. Evaluation of Cognitive Prosthetics In: Mulvenna MD, Nugent CD. (Eds.), Supporting People with Dementia Using Pervasive Health Technologies, Series: Advanced Information and Knowledge Processing, London, Springer-Verlag 2010, Chapter 13, 197-206.

Dissertaties:

• Altena E. Mapping insomnia: brain structure, function and sleep intervention.
• Vrije Universiteit Amsterdam 17 maart 2010
• promotoren: EJW van Someren, DF Swaab, copromotoren: YD van der Werf, Ph Scheltens
• Tolboom N. Imaging Alzheimer’s disease pathology in vivo: towards an early diagnosis.
• Vrije Universiteit Amsterdam 12 februari 2010
• promotoren: Ph Scheltens, AA Lammertsma. copromotoren: BNM van Berckel, WM van der Flier
• Verwey NA. Biochemical markers in dementia: from mice to men.
• Vrije Universiteit Amsterdam 16 april 2010
• promotoren: Ph Scheltens, MA Blankenstein. copromotoren: WM van der Flier, R Veerhuis